CYCLIN INHIBITORS

Abstract

This document describes compounds of formula (I), their intermediates and processes for their preparation: . The present document also describes the use of such compounds and compositions for the treatment of diseases or disorders that are at least in part mediated by one or more cyclins, including cancer.

Description

CYCLIN INHIBITORS CROSS-REFERENCES TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No.63 / 467,651, filed May 19, 2023; U.S. Provisional Application No.63 / 612,533, filed December 20, 2023; and U.S. Provisional Application No.63 / 637,984, filed April 24, 2024, the disclosure of each is hereby incorporated by reference in their entirety for al purposes. BACKGROUND

[0002] Cyclins are a family of proteins that play a central role in the regulation of the cel cycle. Specific cyclins, including Cyclins D, E, A and B, are expressed at the diferent stages of the cel cycle, during which they bind and activate their cognate cyclin dependent kinases (CDKs), including CDKs 1, 2, 4 and 6, to form cyclin-CDK complexes that orchestrate progression and transitions through the diferent stages of the cel cycle. Disruptions of the normal regulatory functions of cyclin-CDK complexes are common drivers of oncogenesis and the rapid proliferation of cancer cels. The central role of cyclins and CDKs in the cel cycle makes these proteins and their complexes atractive targets for treating proliferative disorders and cancer. To date, most inhibitors of cyclin-CDK complexes target the kinase activity of CDKs (“CDK inhibitors”) and include therapeutics both in development and approved for clinical use. Alternative approaches could include disrupting the association of cyclins with CDKs or the interaction of a particular cyclin-CDK complex with its substrates or regulators.

[0003] Although CDK inhibitors have been developed and proven successful in certain cancers, they are curently limited by their relative lack of selectivity, smal therapeutic window, and ultimately the development of resistance. As such, there is a need to develop agents that ofer alternative approaches to inhibiting the function of cyclin-CDK complexes as a means to modulate the cel cycle. Such agents could provide new tools in the treatment of proliferative diseases. The present disclosure addresses this need by providing compounds that inhibit the binding of substrates to various cyclins, thereby disrupting the function of cyclin-CDK complexes. BRIEF SUMMARY

[0004] In one embodiment, provided herein is a compound of Formula (I):whereinR3is (a) C1-6alkyl, C2-6alkenyl, C2-6alkynyl, or C1-6haloalkyl, each substituted with 0 to 5 R3a, (b) C3-12cycloalkyl substituted with 0 to 5 R3b, or (c) heterocycloalkyl having 3 to 12 ring members and 1 to 4 heteroatoms, each independently N, O, or S, wherein the heterocycloalkyl is substituted with 0 to 5 R3c; (g) heteroaryl having 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein the heteroaryl is substituted with 0, 1, 2, 3, 4, or 5 R3g; each R3ais –OH, C1-6alkoxy, C1-6haloalkoxy, or –O–C(O)C1-6alkyl; each R3bis independently C1-6alkyl, C2-6alkenyl, C2-6alkynyl, –OH, C1-6alkoxy, halo, C1-6haloalkyl, C1-6haloalkoxy, or cyano; each R3cis independently C1-6alkyl, halo, C1-6haloalkyl, cyano, C3-6cycloalkyl, or oxo; each R3gis independently C1-6alkyl, halo, C1-6haloalkyl, or C3-6cycloalkyl; R4ais H or C1-6alkyl; R4band R4care each independently H, C1-6alkyl, C1-6haloalkyl, C3-6cycloalkyl, –C1-6alkyl–C3-6cycloalkyl, heterocycloalkyl, –C1-6alkyl–heterocycloalkyl, phenyl, –C1-6alkyl–phenyl, heteroaryl, or –C1-6alkyl–heteroaryl, wherein each heterocycloalkyl has 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S; alternatively, R4cand R4atogether with the carbon and nitrogen to which each is atached combine to form a heterocycloalkyl having 3 to 6 ring members and 1to 3 heteroatoms, each independently N, O, or S, wherein the heterocycloalkyl is substituted with 0 to 4 R4a1; each R4a1is independently C1-6alkyl, –OH, C1-6alkyl–OH, C1-6alkoxy, or halo; R5a is H or C1-6alkyl; R5b and R5c are each independently H, C1-6alkyl, –C1-6alkyl–OH, C2-6alkoxyalkyl, C1-6haloalkyl, –C1-6alkyl–C(O)NR5b1R5b2, –C1-6alkyl–C(O)OR5b1, C3-6cycloalkyl, C1-6alkyl–C3-6cycloalkyl, heterocycloalkyl, –C1-6alkyl– heterocycloalkyl, phenyl, –C1-6alkyl–phenyl, heteroaryl, or –C1-6alkyl–heteroaryl, wherein each heterocycloalkyl has 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and wherein each cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl is substituted with 0 to 3 R5b5; each R5b1and R5b2are independently H, C1-4alkyl, or C1-4haloalkyl; alternatively, R5b1and R5b2together with the nitrogen to which each is atached combine to form a heterocycloalkyl having 3 to 6 ring members and 0 to 1 additional heteroatoms, wherein the heterocycloalkyl is substituted with 0 to 2 R5b3; each R5b3and R5b5 is independently C1-6alkyl, halo, C1-6haloalkyl, or cyano; X6is C6-7alkylene or C6-7alkenylene; R6a is H, C1-6alkyl, C1-6deuteroalkyl, C2-6alkoxyalkyl, C3-6cycloalkyl, –C1-6alkyl– C3-6cycloalkyl, heterocycloalkyl, –C1-6alkyl–heterocycloalkyl, phenyl, –C1-6alkyl–phenyl, heteroaryl, or –C1-6alkyl–heteroaryl, wherein the heterocycloalkyl has 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and the heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S; R6band R6d are each independently H or C1-6alkyl; R7ais H or C1-6alkyl; R7band R7care each independently H, C1-6alkyl, C2-6alkenyl, C1-6haloalkyl, C1-6alkyl–OH, C3-6cycloalkyl, or –C1-6alkyl–C3-6cycloalkyl; R8a is H, C1-6alkyl, C2-6alkoxyalkyl, C3-6cycloalkyl or –C1-6alkyl–C3-6cycloalkyl; R8b, R8d, and R8e are each independently H or C1-6alkyl;ring B is C6-12 aryl or heteroaryl having 5 to 12 ring members and 1 to 6 heteroatoms, each independently N, O or S; the subscript m8 is an integer from 0 to 5; each R8fis independently C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6deuteroalkoxy, halo, C1-6haloalkyl, cyano, –X8f–cyano, C3-12cycloalkyl, –X8f–C3-6cycloalkyl, –CH=CR8f1R8f2, heterocycloalkyl, –X8f–heterocycloalkyl, C6-12aryl, –X8f–C 6-12 aryl, heteroaryl, or –X8f–heteroaryl, wherein each heterocycloalkyl has 3 to 12 ring members and 1 to 4 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 10 ring members and 1 to 4 heteroatoms, each independently N, O, or S, wherein each alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is substituted with 0 to 3 R8f3; alternatively, two R8fgroups on adjacent ring vertices combine to form a C3-6cycloalkyl or a heterocycloalkyl having 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein the cycloalkyl or heterocycloalkyl is substituted with 0 to 3 R8f3; each X8fis independently C1-6alkylene, C2-6alkenylene, –O–C1-6alkylene, C(O), O, or S; each R8f1 and R8f2 are combined with the carbon to which they are atached to form a heterocycloalkyl having 3 to 10 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein the heterocycloalkyl is substituted with 0 to 3 R8f3; each R8f3is independently C1-6alkyl, –Y8–C1-6alkyl, C1-6deuteroalkyl, –Y8–C1-6deuteroalkyl, –OH, –C1-6alkyl–OH, –Y8–C1-6alkyl–OH, –C1-6alkyl–Y8–C1-6alkyl, –(C1-2 alkyl–O)1-4–C1-2 alkyl, C1-6alkoxy, halo, C1-6haloalkyl, –Y8–C1-6haloalkyl, cyano, –C1-6alkyl–cyano, –C1-6alkyl–NR8gR8h, oxo, C3-6cycloalkyl, –X8f3–C3-6cycloalkyl, heterocycloalkyl, –X8f3– heterocycloalkyl, phenyl, –X8f3–phenyl, heteroaryl, or –X8f3–heteroaryl, wherein each heterocycloalkyl has 3 to 12 members and 1 to 4 heteroatoms, each independently N, O, S, or S(O)2, and each heteroaryl has 5 to 10 ring members and 1 to 4 heteroatoms, each independently N, O, or S, and wherein each heterocycloalkyl and heteroaryl are substituted with 0 to 2 C1-4alkyl or halo;each X8f3is independently C1-6alkylene, O, C(O), or S(O)2; each Y8 is independently C(O), C(O)O, N(R8f4)C(O), O, S, or S(O)2; each R8g and R8h is independently H, C1-3alkyl, or C1-6haloalkyl; alternatively, two R8f3groups on the same or adjacent ring vertices combine to form a C3-6cycloalkyl or a heterocycloalkyl having 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein nitrogen atom ring members in the heterocycloalkyl are substituted with 0 to 1 C1-4alkyl; and each R8f4is independently H or C1-6alkyl; or a pharmaceuticaly acceptable salt thereof.

[0005] In another embodiment, the present disclosure provides a pharmaceutical composition comprising a compound of the present disclosure, and a pharmaceuticaly acceptable excipient.

[0006] In another embodiment, the present disclosure provides a method of treating a disease or disorder mediated at least in part by cyclin activity, the method comprising administering to a subject in need thereof, a therapeuticaly efective amount of a compound of the present disclosure, or a pharmaceuticaly acceptable salt thereof, or a pharmaceutical composition of the present disclosure, thereby treating the disorder or condition.

[0007] In another embodiment, the present disclosure provides a method of treating a cancer mediated at least in part by cyclin A, the method comprising administering to a subject in need thereof, a therapeuticaly efective amount of a compound of the present disclosure, or a pharmaceuticaly acceptable salt thereof, or a pharmaceutical composition of the present disclosure, thereby treating the cancer.

[0008] In another embodiment, the present invention provides intermediates useful in the preparation of compounds of Formula (I).

[0009] Other objects, features, and advantages of the present disclosure wil be apparent to one of skil in the art from the folowing detailed description and figures. BRIEF DESCRIPTION OF THE DRAWINGS

[0010] NOT APPLICABLEDETAILED DESCRIPTION I. General

[0011] Provided herein are compounds and compositions that disrupt the typical celular function of cyclins. Also provided herein are, for example, methods of treating or preventing a disease, disorder or condition, or a symptom thereof, mediated by cyclin activity.

[0012] Complexes between cyclins and cyclin dependent kinases (CDKs) are responsible for phosphorylating a wide range of substrates, thereby modulating the activity of the substrates. Many of these substrates are important in the cel cycle and the cyclin and CDKs that regulate these substrates therefore play key roles in regulating the cel cycle, including Cyclins D, A, E and B, and CDKs 1, 2, 4 and 6. Without being bound to any particular theory, certain substrates, including p21, p27, Rb, E2F and CDC6, first bind to the cyclin- CDK complex via a conserved RxL motif within the substrate (Adams et al. Mol Cel Biol. 1996.16(12):6223-33.) and bind to a region with the cyclin that is refered to as an RxL binding domain or a “hydrophobic patch” (Brown et al. Nat Cel Biol.1999.1(7):438-43) and contains a highly conserved MRAIL motif. Compounds that disrupt the binding of substrates to cyclins have been posited to be of potential therapeutic utility, including in the disruption of cancer cel proliferation (Chen et al. Proc Natl Acad Sci U S A.1999.96(8):4325-9).

[0013] Without being bound to any particular theory, it is believed that compounds of the present disclosure inhibit the binding of substrates to the hydrophobic patch region of cyclins including, but not limited to, Cyclins A, E and B. Compounds of the present disclosure include compounds that bind more potently to one or more cyclins. II. Definitions

[0014] As used herein, the term “about” means a range of values including the specified value, which a person of ordinary skil in the art would consider reasonably similar to the specified value. In some embodiments, the term “about” means within a standard deviation using measurements generaly acceptable in the art. In some embodiments, about means a range extending to + / - 10% of the specified value. In some embodiments, about means the specified value.

[0015] “Alkyl” refers to a straight or branched, saturated, aliphatic radical having the number of carbon atoms indicated. Alkyl can include any number of carbons, such as C1-2,C1-3, C1-4, C1-5, C1-6, C1-7, C1-8, C1-9, C1-10, C2-3, C2-4, C2-5, C2-6, C3-4, C3-5, C3-6, C4-5, C4-6and C5-6. For example, C1-6alkyl includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, etc. Alkyl can also refer to alkyl groups having up to 20 carbons atoms, such as, but not limited to heptyl, octyl, nonyl, decyl, etc. Alkyl groups can be substituted or unsubstituted.

[0016] “Alkylene” refers to a straight or branched, saturated, aliphatic radical having the number of carbon atoms indicated, and linking at least two other groups, i.e., a divalent hydrocarbon radical. The two moieties linked to the alkylene can be linked to the same atom or diferent atoms of the alkylene group. For instance, a straight chain alkylene can be the bivalent radical of –(CH2)n–,where n is 1, 2, 3, 4, 5 or 6. Representative alkylene groups include, but are not limited to, methylene, ethylene, propylene, isopropylene, butylene, isobutylene, sec-butylene, pentylene and hexylene. Alkylene groups can be substituted or unsubstituted.

[0017] “Alkenyl” refers to a straight chain or branched hydrocarbon having at least 2 carbon atoms and at least one double bond. Alkenyl can include any number of carbons, such as C2, C2-3, C2-4, C2-5, C2-6, C2-7, C2-8, C2-9, C2-10, C3, C3-4, C3-5, C3-6, C4, C4-5, C4-6, C5, C5-6, and C6. Alkenyl groups can have any suitable number of double bonds, including, but not limited to, 1, 2, 3, 4, 5 or more. Examples of alkenyl groups include, but are not limited to, vinyl (ethenyl), propenyl, isopropenyl, 1-butenyl, 2-butenyl, isobutenyl, butadienyl, 1-pentenyl, 2-pentenyl, isopentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,5-hexadienyl, 2,4-hexadienyl, or 1,3,5-hexatrienyl. Alkenyl groups can be substituted or unsubstituted.

[0018] “Alkenylene” refers to a straight or branched hydrocarbon having at least 2 carbon atoms, one double bond, and linking at least two other groups, i.e., a divalent hydrocarbon radical. Alkenylene can include any number of carbons, such as C2, C2-3, C2-4, C2-5, C2-6, C2-7, C2-8, C2-9, C2-10, C3, C3-4, C3-5, C3-6, C3-6, C3-7, C4, C4-5, C4-6, C4-7, C6-7, C5, C6 and C7.The two moieties linked to the alkenylene can be linked to the same atom or diferent atoms of the alkenylene group. Representative alkenylene groups include, but are not limited to, (E)-hex- 2-enylene, (Z)-hex-2-enylene, (E)-hept-2-enylene, (Z)-hept-2-enylene, (E)-hept-3-enylene, and (Z)-hept-3-enylene. Alkenylene moieties can be in the E or Z isomer. Alkenylene groups can be substituted or unsubstituted.

[0019] “Alkynyl” refers to either a straight chain or branched hydrocarbon having at least 2 carbon atoms and at least one triple bond. Alkynyl can include any number of carbons, such as C2, C2-3, C2-4, C2-5, C2-6, C2-7, C2-8, C2-9, C2-10, C3, C3-4, C3-5, C3-6, C4, C4-5, C4-6, C5, C5-6, and C6. Examples of alkynyl groups include, but are not limited to, acetylenyl, propynyl, 1-butynyl, 2-butynyl, butadiynyl, 1-pentynyl, 2-pentynyl, isopentynyl, 1,3-pentadiynyl, 1,4-pentadiynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 1,3-hexadiynyl, 1,4-hexadiynyl, 1,5-hexadiynyl, 2,4-hexadiynyl, or 1,3,5-hexatriynyl. Alkynyl groups can be substituted or unsubstituted.

[0020] “Alkoxy” refers to an alkyl group having an oxygen atom that connects the alkyl group to the point of atachment: alkyl-O-. As for alkyl group, alkoxy groups can have any suitable number of carbon atoms, such as C1-6. Alkoxy groups include, for example, methoxy, ethoxy, propoxy, iso-propoxy, butoxy, 2-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, pentoxy, hexoxy, etc. The alkoxy groups can be substituted or unsubstituted.

[0021] “Alkoxyalkyl” refers to alkyl group connected to an oxygen atom that is further connected to an second alkyl group, the second alkyl group being the point of atachment to the remainder of the molecule: alkyl-O-alkyl. The alkyl portion can have any suitable number of carbon atoms, such as C2-6. Alkoxyalkyl groups include, for example, methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl, etc. The alkoxy groups can be substituted or unsubstituted.

[0022] “Halo” or “halogen” refers to fluorine, chlorine, bromine and iodine.

[0023] “Haloalkyl” refers to alkyl, as defined above, where some or al of the hydrogen atoms are replaced with halogen atoms. As for alkyl group, haloalkyl groups can have any suitable number of carbon atoms, such as C1-6. For example, haloalkyl includes trifluoromethyl, flouromethyl, etc. In some instances, the term “perfluoro” can be used to define a compound or radical where al the hydrogens are replaced with fluorine. For example, perfluoromethyl refers to 1,1,1-trifluoromethyl.

[0024] “Haloalkoxy” refers to an alkoxy group where some or al of the hydrogen atoms are substituted with halogen atoms. As for an alkyl group, haloalkoxy groups can have any suitable number of carbon atoms, such as C1-6. The alkoxy groups can be substituted with 1, 2, 3, or more halogens. When al the hydrogens are replaced with a halogen, for example by fluorine, the compounds are per-substituted, for example, perfluorinated. Haloalkoxy includes, but is not limited to, trifluoromethoxy, 2,2,2,-trifluoroethoxy, perfluoroethoxy, etc.

[0025] “Cycloalkyl” refers to a saturated or partialy unsaturated, monocyclic, spirocyclic, fused or bridged polycyclic ring assembly containing from 3 to 12 ring atoms, or the number of atoms indicated. Cycloalkyl can include any number of carbons, such as C3-6, C4-6, C5-6, C3-8, C4-8, C5-8, C6-8, C3-9, C3-10, C3-11, and C3-12. Saturated monocyclic cycloalkyl rings include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclooctyl. Saturated bicyclic and polycyclic cycloalkyl rings include, for example, norbornane, [2.2.2] bicyclooctane, decahydronaphthalene and adamantane. Cycloalkyl groups can also be partialy unsaturated, having one or more double or triple bonds in the ring, but cycloalkyl groups are not aromatic. Representative cycloalkyl groups that are partialy unsaturated include, but are not limited to, cyclobuteneyl, cyclopenteneyl, cyclohexeneyl, cyclohexadieneyl (1,3- and 1,4-isomers), cyclohepteneyl, cycloheptadieneyl, cycloocteneyl, cyclooctadieneyl (1,3-, 1,4- and 1,5-isomers), norborneneyl, and norbornadieneyl. When cycloalkyl is a C3-6monocyclic cycloalkyl, exemplary groups include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexeneyl, cyclohexadieneyl (1,3- and 1,4-isomers). When cycloalkyl is a C5-10 fused bicyclic cycloalkyl, exemplary groups include, but are not limited to bicyclo[3.1.0]hexanyl, bicyclo[4.1.0]heptanyl, bicyclo[4.2.0]octanyl, and octahydro-1H-indenyl. When cycloalkyl is a C5-10 bridged polycyclic cycloalkyl, exemplary groups include, but are not limited to bicyclo[2.2.1]heptane, bicyclo[3.1.1]heptane, and bicyclo[2.1.1]hexane. When cycloalkyl is a C5-10 spirocycloalkyl, exemplary groups include, but are not limited to spiro[3.3]heptane, spiro[3.4]octane, spiro[3.5]nonanyl, spiro[2.5]octane, and spiro[2.4]heptane. Cycloalkyl groups can be substituted or unsubstituted.

[0026] “Heterocycloalkyl” refers to a saturated or partialy unsaturated, monocyclic, spirocyclic, fused or bridged polycyclic ring assembly having from 3 to 12 ring members and from 1 to 4 heteroatoms of N, O and S. The heteroatoms can also be oxidized, such as, but not limited to, -S(O)- and -S(O)2-. Heterocycloalkyl groups can include any number of ring atoms, such as, 3 to 6, 4 to 6, 5 to 6, 3 to 8, 4 to 8, 5 to 8, 6 to 8, 3 to 9, 3 to 10, 3 to 11, or 3 to 12 ring members. Any suitable number of heteroatoms can be included in the heterocycloalkyl groups, such as 1, 2, 3, or 4, or 1 to 2, 1 to 3, 1 to 4, 2 to 3, 2 to 4, or 3 to 4. The heterocycloalkyl group can include groups such as aziridine, azetidine, pyrolidine, piperidine, azepane, azocane, quinuclidine, pyrazolidine, imidazolidine, piperazine (1,2-, 1,3- and 1,4-isomers), oxirane, oxetane, tetrahydrofuran, oxane (tetrahydropyran), tetrahydropyridine, oxepane, thirane, thietane, thiolane (tetrahydrothiophene), thiane(tetrahydrothiopyran), oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, dioxolane, dithiolane, morpholine, thiomorpholine, dioxane, or dithiane. Heterocycloalkyl groups can be unsubstituted or substituted.

[0027] The heterocycloalkyl groups can be linked via any position on the ring. For example, aziridine can be 1- or 2-aziridine, azetidine can be 1- or 2- azetidine, pyrolidine can be 1-, 2- or 3-pyrolidine, piperidine can be 1-, 2-, 3- or 4-piperidine, pyrazolidine can be 1-, 2-, 3-, or 4-pyrazolidine, imidazolidine can be 1-, 2-, 3- or 4-imidazolidine, piperazine can be 1-, 2-, 3- or 4-piperazine, tetrahydrofuran can be 1- or 2-tetrahydrofuran, oxazolidine can be 2-, 3-, 4- or 5-oxazolidine, isoxazolidine can be 2-, 3-, 4- or 5-isoxazolidine, thiazolidine can be 2-, 3-, 4- or 5-thiazolidine, isothiazolidine can be 2-, 3-, 4- or 5- isothiazolidine, and morpholine can be 2-, 3- or 4-morpholine.

[0028] When heterocycloalkyl is a monocyclic heterocycloalkyl having 3 to 6 ring members and 1 to 3 heteroatoms, representative members include, but are not limited to, pyrolidine, piperidine, tetrahydrofuran, oxane, tetrahydrothiophene, thiane, pyrazolidine, imidazolidine, piperazine, oxazolidine, isoxzoalidine, thiazolidine, isothiazolidine, morpholine, thiomorpholine, dioxane and dithiane. Heterocycloalkyl can also be monocyclic heterocycloalkyl having 5 to 6 ring members and 1 to 2 heteroatoms, with representative members including, but not limited to, pyrolidine, piperidine, tetrahydrofuran, tetrahydrothiophene, pyrazolidine, imidazolidine, piperazine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, and morpholine.

[0029] “Aryl” refers to an aromatic ring system having any suitable number of ring atoms and any suitable number of rings. Aryl groups can include any suitable number of ring atoms, such as, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 ring atoms, as wel as from 6 to 10, 6 to 12, or 6 to 14 ring members. Aryl groups can be monocyclic, fused to form bicyclic or tricyclic groups, or linked by a bond to form a biaryl group. Representative aryl groups include phenyl, naphthyl and biphenyl. Other aryl groups include benzyl, having a methylene linking group. Some aryl groups have from 6 to 12 ring members, such as phenyl, naphthyl or biphenyl. Other aryl groups have from 6 to 10 ring members, such as phenyl or naphthyl. Some other aryl groups have 6 ring members, such as phenyl. Aryl groups can be substituted or unsubstituted.

[0030] “Heteroaryl” refers to a monocyclic or fused bicyclic or tricyclic aromatic ring assembly containing 5 to 12 ring atoms, where from 1 to 6 of the ring atoms are a heteroatomsuch as N, O or S. The heteroatoms can also be oxidized, such as, but not limited to, -S(O)- and -S(O)2-. Heteroaryl groups can include any number of ring atoms, such as, 5 to 6, 5 to 8, 5 to 9, 5 to 10, 5 to 12, or 9 to 12 ring members. Any suitable number of heteroatoms can be included in the heteroaryl groups, such as 1, 2, 3, 4, 5, or 6, or 1 to 2, 1 to 3, 1 to 4, 1 to 5, 2 to 3, 2 to 4, 2 to 5, 2 to 6, 3 to 4, 3 to 5, or 3 to 6. Heteroaryl groups can have from 5 to 8 ring members and from 1 to 4 heteroatoms, or from 5 to 8 ring members and from 1 to 3 heteroatoms, or from 5 to 6 ring members and from 1 to 4 heteroatoms, or from 5 to 6 ring members and from 1 to 3 heteroatoms. The heteroaryl group can include groups such as pyrole, pyridine, imidazole, pyrazole, triazole, tetrazole, pyrazine, pyrimidine, pyridazine, triazine (1,2,3-, 1,2,4- and 1,3,5-isomers), thiophene, furan, thiazole, isothiazole, oxazole, and isoxazole. The heteroaryl groups can also be fused to aromatic ring systems, such as a phenyl ring, to form members including, but not limited to, benzopyroles such as indole and isoindole, benzopyridines such as quinoline and isoquinoline, benzopyrazine (quinoxaline), benzopyrimidine (quinazoline), benzopyridazines such as phthalazine and cinnoline, benzothiophene, and benzofuran. Other heteroaryl groups include heteroaryl rings linked by a bond, such as bipyridine. Heteroaryl groups can be substituted or unsubstituted.

[0031] The heteroaryl groups can be linked via any position on the ring. For example, pyrole includes 1-, 2- and 3-pyrole, pyridine includes 2-, 3- and 4-pyridine, imidazole includes 1-, 2-, 4- and 5-imidazole, pyrazole includes 1-, 3-, 4- and 5-pyrazole, triazole includes 1-, 4- and 5-triazole, tetrazole includes 1- and 5-tetrazole, pyrimidine includes 2-, 4-, 5- and 6- pyrimidine, pyridazine includes 3- and 4-pyridazine, 1,2,3-triazine includes 4- and 5-triazine, 1,2,4-triazine includes 3-, 5- and 6-triazine, 1,3,5-triazine includes 2-triazine, thiophene includes 2- and 3-thiophene, furan includes 2- and 3-furan, thiazole includes 2-, 4- and 5-thiazole, isothiazole includes 3-, 4- and 5-isothiazole, oxazole includes 2-, 4- and 5- oxazole, isoxazole includes 3-, 4- and 5-isoxazole, indole includes 1-, 2- and 3-indole, isoindole includes 1- and 2-isoindole, quinoline includes 2-, 3- and 4-quinoline, isoquinoline includes 1-, 3- and 4-isoquinoline, quinazoline includes 2- and 4-quinoazoline, cinnoline includes 3- and 4-cinnoline, benzothiophene includes 2- and 3-benzothiophene, and benzofuran includes 2- and 3-benzofuran.

[0032] Some heteroaryl groups include those having from 5 to 10 ring members and from 1 to 3 ring atoms including N, O or S, such as pyrrole, pyridine, imidazole, pyrazole, triazole, pyrazine, pyrimidine, pyridazine, triazine (1,2,3-, 1,2,4- and 1,3,5-isomers), thiophene, furan,thiazole, isothiazole, oxazole, isoxazole, indole, isoindole, quinoline, isoquinoline, quinoxaline, quinazoline, phthalazine, cinnoline, benzothiophene, and benzofuran. Other heteroaryl groups include those having from 5 to 8 ring members and from 1 to 3 heteroatoms, such as pyrole, pyridine, imidazole, pyrazole, triazole, pyrazine, pyrimidine, pyridazine, triazine (1,2,3-, 1,2,4- and 1,3,5-isomers), thiophene, furan, thiazole, isothiazole, oxazole, and isoxazole. Some other heteroaryl groups include those having from 9 to 12 ring members and from 1 to 3 heteroatoms, such as indole, isoindole, quinoline, isoquinoline, quinoxaline, quinazoline, phthalazine, cinnoline, benzothiophene, benzofuran and bipyridine. Stil other heteroaryl groups include those having from 5 to 6 ring members and from 1 to 2 ring atoms including N, O or S, such as pyrole, pyridine, imidazole, pyrazole, pyrazine, pyrimidine, pyridazine, thiophene, furan, thiazole, isothiazole, oxazole, and isoxazole.

[0033] “Thiophenyl” refers to a thiophene radical.

[0034] As used herein, the term “oxo” refers to an oxygen atom connected to the point of atachment by a double bond (=O).

[0035] “Pharmaceuticaly acceptable excipient” refers to a substance that aids the formulation and / or administration of an active agent to a subject. Pharmaceutical excipients useful in the present disclosure include, but are not limited to, binders, filers, disintegrants, lubricants, coatings, sweeteners, flavors and colors. One of skil in the art wil recognize that other pharmaceutical excipients are useful in the present disclosure.

[0036] “Subject” refers to animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like. In some embodiments, the subject is a human.

[0037] “Administering” refers to oral administration, administration as a suppository, topical contact, parenteral, intravenous, intraperitoneal, intramuscular, intralesional, intranasal or subcutaneous administration, intrathecal administration, or the implantation of a slow-release device e.g., a mini-osmotic pump, to the subject.

[0038] “Therapeuticaly efective amount” refers to a dose that produces therapeutic efects for which it is administered. The exact dose wil depend on the purpose of the treatment, and wil be ascertainable by one skiled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols.1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington:The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincot, Wiliams & Wilkins)

[0039] “Treat”, “treating” and “treatment” refers to any indicia of success in the treatment or amelioration of an injury, pathology, condition, or symptom (e.g., pain), including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the symptom, injury, pathology or condition more tolerable to the patient; decreasing the frequency or duration of the symptom or condition. The treatment or amelioration of symptoms can be based on any objective or subjective parameter; including, e.g., the result of a physical examination. III. Compounds

[0040] In some embodiments, the present disclosure provides a compound of Formula (I):R3is (a) C1-6alkyl, C2-6alkenyl, C2-6alkynyl, or C1-6haloalkyl, each substituted with 0 to 5 R3a, (b) C3-12cycloalkyl substituted with 0 to 5 R3b, or (c) heterocycloalkyl having 3 to 12 ring members and 1 to 4 heteroatoms, each independently N, O, or S, wherein the heterocycloalkyl is substituted with 0 to 5 R3c; (g) heteroaryl having 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein the heteroaryl is substituted with 0, 1, 2, 3, 4, or 5 R3g; each R3ais –OH, C1-6alkoxy, C1-6haloalkoxy, or –O–C(O)C1-6alkyl; each R3bis independently C1-6alkyl, C2-6alkenyl, C2-6alkynyl, –OH, C1-6alkoxy, halo, C1-6haloalkyl, C1-6haloalkoxy, or cyano;each R3cis independently C1-6alkyl, halo, C1-6haloalkyl, cyano, C3-6cycloalkyl, or oxo; each R3gis independently C1-6alkyl, halo, C1-6haloalkyl, or C3-6cycloalkyl; R4ais H or C1-6alkyl; R4band R4care each independently H, C1-6alkyl, C1-6haloalkyl, C3-6cycloalkyl, –C1-6alkyl–C3-6cycloalkyl, heterocycloalkyl, –C1-6alkyl–heterocycloalkyl, phenyl, –C1-6alkyl–phenyl, heteroaryl, or –C1-6alkyl–heteroaryl, wherein each heterocycloalkyl has 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S; alternatively, R4cand R4atogether with the carbon and nitrogen to which each is atached combine to form a heterocycloalkyl having 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein the heterocycloalkyl is substituted with 0 to 4 R4a1; each R4a1is independently C1-6alkyl, –OH, C1-6alkyl–OH, C1-6alkoxy, or halo; R5a is H or C1-6alkyl; R5b and R5c are each independently H, C1-6alkyl, –C1-6alkyl–OH, C2-6alkoxyalkyl, C1-6haloalkyl, –C1-6alkyl–C(O)NR5b1R5b2, –C1-6alkyl–C(O)OR5b1, C3-6cycloalkyl, C1-6alkyl–C3-6cycloalkyl, heterocycloalkyl, –C1-6alkyl– heterocycloalkyl, phenyl, –C1-6alkyl–phenyl, heteroaryl, or –C1-6alkyl–heteroaryl, wherein each heterocycloalkyl has 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and wherein each cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl is substituted with 0 to 3 R5b5; each R5b1and R5b2are independently H, C1-4alkyl, or C1-4haloalkyl; alternatively, R5b1and R5b2together with the nitrogen to which each is atached combine to form a heterocycloalkyl having 3 to 6 ring members and 0 to 1 additional heteroatoms, wherein the heterocycloalkyl is substituted with 0 to 2 R5b3; each R5b3and R5b5 is independently C1-6alkyl, halo, C1-6haloalkyl, or cyano; X6is C6-7alkylene or C6-7alkenylene;R6a is H, C1-6alkyl, C1-6deuteroalkyl, C2-6alkoxyalkyl, C3-6cycloalkyl, –C1-6alkyl– C3-6cycloalkyl, heterocycloalkyl, –C1-6alkyl–heterocycloalkyl, phenyl, –C1-6alkyl–phenyl, heteroaryl, or –C1-6alkyl–heteroaryl, wherein the heterocycloalkyl has 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and the heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S; R6band R6d are each independently H or C1-6alkyl; R7ais H or C1-6alkyl; R7band R7care each independently H, C1-6alkyl, C2-6alkenyl, C1-6haloalkyl, C1-6alkyl–OH, C3-6cycloalkyl, or –C1-6alkyl–C3-6cycloalkyl; R8a is H, C1-6alkyl, C2-6alkoxyalkyl, C3-6cycloalkyl or –C1-6alkyl–C3-6cycloalkyl; R8b, R8d, and R8e are each independently H or C1-6alkyl; ring B is C6-12 aryl or heteroaryl having 5 to 12 ring members and 1 to 6 heteroatoms, each independently N, O or S; the subscript m8 is an integer from 0 to 5; each R8fis independently C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6deuteroalkoxy, halo, C1-6haloalkyl, cyano, –X8f–cyano, C3-12cycloalkyl, –X8f–C3-6cycloalkyl, –CH=CR8f1R8f2, heterocycloalkyl, –X8f–heterocycloalkyl, C6-12aryl, –X8f–C 6-12 aryl, heteroaryl, or –X8f–heteroaryl, wherein each heterocycloalkyl has 3 to 12 ring members and 1 to 4 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 10 ring members and 1 to 4 heteroatoms, each independently N, O, or S, wherein each alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is substituted with 0 to 3 R8f3; alternatively, two R8fgroups on adjacent ring vertices combine to form a C3-6cycloalkyl or a heterocycloalkyl having 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein the cycloalkyl or heterocycloalkyl is substituted with 0 to 3 R8f3; each X8fis independently C1-6alkylene, C2-6alkenylene, –O–C1-6alkylene, C(O), O, or S; each R8f1 and R8f2 are combined with the carbon to which they are atached to form a heterocycloalkyl having 3 to 10 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein the heterocycloalkyl is substituted with 0 to 3 R8f3;each R8f3is independently C1-6alkyl, –Y8–C1-6alkyl, C1-6deuteroalkyl, –Y8–C1-6deuteroalkyl, –OH, –C1-6alkyl–OH, –Y8–C1-6alkyl–OH, –C1-6alkyl–Y8–C1-6alkyl, –(C1-2 alkyl–O)1-4–C1-2 alkyl, C1-6alkoxy, halo, C1-6haloalkyl, –Y8–C1-6haloalkyl, cyano, –C1-6alkyl–cyano, –C1-6alkyl–NR8gR8h, oxo, C3-6cycloalkyl, –X8f3–C3-6cycloalkyl, heterocycloalkyl, –X8f3– heterocycloalkyl, phenyl, –X8f3–phenyl, heteroaryl, or –X8f3–heteroaryl, wherein each heterocycloalkyl has 3 to 12 members and 1 to 4 heteroatoms, each independently N, O, S, or S(O)2, and each heteroaryl has 5 to 10 ring members and 1 to 4 heteroatoms, each independently N, O, or S, and wherein each heterocycloalkyl and heteroaryl are substituted with 0 to 2 C1-4alkyl or halo; each X8f3is independently C1-6alkylene, O, C(O), or S(O)2; each Y8 is independently C(O), C(O)O, N(R8f4)C(O), O, S, or S(O)2; each R8g and R8h is independently H, C1-3alkyl, or C1-6haloalkyl; alternatively, two R8f3groups on the same or adjacent ring vertices combine to form a C3-6cycloalkyl or a heterocycloalkyl having 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein nitrogen atom ring members in the heterocycloalkyl are substituted with 0 to 1 C1-4alkyl; and each R8f4is independently H or C1-6alkyl; or a pharmaceuticaly acceptable salt thereof.

[0041] In some embodiments, the present disclosure provides a compound of Formula (I):wherein R3is (a) C1-6alkyl, C2-6alkenyl, C2-6alkynyl, or C1-6haloalkyl, each substituted with 0 to 5 R3a, (b) C3-12cycloalkyl substituted with 0 to 5 R3b, or(c) heterocycloalkyl having 3 to 12 ring members and 1 to 4 heteroatoms, each independently N, O, or S, wherein the heterocycloalkyl is substituted with 0 to 5 R3c; each R3ais –OH, C1-6alkoxy, C1-6haloalkoxy, or –O–C(O)C1-6alkyl; each R3bis independently C1-6alkyl, C2-6alkenyl, C2-6alkynyl, –OH, C1-6alkoxy, halo, C1-6haloalkyl, C1-6haloalkoxy, or cyano; each R3cis independently C1-6alkyl, C1-6haloalkyl, C3-6cycloalkyl, or oxo; R4ais H or C1-6alkyl; R4band R4care each independently H, C1-6alkyl, C3-6cycloalkyl, –C1-6alkyl–C3-6cycloalkyl, heterocycloalkyl, –C1-6alkyl–heterocycloalkyl, phenyl, –C1-6alkyl–phenyl, heteroaryl, or –C1-6alkyl–heteroaryl, wherein each heterocycloalkyl has 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S; alternatively, R4cand R4atogether with the carbon and nitrogen to which each is atached combine to form a heterocycloalkyl having 3 to 6 ring members, wherein the heterocycloalkyl is substituted with 0 to 4 R4a1; each R4a1is independently C1-6alkyl, –OH, C1-6alkyl–OH, C1-6alkoxy, or halo; R5a is H or C1-6alkyl; R5b and R5c are each independently H, C1-6alkyl, –C1-6alkyl–OH, C2-6alkoxyalkyl, C1-6haloalkyl, C3-6cycloalkyl, C1-6alkyl–C3-6cycloalkyl, heterocycloalkyl, – C1-6alkyl–heterocycloalkyl, phenyl, –C1-6alkyl–phenyl, heteroaryl, or –C1-6alkyl–heteroaryl, wherein each heterocycloalkyl has 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and wherein each cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl is substituted with 0 to 3 R5b5; each R5b5 is independently C1-6alkyl, halo, or C1-6haloalkyl; X6is C6-7alkylene or C6-7alkenylene; R6a is H, C1-6alkyl, C2-6alkoxyalkyl, C3-6cycloalkyl, –C1-6alkyl–C3-6cycloalkyl, heterocycloalkyl, –C1-6alkyl–heterocycloalkyl, phenyl, –C1-6alkyl–phenyl, heteroaryl, or –C1-6alkyl–heteroaryl, wherein the heterocycloalkyl has 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and theheteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S; R6band R6d are each independently H or C1-6alkyl; R7ais H or C1-6alkyl; R7band R7care each independently H, C1-6alkyl, C2-6alkenyl, C1-6haloalkyl, C1-6alkyl–OH, C3-6cycloalkyl, or –C1-6alkyl–C3-6cycloalkyl; R8a is H, C1-6alkyl, C2-6alkoxyalkyl, C3-6cycloalkyl or –C1-6alkyl–C3-6cycloalkyl; R8b, R8d, and R8e are each independently H or C1-6alkyl; ring B is C 6-12 aryl or heteroaryl having 5 to 12 ring members and 1 to 6 heteroatoms, each independently N, O or S; the subscript m8 is an integer from 0 to 5; each R8fis independently C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6deuteroalkoxy, halo, C1-6haloalkyl, cyano, –X8f–cyano, C3-6cycloalkyl, –X8f–C3-6cycloalkyl, –CH=CR8f1R8f2, heterocycloalkyl, –X8f–heterocycloalkyl, C 6-12 aryl, –X8f–C 6-12 aryl, heteroaryl, or –X8f–heteroaryl, wherein each heterocycloalkyl has 3 to 12 ring members and 1 to 4 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 10 ring members and 1 to 4 heteroatoms, each independently N, O, or S, wherein each alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is substituted with 0 to 3 R8f3; alternatively, two R8fgroups on adjacent ring vertices combine to form a C3-6cycloalkyl or a heterocycloalkyl having 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein the cycloalkyl or heterocycloalkyl is substituted with 0 to 3 R8f3; each X8fis independently C1-6alkylene, C2-6alkenylene, –O–C1-6alkylene, O, or S; each R8f1 and R8f2 are combined with the carbon to which they are atached to form a heterocycloalkyl having 3 to 10 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein the heterocycloalkyl is substituted with 0 to 3 R8f3; each R8f3is independently C1-6alkyl, –Y8–C1-6alkyl, C1-6deuteroalkyl, –Y8–C1-6deuteroalkyl, –OH, –C1-6alkyl–OH, –Y8–C1-6alkyl–OH, –C1-6alkyl–Y8–C1-6alkyl, –(C1-2 alkyl–O)1-4–C1-2 alkyl, C1-6alkoxy, halo, C1-6haloalkyl, –Y8–C1-6haloalkyl, cyano, –C1-6alkyl–cyano, oxo, C3-6cycloalkyl,–X8f3–C3-6cycloalkyl, heterocycloalkyl, –X8f3– heterocycloalkyl, phenyl, – X8f3–phenyl, heteroaryl, or –X8f3–heteroaryl, wherein each heterocycloalkyl has 3 to 12 members and 1 to 4 heteroatoms, each independently N, O, S, or S(O)2, and each heteroaryl has 5 to 10 ring members and 1 to 4 heteroatoms, each independently N, O, or S, and wherein nitrogen atom ring members in each heterocycloalkyl and heteroaryl are substituted with 0 to 1 C1-4alkyl; each X8f3is independently C1-6alkylene, O, C(O), or S(O)2; each Y8 is independently C(O), C(O)O, N(R8f4)C(O), O, S, or S(O)2; alternatively, two R8f3groups on the same or adjacent ring vertices combine to form a C3-6cycloalkyl or a heterocycloalkyl having 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein nitrogen atom ring members in the heterocycloalkyl are substituted with 0 to 1 C1-4alkyl; and each R8f4is independently H or C1-6alkyl; or a pharmaceuticaly acceptable salt thereof.

[0042] In some embodiments, the present disclosure provides a compound of Formula (I):wherein R3is (a) C1-6alkyl, C2-6alkenyl, C2-6alkynyl, or C1-6haloalkyl, each substituted with 0 to 5 R3a, (b) C3-12cycloalkyl substituted with 0 to 5 R3b, or (c) heterocycloalkyl having 3 to 12 ring members and 1 to 4 heteroatoms, each independently N, O, or S, wherein the heterocycloalkyl is substituted with 0 to 5 R3c; each R3ais –OH, C1-6alkoxy, C1-6haloalkoxy, or –O–C(O)C1-6alkyl; each R3bis independently C1-6alkyl, C2-6alkenyl, C2-6alkynyl, –OH, C1-6alkoxy, halo, C1-6haloalkyl, C1-6haloalkoxy, or cyano;each R3cis independently C1-6alkyl, C1-6haloalkyl, C3-6cycloalkyl, or oxo; R4ais H or C1-6alkyl; R4band R4care each independently H, C1-6alkyl, C3-6cycloalkyl, –C1-6alkyl–C3-6cycloalkyl, heterocycloalkyl, –C1-6alkyl–heterocycloalkyl, phenyl, –C1-6alkyl–phenyl, heteroaryl, or –C1-6alkyl–heteroaryl, wherein each heterocycloalkyl has 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S; alternatively, R4cand R4atogether with the carbon and nitrogen to which each is atached combine to form a heterocycloalkyl having 3 to 6 ring members, wherein the heterocycloalkyl is substituted with 0 to 4 R4a1; each R4a1is independently C1-6alkyl, –OH, C1-6alkyl–OH, C1-6alkoxy, or halo; R5a is H or C1-6alkyl; R5b and R5c are each independently H, C1-6alkyl, –C1-6alkyl–OH, C2-6alkoxyalkyl, C1-6haloalkyl, C3-6cycloalkyl, C1-6alkyl–C3-6cycloalkyl, heterocycloalkyl, – C1-6alkyl–heterocycloalkyl, phenyl, –C1-6alkyl–phenyl, heteroaryl, or –C1-6alkyl–heteroaryl, wherein each heterocycloalkyl has 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and wherein each cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl is substituted with 0 to 3 R5b5; each R5b5 is independently C1-6alkyl, halo, or C1-6haloalkyl; X6is C6-7alkylene or C6-7alkenylene; R6a is H, C1-6alkyl, C2-6alkoxyalkyl, C3-6cycloalkyl, –C1-6alkyl–C3-6cycloalkyl, heterocycloalkyl, –C1-6alkyl–heterocycloalkyl, phenyl, –C1-6alkyl–phenyl, heteroaryl, or –C1-6alkyl–heteroaryl, wherein the heterocycloalkyl has 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and the heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S; R6band R6d are each independently H or C1-6alkyl; R7ais H or C1-6alkyl; R7band R7care each independently H, C1-6alkyl, C2-6alkenyl, C1-6haloalkyl, C1-6alkyl–OH, C3-6cycloalkyl, or –C1-6alkyl–C3-6cycloalkyl;R8a is H, C1-6alkyl, C2-6alkoxyalkyl, C3-6cycloalkyl or –C1-6alkyl–C3-6cycloalkyl; R8b, R8d, and R8e are each independently H or C1-6alkyl; ring B is aryl or heteroaryl having 5 to 12 ring members and 1 to 6 heteroatoms, each independently N, O or S; the subscript m8 is an integer from 0 to 5; each R8fis independently C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6deuteroalkoxy, halo, C1-6haloalkyl, cyano, –X8f–cyano, C3-12cycloalkyl, –X8f–C3-6cycloalkyl, –CH=CR8f1R8f2, heterocycloalkyl, –X8f–heterocycloalkyl, aryl, –X8f–aryl, heteroaryl, or –X8f–heteroaryl, wherein each heterocycloalkyl has 3 to 12 ring members and 1 to 4 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 10 ring members and 1 to 4 heteroatoms, each independently N, O, or S, wherein each alkynyl, cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl is substituted with 0 to 3 R8f3; alternatively, two R8fgroups on adjacent ring vertices combine to form a C3-6cycloalkyl or a heterocycloalkyl having 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O or S; each X8fis independently C1-6alkylene, C2-6alkenylene, O, or S; each R8f1 and R8f2 are combined with the carbon to which they are atached to form a heterocycloalkyl having 3 to 10 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein the heterocycloalkyl is substituted with 0 to 3 R8f3; each R8f3is independently C1-6alkyl, –Y8–C1-6alkyl, C1-6deuteroalkyl, –Y8–C1-6deuteroalkyl, –OH, –C1-6alkyl–OH, –Y8–C1-6alkyl–OH, –C1-6alkyl–Y8–C1-6alkyl, C1-6alkoxy, halo, C1-6haloalkyl, –Y8–C1-6haloalkyl, cyano, –C1-6alkyl–cyano, oxo, C3-6cycloalkyl, –X8f3–C3-6cycloalkyl, heterocycloalkyl, –X8f3– heterocycloalkyl, phenyl, –X8f3–phenyl, heteroaryl, or –X8f3–heteroaryl, wherein each heterocycloalkyl has 3 to 12 members and 1 to 4 heteroatoms, each independently N, O, S, or S(O)2, and each heteroaryl has 5 to 10 ring members and 1 to 4 heteroatoms, each independently N, O, or S, and wherein nitrogen atom ring members in each heterocycloalkyl and heteroaryl are substituted with 0 to 1 C1-4alkyl; each X8f3is independently C1-6alkylene, O, C(O), or S(O)2; each Y8 is independently C(O), C(O)O, N(R8f4)C(O), O, S, or S(O)2;alternatively, two R8f3groups on adjacent ring vertices combine to form a C3-6cycloalkyl or a heterocycloalkyl having 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O or S; and each R8f4is independently H or C1-6alkyl; or a pharmaceuticaly acceptable salt thereof.

[0043] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I) having the structure of Formula (Ib):

[0044] R3, R4a, R4c, R5a, R5c, R6a, X6, R6d, R8a, m8, R8f, and ring B can each independently be as defined for any embodiment of Formula (Ib) as described herein.

[0045] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I) having the structure of Formula (Ib1):

[0046] R3, R4a, R4c, R5a , R5c, R6a, X6, R6d, R8a, m8, R8f, and ring B can each independently be as defined for any embodiment of Formula (Ib1) as described herein.

[0047] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I) having the structure of Formula (Ic):

[0048] R3, R4a1, R5a , R5c, R6a, X6, R6d, R8a, m8, R8f, and ring B can each independently be as defined for any embodiment of Formula (Ic) as described herein.

[0049] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I) having the structure of Formula (Ic1):

[0050] R3, R4a1, R5a 5c 6a , R, R, X6, R6d, R8a, m8, R8f, and ring B can each independently be as defined for any embodiment of Formula (Ic1) as described herein.

[0051] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I) having the structure of Formula (Id):, wherein the dashed bond is absent or a single bond.

[0052] R3, R4al, R5a, R5c, R6a, R6d, R8a, m8, R8f, and ring B can each independently be as defined for any embodiment of Formula (Id) as described herein. When the dashed line is a single bond in Formula (Id), the wavy bond attached to the double bond indicates E, Z, or a mixture of both isomers.

[0053] In some embodiments, the compound, or the pharmaceutically acceptable salt thereof, is the compound of Formula (I) having the structure of Formula (Idl):wherein the dashed bond is absent or a single bond.

[0054] R3, R4al, R5aR5C, R6a, R6d, R8a, m8, R8f, and ring B can each independently be as defined for any embodiment of Formula (Idl) as described herein. When the dashed line is a bond in Formula (Idl), the wavy line attached to the double bond indicates E, Z, or a mixture or both linkages.Residue 3

[0055] In some embodiments, the compound, or the pharmaceutically acceptable salt thereof, is the compound of Formula (I), (lb), (Ibl), (Ic), (Icl ), (Id), or (Idl), wherein R3is (a) C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, or C1.6 haloalkyl substituted with 0 to 5 R3a. In some embodiments, the compound, or the pharmaceutically acceptable salt thereof, is the compound of Formula (I), (lb), (Ibl), (Ic), (Icl), (Id), or (Idl), wherein R3is (a) C1-6alkyl or C1-6haloalkyl substituted with 0 to 2 R3a. In some embodiments, the compound, or the pharmaceutically acceptable salt thereof, is the compound of Formula (I), (lb), (Ibl), (Ic), (Icl), (Id), or (Idl), wherein R3is (a) C1-6alkyl substituted with 0 to 2 R3a. In some embodiments, the compound, or the pharmaceutically acceptable salt thereof, is the compound of Formula (I), (lb), (Ibl), (Ic), (Icl), (Id), or (Idl), wherein R3is (a) C1-6haloalkyl substituted with 0 to 2 R3a. These embodiments of R3can be combined with any of the embodiments described herein for R3a.

[0056] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R3ais –OH or C1-6alkoxy. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R3ais –OH. These embodiments of R3acan be combined with any of the relevant embodiments described herein for R3.

[0057] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R3is (b) C3-12cycloalkyl substituted with 0 to 3 R3b. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R3is (b) C3-7 cycloalkyl substituted with 0 to 3 R3b. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R3is (b) C5-6 cycloalkyl substituted with 0 to 2 R3b. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R3is (b) C-4 cycloalkyl substituted with 0 to 2 R3b. These embodiments of R3can be combined with any of the embodiments described herein for R3b.

[0058] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R3bis halo, C1-4haloalkyl, or cyano. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R3bis halo or C1-4haloalkyl. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R3bis fluoro or trifluoromethyl. These embodiments of R3bcan be combined with any of the relevant embodiments described herein for R3.

[0059] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R3is (c) heterocycloalkyl having 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein the heterocycloalkyl is substituted with 0 to 5 R3c. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R3is (c)heterocycloalkyl having 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein the heterocycloalkyl is substituted with 0 to 2 R3c. These embodiments of R3can be combined with any of the relevant embodiments described herein for R3c.

[0060] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R3cis halo or C1-4haloalkyl. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R3cis fluoro or trifluoromethyl. These embodiments of R3ccan be combined with any of the embodiments described herein for R3.

[0061] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R3is (g) heteroaryl having 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein the heteroaryl is substituted with 0, 1, 2, 3, 4, or 5 R3g.

[0062] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R3gis independently C1-6alkyl, halo, C1-6haloalkyl, or C3-6cycloalkyl.

[0063] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R3is

[0064] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R3is

[0065] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R3is

[0066] Any of the embodiments described herein for residue 3 can be combined with any of the embodiments described herein for residues 4, 5, 6, 7, and 8. For example, any of the embodiments of R3as described herein, can be combined with any of the embodiments described herein for R4a, R4b, R4c, R5a, R5b, R5c, X6, R6a, R6b, R6d, R7a, R7b, R7c, R8a, R8b, R8d, R8e, ring B, m8, and R8f. Residue 4

[0067] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), or (Ib1), wherein R4a, R4b, and R4care each independently H or C1-6alkyl; alternatively, R4cand R4atogether with the carbon and nitrogen to which each is atached combine to form a heterocycloalkyl having 4 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein the heterocycloalkyl is substituted with 0 to 2 R4a1; and each R4a1is independently halo.

[0068] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), or (Ib1), wherein R4a, R4b, and R4care each independently H or C1-6alkyl;alternatively, R4cand R4atogether with the carbon and nitrogen to which each is atached combine to form a heterocycloalkyl having 4 to 6 ring members, wherein the heterocycloalkyl is substituted with 0 to 2 R4a1; and each R4a1is independently halo.

[0069] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), or (Ib1), wherein R4a, R4b, and R4care each independently H or C1-6alkyl.

[0070] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), or (Ib1), wherein R4bis H or C1-6alkyl; and R4cand R4atogether with the carbon and nitrogen to which each is atached combine to form a heterocycloalkyl having 4 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein the heterocycloalkyl is substituted with 0 to 3 R4a1.

[0071] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), or (Ib1), wherein R4bis H or C1-6alkyl; and R4cand R4atogether with the carbon and nitrogen to which each is atached combine to form a heterocycloalkyl having 4 to 6 ring members, wherein the heterocycloalkyl is substituted with 0 to 3 R4a1.

[0072] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), or (Ib1), wherein R4aand R4bare each H; and R4cis ethyl; alternatively, R4cand R4atogether with the carbon and nitrogen to which each is atached combine to form a pyrrolidinyl, substituted with 0 to 2 fluoro.

[0073] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), or (Ib1), wherein R4bis H; and R4cand R4atogether with the carbon and nitrogen to which each is atached combine to form a pyrolidinyl, substituted with 0 to 2 R4a1.

[0074] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), (Id1), wherein R4a1is C1-6alkyl or halo. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), (Id1), wherein R4a1is halo. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), (Id1), wherein R4a1is fluoro. These embodiments of R4a1can be combined with any of the relevant embodiments described herein for R4.

[0075] The embodiments described herein for R4a, R4band R4ccan be present in any combination. In addition, the embodiments described herein for residue 4 can be present in combination with any of the embodiments described herein for residues 3, 5, 6, 7, and 8. For example, any of the embodiments of R4a, R4band R4cas described herein, can be combined with any of the embodiments described herein for R3, R5a, R5b, R5c, X6, R6a, R6b, R6d, R7a, R7b, R7c, R8a, R8b, R8d, R8e, ring B, m8, and R8f. Residue 5

[0076] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R5a is H or C1-6alkyl; R5b and R5c are each independently H, C1-6alkyl, –C1-6alkyl–OH, C2-6alkoxyalkyl, C1-6haloalkyl, C3-6cycloalkyl, or C1-4alkyl–C3-6cycloalkyl, wherein each cycloalkyl is substituted with 0 to 3 R5b5; and each R5b5 is independently C1-4alkyl, halo, or C1-4haloalkyl.

[0077] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R5a is H or C1-6alkyl; R5b and R5c are each independently H, –C1-6alkyl–C(O)NR5b1R5b2, or –C1-6alkyl– C(O)OR5b1; each R5b1and R5b2are independently H, C1-4alkyl, or C1-4haloalkyl; alternatively, R5b1and R5b2together with the nitrogen to which each is atached combine to form a heterocycloalkyl having 3 to 6 ring members and 0 to 1 additional heteroatoms, wherein the heterocycloalkyl is substituted with 0 to 2 R5b3; andeach R5b3is independently C1-6alkyl, halo, C1-6haloalkyl, or cyanoeach R5b5 is independently C1-4alkyl, halo, or C1-4haloalkyl.

[0078] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R5a is H or C1-6alkyl; and R5b and R5c are each independently H, C1-6alkyl, C3-6cycloalkyl, C1-4alkyl–C3-6cycloalkyl.

[0079] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R5a is H or C1-6alkyl; R5b is H; and R5c is C3-6cycloalkyl or C1-4alkyl–C3-6cycloalkyl.

[0080] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R5a and R5b are each H; and R5c is H, methyl, ethyl,

[0081] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R5a and R5b are each H; and R5c is H, methyl, ethyl,, ,

[0082] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R5a is H or C1-6alkyl; R5b is H; and.

[0083] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R5a is H or C1-6alkyl; R5b is H; and.

[0084] The embodiments described herein for R5a, R5b and R5c can be present in any combination. In addition, the embodiments described herein for residue 5 can be present in combination with any of the embodiments described herein for residues 3, 4, 6, 7, and 8. For example, any of the embodiments of R5a, R5b and R5c as described herein, can be combined with any of the embodiments described herein for R3, R4a, R4b, R4c, X6, R6a, R6b, R6d, R7a, R7b, R7c, R8a, R8b, R8d, R8e, ring B, m8, and R8f. Residue 6

[0085] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), or (Ic1), wherein X6is C6-7alkylene. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), or (Ic1), wherein X6is C6-7alkenylene. These embodiments of X6can be combined with any of the embodiments described herein for R6a, R6band R6d.

[0086] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), or (Ic1), wherein X6iswherein the wavy bond atached to the double bond indicates E, Z, or a mixture of both isomers. These embodiments of X6can be combined with any of the embodiments described herein for R6a, R6band R6d.

[0087] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), or (Ic1), wherein X6is, wherein the wavy bond atached to the double bond indicates E, Z, or a mixture of both isomers. This embodiment of X6can be combined with any of the embodiments described herein for R6a, R6band R6d.

[0088] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), or (Ic1), wherein X6is. This embodiment of X6can be combined with any of the embodiments described herein for R6a, R6band R6d.

[0089] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R6a is H, C1-4alkyl, C1-4deuteroalkyl, or –C1-4alkyl–C3-6cycloalkyl; and R6band R6d are each independently H or C1-6alkyl. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R6a is H, C1-4alkyl, or –C1-4alkyl–C3-6cycloalkyl; and R6band R6d are each independently H or C1-6alkyl. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R6a is C1-4alkyl; R6bis H; and R6d is C1-4alkyl. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R6a is C1-4alkyl; and R6band R6d are each H. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R6a, R6b, and R6d are each H. These embodiments of R6a, R6band R6d can be combined with any of the embodiments described herein for X6.

[0090] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R6a is H, methyl, ethyl,; R6bis H; and R6d is H, methyl, or ethyl. This embodiment of R6a, R6band R6d can be combined with any of the embodiments described herein for X6.

[0091] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R6a is H, methyl, ethyl, or; R6bis H; and R6d is H, methyl, or ethyl. This embodiment of R6a, R6band R6d can be combined with any of the embodiments described herein for X6.

[0092] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), whereinR6a is H, methyl, ethyl, or; R6bis H; and R6d is H or methyl. This embodiment of R6a, R6band R6d can be combined with any of the embodiments described herein for X6.

[0093] The embodiments described herein for X6, R6a, R6band R6d can be present in any combination. In addition, the embodiments described herein for residue 6 can be present in combination with any of the embodiments described herein for residues 3, 4, 5, 7, and 8. For example, any of the embodiments of X6, R6a, R6band R6d as described herein, can be combined with any of the embodiments described herein for R3, R4a, R4b, R4c, R5a, R5b, R5c, R7a, R7b, R7c, R8a, R8b, R8d, R8e, ring B, m8, and R8f. Residue 7

[0094] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), wherein R7aand R7bare each independently H or C1- 6 alkyl; and R7cis C1-6alkyl, C2-6alkenyl, C1-6haloalkyl, C1-6alkyl–OH, or –C1-6alkyl–C3-6cycloalkyl.

[0095] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), wherein R7aand R7bare each independently H or C1- 6 alkyl; and R7cis C1-6alkyl or C1-6haloalkyl.

[0096] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), wherein R7aand R7bare each H; and R7cis C1-6alkyl.

[0097] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), wherein R7aand R7bare each H; and R7cis isobutyl,, , , .

[0098] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), wherein R7aand R7bare each H; and R7cis isobutyl.

[0099] The embodiments described herein for R7a, R7band R7ccan be present in any combination. In addition, the embodiments described herein for residue 7 can be present in combination with any of the embodiments described herein for residues 3, 4, 5, 6, and 8. For example, any of the embodiments of R7a, R7band R7cas described herein, can be combinedwith any of the embodiments described herein for R3, R4a, R4b, R4c, R5a, R5b, R5c, X6, R6a, R6b, R6d, R8a, R8b, R8d, R8e, ring B, m8, and R8f. Residue 8

[0100] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R8a, R8b, R8d, and R8e are each independently H or C1-6alkyl. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R8a is H or methyl; and R8b, R8d and R8e are each H. These embodiments of R8a, R8b, R8d, and R8e can be combined with any of the embodiments described herein for m8, ring B, R8f, and R8f3.

[0101] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein ring B is phenyl or heteroaryl having 5 to 6 ring members and 1 to 3 heteroatoms, wherein each heteroatom is N, O, or S. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein ring B is phenyl. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein ring B is naphthyl. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein ring B is biphenyl. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein ring B is a heteroaryl having 5 to 6 ring members and 1 to 3 heteroatoms, wherein each heteroatom is N, O, or S. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein ring B is thiophenyl. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein ring B is a heteroaryl having 5 to 6 ring members and 1 to 3 heteroatoms, wherein each heteroatom is N. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein ring B is pyridyl. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein ring B is benzofuranyl. In some embodiments, the compound, or thepharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein ring B is indolyl. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein ring B is indazolyl. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein ring B is quinolinyl. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein ring B is pyrid-3-yl. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein ring B is phenyl or pyridyl. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein ring B is phenyl or pyrid-3-yl. These embodiments of ring B can be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, R8f, and R8f3.

[0102] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein the subscript m8 is 1, 2, or 3. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein the subscript m8 is 0. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein the subscript m8 is 1. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein the subscript m8 is 2. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein the subscript m8 is 3. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein the subscript m8 is 4. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein the subscript m8 is 5. These embodiments of m8 can be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, R8f, R8f3, and ring B.

[0103] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein the moiety. These embodiments can be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, R8f, R8f3, m8 and ring B.

[0104] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein the moiety. These embodiments can be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, R8f, R8f3, m8 and ring B.

[0105] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein the moiety. These embodiments can be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, R8f, R8f3, m8 and ring B.

[0106] In some embodiments, at least one R8fis halo. In some embodiments, at least one R8fis fluoro or chloro. These embodiments of R8fcan be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, and R8f3.

[0107] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R8fis independently C1-6alkyl, C2-6alkenyl, C1-6alkoxy, C1-6deuteroalkoxy, halo, C1-6haloalkyl, cyano, or –X8f–cyano. These embodiments of R8fcan be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, and R8f3.

[0108] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R8fis independently halo, C3-6cycloalkyl, –X8f–C3-6cycloalkyl, –CH=CR8f1R8f2, heterocycloalkyl, –X8f–heterocycloalkyl, phenyl, –X8f–phenyl, heteroaryl, or –X8f–heteroaryl, wherein each heterocycloalkyl has 3 to 10 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 10 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein each cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl is substituted with 0 to 3 R8f3; each X8fis independently C1-6alkylene, C2-6alkenylene, O, or S; and each R8f1 and R8f2 are combined with the carbon to which they are atached to form a heterocycloalkyl having 3 to 10 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein the heterocycloalkyl is substituted with 0 to 3 R8f3. These embodiments of R8fcan be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, and R8f3.

[0109] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R8fis independently halo, C3-6cycloalkyl, –X8f–C3-6cycloalkyl, –CH=CR8f1R8f2, heterocycloalkyl, –X8f–heterocycloalkyl, heteroaryl, or –X8f–heteroaryl, wherein each heterocycloalkyl has 3 to 10 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 10 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein each cycloalkyl, heterocycloalkyl, and heteroaryl is substituted with 0 to 3 R8f3; each X8fis independently C1-6alkylene, C2-6alkenylene, O, or S; and each R8f1 and R8f2 are combined with the carbon to which they are atached to form a heterocycloalkyl having 3 to 10 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein the heterocycloalkyl is substituted with 0 to 3 R8f3. These embodiments of R8fcan be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, and R8f3.

[0110] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each X8fis independently C1-6alkylene. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each X8fis independently C2-6alkenylene. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each X8fis independently –O–C1-6alkylene. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each X8fis independently C(O). In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each X8fis independently O. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each X8fis independently S. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each X8fis independently C1-6alkylene or O. These embodiments of R8fcan be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, and R8f3.

[0111] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R8fis independently halo, C3-6cycloalkyl, –CH=CR8f1R8f2, heterocycloalkyl, phenyl, or heteroaryl, wherein each heterocycloalkyl has 3 to 10 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 10 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein each cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl is substituted with 0 to 3 R8f3; each R8f1 and R8f2 are combined with the carbon to which they are atached to form a heterocycloalkyl having 3 to 10 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein the heterocycloalkyl is substituted with 0 to 3 R8f3. These embodiments of R8fcan be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, and R8f3.

[0112] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R8fis independently C1-4alkyl, C2-4alkenyl, C1-4alkoxy, C1-4deuteroalkoxy, halo, C1-4haloalkyl, cyano, or –C1-2 alkyl–cyano. These embodiments of R8fcan be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, and R8f3.

[0113] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R8fis independently halo, C3-6cycloalkyl, –O–C3-6cycloalkyl, heterocycloalkyl, –C2-4alkenyl–heterocycloalkyl, –O–heterocycloalkyl, –CH=CR8f1R8f2, phenyl, –O–phenyl, heteroaryl, or –O–heteroaryl, wherein each heterocycloalkyl has 3 to 9 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 9 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein each cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl is substituted with 0 to 3 R8f3; and R8f1 and R8f2 are combined with the carbon to which they are atached to form a heterocycloalkyl having 3 to 10 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein the heterocycloalkyl is substituted with 0 to 3 R8f3. These embodiments of R8fcan be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, and R8f3.

[0114] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R8fis independently halo, C3-6cycloalkyl, –O–C3-6cycloalkyl, heterocycloalkyl, –C2-4alkenyl–heterocycloalkyl, –O–heterocycloalkyl, phenyl, –O–phenyl, heteroaryl, or –O– heteroaryl, wherein each heterocycloalkyl has 3 to 6 ring members and 1 to 2 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein each cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl is substituted with 0 to 3 R8f3. These embodiments of R8fcan be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, and R8f3.

[0115] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R8fis independently halo, C3-6cycloalkyl, –O–C3-6cycloalkyl, heteroaryl, or –O–heteroaryl, wherein each heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein each cycloalkyl, and heteroaryl is substituted with 0 to 3 R8f3. These embodiments of R8fcan be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, and R8f3.

[0116] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R8fis independently halo, heterocycloalkyl, –O–heterocycloalkyl, phenyl, or –O–phenyl, wherein each heterocycloalkyl has 3 to 6 ring members and 1 to 2 heteroatoms, each independently N, O, or S, wherein each heterocycloalkyl and phenyl is substituted with 0 to 3 R8f3. These embodiments of R8fcan be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, and R8f3.

[0117] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R8fis independently halo, heterocycloalkyl, or –O–heterocycloalkyl, wherein each heterocycloalkyl has 3 to 6 ring members and 1 to 2 heteroatoms, each independently N, O, or S, wherein each heterocycloalkyl is substituted with 0 to 3 R8f3. These embodiments of R8fcan be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, and R8f3.

[0118] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R8f3is independently C1-6alkyl, –Y8–C1-6alkyl, C1-6deuteroalky, –Y8–C1-6deuteroalkyl, –OH, –C1-6alkyl–OH, –Y8–C1-6alkyl–OH, –C1-6alkyl–Y8–C1-6alkyl, halo, C1-6haloalkyl, –Y8–C1-6haloalkyl, or oxo; each Y8 is independently C(O), C(O)O, N(R8f4)C(O), O, S, or S(O)2; and each R8f4is independently H or C1-6alkyl. These embodiments of R8f3can be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, and R8f.

[0119] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R8f3is independently C1-6alkyl, –Y8–C1-6alkyl, C1-6deuteroalky, –Y8–C1-6deuteroalkyl, –OH, –C1-6alkyl–OH, –Y8–C1-6alkyl–OH, –C1-6alkyl–Y8–C1-6alkyl, halo, C1-6haloalkyl, –Y8–C1-6haloalkyl, –C1-6alkyl–NR8gR8h, or oxo; each Y8 is independently C(O), C(O)O, N(R8f4)C(O), O, S, or S(O)2; and each R8f4is independently H or C1-6alkyl. These embodiments of R8f3can be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, and R8f.

[0120] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each each R8g and R8h is independently H, C1-3alkyl, or C1-3haloalkyl.

[0121] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each Y8 is independently –Y8–C1-6alkyl. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each Y8 is independently –Y8–methyl. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each Y8 is independently C(O). In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each Y8 is independently C(O)O. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each Y8 is independently NHC(O). In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each Y8 is independently O. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each Y8 is independently S. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each Y8 is independently S(O)2. These embodiments of Y8 can be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, R8f, and R8f3.

[0122] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R8f3is independently C1-6alkyl, C1-6deuteroalky, –OH, –C1-6alkyl–OH, halo, C1-6haloalkyl, or oxo. These embodiments of R8f3can be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, and R8f.

[0123] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R8f3is independently C1-6alkyl or –Y8–C1-6alkyl. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic),(Ic1), (Id), or (Id1), wherein each Y8 is independently a C(O) or C(O)O. These embodiments of R8f3and Y8 can be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, and R8f.

[0124] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R8f3is independently C3-6cycloalkyl, –X8f3–C3-6cycloalkyl, heterocycloalkyl, or –X8f3–heterocycloalkyl, wherein each heterocycloalkyl has 3 to 6 members and 1 to 2 heteroatoms, each independently N, O, S, or S(O)2; and each X8f3is independently C1-6alkylene, C(O), or S(O)2. These embodiments of R8f3can be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, and R8f.

[0125] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each X8f3is independently C1-6alkylene. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each X8f3is independently C(O). In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each X8f3is independently S(O)2. These embodiments of X8f3can be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, R8f, and R8f3.

[0126] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R8f3is independently C3-6cycloalkyl or heterocycloalkyl, wherein each heterocycloalkyl has 3 to 6 members and 1 to 2 heteroatoms, each independently N, O, S, or S(O)2. These embodiments of R8f3can be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, and R8f.

[0127] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein two R8f3groups on adjacent ring vertices combine to form a heterocycloalkyl having 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O or S. These embodiments of R8f3can be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, and R8f.

[0128] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R8f3is independently C1-4alkyl, C1-4alkoxy, C2-6alkoxyalkyl, –S(O)2–C1-4alkyl, –C1-4alkyl–S(O)2–C1-4alkyl, halo, C1-4haloalkyl, oxo, –C(O)–C1-4alkyl, or –C(O)O–C1-4alkyl. These embodiments of R8f3can be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, and R8f.

[0129] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein each R8f3is independently C1-4alkyl, C1-4alkoxy, C2-6alkoxyalkyl, halo, C1-4haloalkyl, oxo, – S(O)2–C1-4alkyl, –C1-4alkyl–S(O)2–C1-4alkyl,–C(O)–C1-4alkyl, –C(O)O–C1-4alkyl, C3-6cycloalkyl, –C(O)–C3-6cycloalkyl, –S(O)2–C3-6cycloalkyl, heterocycloalkyl, –C1-4alkyl– heterocycloalkyl, or –S(O)2–heterocycloalkyl, wherein each heterocycloalkyl has 4 to 6 members and 1 to 2 heteroatoms, each independently N, O, S, or S(O)2; alternatively, two R8f3groups on adjacent ring vertices combine to form a non-aromatic cyclic moiety having 3 to 6 ring members and 0 to 2 additional heteroatoms, each independently N, O or S. These embodiments of R8f3can be combined with any of the embodiments described herein for R8a, R8b, R8d, R8e, m8, ring B, and R8f.

[0130] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein m8 is 1, 2, or 3; and each R8fis independently methyl, isopropyl, isobutyl, methoxy, ethoxy, fluoro, chloro, cyano,, , , , , , , ,alternatively, ring B and three R8fgroups form the moiety, wherein the wavy line identifies atachment to the remainder of the molecule.

[0131] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein m8 is 1, 2, or 3; and each R8fis independently methyl, isopropyl, isobutyl, methoxy, ethoxy, fluoro, chloro, cyano,, , , , , ,alternatively, ring B and three R8fgroups form the moiety, , , wherein the wavy line identifies atachment to the remainder of the molecule.

[0132] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein m8 is 1, 2, or 3; and each R8fis independently methyl, isopropyl, isobutyl, methoxy, ethoxy, fluoro, chloro,alternatively, ring B and three R8fgroups form the moiety , wherein the wavy line identifies atachment to the remainder of the molecule.

[0133] The embodiments described herein for R8a, R8b, R8d, R8e, m8, R8f, and ring B can be present in any combination. In addition, the embodiments described herein for residue 8 can be present in combination with any of the embodiments described herein for residues 3, 4, 5, 6, and 7. For example, any of the embodiments of R8a, R8b, R8d, R8e, m8, R8f, and ring B as described herein, can be combined with any of the embodiments described herein for R3, R4a, R4b, R4c, R5a, R5b, R5c, X6, R6a, R6b, R6d, R7a, R7b, and R7c. Residues 3 to 8

[0134] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R3is ,, R4aand R4bare each H;R4cis ethyl; alternatively, R4cand R4atogether with the carbon and nitrogen to which each is atached combine to form a pyrolidinyl, substituted with 0 to 2 fluoro; R5a and R5b are each H; R5c is H, methyl, ethyl,X6is, , or ; R6a is H, methyl, ethyl,R6bis H; R6d is H, methyl, or ethyl; R7aand R7bare each H; R7cis isobutyl,, , , R8a is H or methyl; R8b, R8d and R8e are each H;ring B is phenyl, naphthyl, biphenyl, thiophenyl, pyridyl, benzofuranyl, indolyl, indazolyl, or quinolinyl; m8 is 1, 2, or 3; and each R8fis independently methyl, isopropyl, isobutyl, methoxy, ethoxy, fluoro, chloro, cyano,, , , , , , , ,,, , , , , , , ,, , , , , , ,; alternatively, ring B and three R8fgroups form the moietywherein the wavy line identifies atachment to the remainder of the molecule.

[0135] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R3is ,, , , , R4aand R4bare each H; R4cis ethyl; alternatively, R4cand R4atogether with the carbon and nitrogen to which each is atached combine to form a pyrolidinyl, substituted with 0 to 2 fluoro;R5a and R5b are each H; R5c is H, methyl, ethyl,X6isR6a is H, methyl, ethyl, orR6bis H; R6d is H, methyl, or ethyl; R7aand R7bare each H; R7cis isobutyl,R8a is H or methyl; R8b, R8d and R8e are each H; ring B is phenyl, biphenyl, or pyrid-3-yl; m8 is 1, 2, or 3; and each R8fis independently methyl, isopropyl, isobutyl, methoxy, ethoxy, fluoro, chloro, cyano,,alternatively, ring B and three R8fgroups form the moietywherein the wavy line identifies atachment to the remainder of the molecule.

[0136] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1), (Id), or (Id1), wherein R3is R4aand R4bare each H; R4cis ethyl; alternatively, R4cand R4atogether with the carbon and nitrogen to which each is atached combine to form a pyrolidinyl, substituted with 0 to 2 fluoro; R5a and R5b are each H; R5c is H, methyl, ethyl, X6isR6a is H, methyl, ethyl, or 6Rbis H; R6d is H or methyl; R7aand R7bare each H; R7cis isobutyl,R8a is H or methyl; R8b, R8d and R8e are each H; ring B is phenyl or pyrid-3-yl; m8 is 1, 2, or 3; and each R8fis independently methyl, isopropyl, isobutyl, methoxy, ethoxy, fluoro, chloro,,, , , , , , ,alternatively, ring B and three R8fgroups form the moiety, wherein the wavy line identifies atachment to the remainder of the molecule.

[0137] For the above embodiment, R3, R4a, R4b, R4c, R5a, R5b, R5c, X6, R6a, R6b, R6d, R7a, R7b, R7c, R8a, R8b, R8d, R8e, ring B, m8, and R8fcan each independently be as defined for any embodiment of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) as described herein.

[0138] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) having the structure of any one of Examples 1-426. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) having the structure of any one of Examples 1-389. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) having the structure of any one of Examples 1-334. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) having the structure of any one of Examples 1-50. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) having the structure of any one of Examples 51-100. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) having the structure of any one of Examples 101-150. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) having the structure of any one of Examples 151-200. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) having the structure of any one of Examples 201-250. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) having the structure of any one of Examples 251-300. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) having the structure of any one of Examples 301-334. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) having the structure of any one of Examples 335-389. In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) having the structure of any one of Examples 390-426.

[0139] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I) having the structure.

[0140] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I) having the structure.

[0141] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I) having the structure.

[0142] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I) having the structure.

[0143] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I) having the structure.

[0144] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I) having the structure.

[0145] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I) having the structure,

[0146] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I) having the structure.

[0147] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I) having the structure.

[0148] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I) having the structure.

[0149] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I) having the structure.

[0150] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I) having the structure.

[0151] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I) having the structure.

[0152] In some embodiments, the compound, or the pharmaceuticaly acceptable salt thereof, is the compound of Formula (I) having the structure.

[0153] The present disclosure includes al tautomers and stereoisomers of the compounds described herein, either in admixture or in pure or substantialy pure form. The compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) can have asymmetric centers at one or more carbon atoms, and therefore compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) can exist in diastereomeric or enantiomeric forms or mixtures thereof. Al conformational isomers (e.g., cis and trans isomers) and al optical isomers (e.g., enantiomers and diastereomers), racemic, diastereomeric and other mixtures of such isomers, as wel as solvates, hydrates, and tautomers are within the scope of the present disclosure. Compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) can be prepared using diastereomers,enantiomers or racemic mixtures as starting materials. Furthermore, diastereomer and enantiomer products can be separated by chromatography, fractional crystalization or other methods known to those of skil in the art. Unless otherwise indicated, when a stereochemical depiction is shown, it is meant that the isomer with the depicted stereochemistry is present and substantialy free of the other isomer(s). “Substantialy free of” another isomer indicates at least an 80 / 20 ratio of the two isomers, more preferably 90 / 10, or 95 / 5 or more. When a structure includes a wavy bond atached to a double bond, this indicates E, Z, or a mixture of both isomers.

[0154] The compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) can also be in the salt forms, such as acid or base salts of the compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1). Ilustrative examples of pharmaceuticaly acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, and the like) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid and the like) salts, quaternary ammonium (methyl iodide, ethyl iodide, and the like) salts. It is understood that the pharmaceuticaly acceptable salts are non-toxic. Additional information on suitable pharmaceuticaly acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, which is incorporated herein by reference.

[0155] Pharmaceuticaly acceptable salts of the acidic compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) are salts formed with bases, namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, as wel as ammonium salts, such as ammonium, trimethyl-ammonium, diethylammonium, and tris-(hydroxymethyl)-methyl-ammonium salts.

[0156] Similarly acid addition salts, such as of mineral acids, organic carboxylic and organic sulfonic acids, e.g., hydrochloric acid, methanesulfonic acid, maleic acid, are also possible provided a basic group, such as pyridyl, constitutes part of the structure.

[0157] The neutral forms of the compounds can be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound difers from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present disclosure.

[0158] The present disclosure also includes isotopicaly-labeled compounds of Formula(I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1), wherein one or more atoms are replaced by one or more atoms having specific atomic mass or mass numbers. Examples of isotopes that can be incorporated into compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) include, but are not limited to, isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, sulfur, and chlorine (such as2H,3H,13C,14C,15N,18O,17O,18F,35S and36Cl). Isotopicaly-labeled compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) can be useful in assays of the tissue distribution of the compounds and their prodrugs and metabolites; preferred isotopes for such assays include3H and14C. In addition, in certain circumstances substitution with heavier isotopes, such as deuterium (2H), can provide increased metabolic stability, which ofers therapeutic advantages such as increased in vivo half-life or reduced dosage requirements. Isotopicaly-labeled compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) can generaly be prepared according to methods known in the art. IV. Compositions

[0159] The compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) described herein are useful in the manufacture of a pharmaceutical composition or a medicament for modulating one or more cyclins (e.g. cyclin A, cyclin B, cycline E). In some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound of the present disclosure, and a pharmaceuticaly acceptable excipient. In some embodiments, a pharmaceutical composition or medicament comprising one or more compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) can be administered to a subject for the treatment of a cancer.

[0160] Pharmaceutical compositions or medicaments for use in the present disclosure can be formulated by standard techniques or methods wel-known in the art of pharmacy using one or more physiologicaly acceptable cariers or excipients. Suitable pharmaceutical cariers are described herein and in, e.g., “Remington’s Pharmaceutical Sciences” by E.W. Martin. Compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) and their physiologicaly acceptable salts and solvates can be formulated for administration by any suitable route, including, but not limited to, oraly, topicaly, nasaly, rectaly, pulmonary, parenteraly (e.g., intravenously, subcutaneously, intramuscularly, etc.), and combinations thereof. In some embodiments, the compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) is dissolved in a liquid, for example, water. The most suitable route of administrationfor a compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) in any given case wil depend, in part, on the nature, severity, and optionaly, and the stage of the cancer.

[0161] The pharmaceutical compositions or medicaments of the present disclosure can include a compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) with as an active ingredient and a pharmaceuticaly acceptable carrier and / or excipient or diluent. Any carrier and / or excipient suitable for the form of preparation desired for administration is contemplated for use with the compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) disclosed herein.

[0162] In some embodiments, the pharmaceutical compositions or medicaments described herein are suitable for systemic administration. Systemic administration includes enteral administration (e.g., absorption of the compound through the gastrointestinal tract) or parenteral administration (e.g., injection, infusion, or implantation). In some embodiments, the pharmaceutical compositions or medicaments can be administered via a syringe or intravenously. In preferred embodiments, the pharmaceutical compositions or medicaments are injected subcutaneously.

[0163] For oral administration, a pharmaceutical composition or a medicament can take the form of, e.g., a tablet or a capsule prepared by conventional means with a pharmaceuticaly acceptable excipient. Prefered are tablets and gelatin capsules comprising the active ingredient(s), together with (a) diluents or filers, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, celulose (e.g., ethyl celulose, microcrystaline celulose), glycine, pectin, polyacrylates and / or calcium hydrogen phosphate, calcium sulfate, (b) lubricants, e.g., silica, anhydrous coloidal silica, talcum, stearic acid, its magnesium or calcium salt (e.g., magnesium stearate or calcium stearate), metalic stearates, coloidal silicon dioxide, hydrogenated vegetable oil, corn starch, sodium benzoate, sodium acetate and / or polyethyleneglycol; for tablets also (c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcelulose, sodium carboxymethylcelulose, polyvinylpyrolidone and / or hydroxypropyl methylcelulose; if desired (d) disintegrants, e.g., starches (e.g., potato starch or sodium starch), glycolate, agar, alginic acid or its sodium salt, or efervescent mixtures; (e) weting agents, e.g., sodium lauryl sulfate, and / or (f) absorbents, colorants, flavors and sweeteners. In some embodiments, the tablet contains a mixture of hydroxypropyl methylcelulose, polyethyleneglycol 6000 and titatium dioxide. Tablets can be either film coated or enteric coated according to methods known in the art.

[0164] Liquid preparations for oral administration can take the form of, for example, solutions, syrups, or suspensions, or they can be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations can be prepared by conventional means with pharmaceuticaly acceptable additives, for example, suspending agents, for example, sorbitol syrup, celulose derivatives, or hydrogenated edible fats; emulsifying agents, for example, lecithin or acacia; non-aqueous vehicles, for example, almond oil, oily esters, ethyl alcohol, or fractionated vegetable oils; and preservatives, for example, methyl or propyl-p-hydroxybenzoates or sorbic acid. The preparations can also contain bufer salts, flavoring, coloring, and / or sweetening agents as appropriate. If desired, preparations for oral administration can be suitably formulated to give controled release of the active compound.

[0165] Typical formulations for topical administration include creams, ointments, sprays, lotions, and patches. The pharmaceutical composition can, however, be formulated for any type of administration, e.g., intradermal, subdermal, intravenous, intramuscular, intranasal, intracerebral, intratracheal, intraarterial, intraperitoneal, intravesical, intrapleural, intracoronary or intratumoral injection, with a syringe or other devices. Formulation for administration by inhalation (e.g., aerosol), or for oral, rectal, or vaginal administration is also contemplated.

[0166] Pharmaceutical compositions for pulmonary administration include, but are not limited to, dry powder compositions consisting of the powder of a compound described herein, or a salt thereof, and the powder of a suitable carrier and / or lubricant. The compositions for pulmonary administration can be inhaled from any suitable dry powder inhaler device known to a person skiled in the art. In certain instances, the compositions can be conveniently delivered in the form of an aerosol spray from pressurized packs or a nebulizer, with the use of a suitable propelant, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, for example, gelatin for use in an inhaler or insuflator can be formulated containing a powder mix of the compound(s) and a suitable powder base, for example, lactose or starch.

[0167] The compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) can also be formulated in rectal compositions, for example, suppositories or retention enemas, forexample, containing conventional suppository bases, for example, cocoa buter or other glycerides.

[0168] The compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) set forth herein can be formulated for parenteral administration by injection, for example by bolus injection. Formulations for injection can be presented in unit dosage form, for example, in ampoules or in multi-dose containers, with an added preservative. Injectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are preferably prepared from faty emulsions or suspensions. The compositions can be sterilized and / or contain adjuvants, such as preserving, stabilizing, weting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and / or bufers. Alternatively, the compound(s) can be in powder form for reconstitution with a suitable vehicle, for example, sterile pyrogen-free water, before use. In addition, they may also contain other therapeuticaly valuable substances. The compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1 to 75%, preferably about 1 to 50%, of the compound(s).

[0169] In some embodiments, the compositions described herein are prepared with a polysaccharide such as chitosan or derivatives thereof (e.g., chitosan succinate, chitosan phthalate, etc.), pectin and derivatives thereof (e.g., amidated pectin, calcium pectinate, etc.), chondroitin and derivatives thereof (e.g., chondroitin sulfate), and alginates.

[0170] In some embodiments, the compositions described herein further include a pharmaceutical surfactant. In other embodiments, the compositions further include a cryoprotectant. Non-limiting examples of cryoprotectants include glucose, sucrose, trehalose, lactose, sodium glutamate, PVP, cyclodextrin, 2-hydroxypropyl-13-cyclodextrin (HPI3CD) glycerol, maltose, mannitol, saccharose, and mixtures thereof. V. Methods

[0171] The present disclosure contemplates the use of the compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) described herein in the treatment or prevention of diseases or disorders modulated, at least in part, by one or more cyclins. In some embodiments, the cyclin mediated disease is a proliferative condition or disorder, including cancer. In some embodiments, the present disclosure provides a method of treating a cancer mediated at least in part by cyclin activity, the method comprising administering to a subject in need there of, atherapeuticaly efective amount of a compound of the present disclosure, or a pharmaceuticaly acceptable salt thereof, or a pharmaceutical composition of the present disclosure, thereby treating the cancer.

[0172] In some embodiments, provided herein are compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) for use in therapy.

[0173] The present disclosure contemplates the use of the compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) described herein in the treatment or prevention of diseases or disorders modulated, at least in part, by cyclin A. In some embodiments, the cyclin A mediated disease is a proliferative condition or disorder, including cancer. In some embodiments, the present disclosure provides a method of treating a cancer mediated at least in part by cyclin A, the method comprising administering to a subject in need there of, a therapeuticaly efective amount of a compound of the present disclosure, or a pharmaceuticaly acceptable salt thereof, or a pharmaceutical composition of the present disclosure, thereby treating the cancer.

[0174] In some embodiments, provided herein are methods of treating a proliferative condition or disorder mediated at least in part by cyclin A comprising administering a compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) described herein.

[0175] In some embodiments, provided herein are compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) for use in a method for treating a proliferative condition or disorder mediated at least in part by cyclin A.

[0176] In some embodiments, provided herein are uses of compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) for the manufacture of a medicament for the treatment of a proliferative condition or disorder mediated at least in part by cyclin A.

[0177] The present disclosure contemplates the use of the compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) described herein in the treatment or prevention of diseases or disorders modulated, at least in part, by cyclin B. In some embodiments, the cyclin B mediated disease is a proliferative condition or disorder, including cancer. In some embodiments, the present disclosure provides a method of treating a cancer mediated at least in part by cyclin B, the method comprising administering to a subject in need there of, a therapeuticaly efective amount of a compound of the present disclosure, or apharmaceuticaly acceptable salt thereof, or a pharmaceutical composition of the present disclosure, thereby treating the cancer.

[0178] In some embodiments, provided herein are methods of treating a proliferative condition or disorder mediated at least in part by cyclin B comprising administering a compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) described herein.

[0179] In some embodiments, provided herein are compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) for use in a method for treating a proliferative condition or disorder mediated at least in part by cyclin B.

[0180] In some embodiments, provided herein are uses of compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) for the manufacture of a medicament for the treatment of a proliferative condition or disorder mediated at least in part by cyclin B.

[0181] The present disclosure contemplates the use of the compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) described herein in the treatment or prevention of diseases or disorders modulated, at least in part, by cyclin E. In some embodiments, the cyclin E mediated disease is a proliferative condition or disorder, including cancer. In some embodiments, the present disclosure provides a method of treating a cancer mediated at least in part by cyclin E, the method comprising administering to a subject in need there of, a therapeuticaly efective amount of a compound of the present disclosure, or a pharmaceuticaly acceptable salt thereof, or a pharmaceutical composition of the present disclosure, thereby treating the cancer.

[0182] In some embodiments, provided herein are methods of treating a proliferative condition or disorder mediated at least in part by cyclin E comprising administering a compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) described herein.

[0183] In some embodiments, provided herein are compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) for use in a method for treating a proliferative condition or disorder mediated at least in part by cyclin E.

[0184] In some embodiments, provided herein are uses of compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) for the manufacture of a medicament for the treatment of a proliferative condition or disorder mediated at least in part by cyclin E.

[0185] In some embodiments, the compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) described herein can be used to treat or prevent a proliferative condition or disorder, including a cancer, for example, cancer of the uterus, cervix, breast, prostate, testes, gastrointestinal tract (e.g., esophagus, oropharynx, stomach, smal or large intestines, colon, or rectum), kidney, renal cel, bladder, bone, bone marow, skin, head or neck, liver, gal bladder, bile ducts, heart, lung (e.g., non-smal-cel lung carcinoma, smal cel lung cancer), pancreas, salivary gland, adrenal gland, thyroid, brain, ganglia, central nervous system (CNS) and peripheral nervous system (PNS), and cancers of the hematopoietic system and the immune system (e.g., spleen or thymus).

[0186] The present disclosure also provides methods of treating or preventing other cancer- related diseases, disorders or conditions, including, for example, virus-induced cancers (e.g., epithelial cel cancers, endothelial cel cancers, squamous cel carcinomas and papilomavirus), adenocarcinomas, lymphomas, carcinomas, melanomas, leukemias, myelomas, sarcomas, teratocarcinomas, chemicaly-induced cancers, metastasis, and angiogenesis.

[0187] In some embodiments, the tumor or cancer is colon cancer, ovarian cancer, breast cancer, melanoma, lung cancer, glioblastoma, or leukemia.

[0188] In some embodiments, the tumor or cancer is smal cel lung cancer (SCLC).

[0189] The use of the term(s) cancer-related diseases, disorders and conditions is meant to refer broadly to conditions that are associated, directly or indirectly, with cancer, and includes, e.g., angiogenesis and precancerous conditions such as dysplasia.

[0190] In some embodiments, the cancer is a blood cancer (e.g., leukemia, lymphoma, multiple myeloma).

[0191] In some embodiments, the leukemia is acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, or hairy cel leukemia.

[0192] In some embodiments, the lymphoma is non-Hodgkin's lymphoma, Hodgkin's lymphoma, B-cel lymphoma, or Burkit's lymphoma.

[0193] In some embodiments, the cancer is an Rb mutated cancer. In some embodiments, the cancer has a mutation in the Rb / E2F pathway.VI. Administration

[0194] The present disclosure contemplates the administration of compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) and compositions thereof, in any appropriate manner. Suitable routes of administration include oral, parenteral (e.g., intramuscular, intravenous, subcutaneous (e.g., injection or implant), intraperitoneal, intracisternal, intraarticular, intraperitoneal, intracerebral (intraparenchymal) and intracerebroventricular), nasal, vaginal, sublingual, intraocular, rectal, topical (e.g., transdermal), buccal and inhalation.

[0195] Pharmaceutical compositions comprising compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) are preferably in unit dosage form. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

[0196] Compounds of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) or pharmaceutical compositions or medicaments thereof can be administered to a subject diagnosed or suspected of having a disease or disorder mediated at least in part by cyclin A in an amount suficient to elicit an efective therapeutic response in the subject.

[0197] The dosage of compounds administered is dependent on a variety of factors including the subject’s body weight, age, individual condition, and / or on the form of administration. The size of the dose wil also be determined by the existence, nature, and extent of any adverse efects that accompany the administration of a particular compound in a particular subject. Typicaly, a dosage of the active compounds is a dosage that is suficient to achieve the desired efect. Optimal dosing schedules can be calculated from measurements of compound accumulation in the body of a subject. In general, dosage can be given once or more daily, weekly, or monthly. Persons of ordinary skil in the art can easily determine optimum dosages, dosing methodologies, and repetition rates.

[0198] In some embodiments, a unit dosage for oral administration of a compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) described herein to a subject (e.g., a human) of about 50 to about 70 kg may contain between about 1 and about 5,000 mg, about 1 and about 3,000 mg, about 1 and about 2,000 mg, or about 1 to about 1,000 mg of the compound(s).

[0199] In some embodiments, a unit dosage for subcutaneous administration of a compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) described herein to a subject (e.g., human) of about 50 to about 70 kg may contain between about 0.1 and about 500 mg, about 0.5 and about 300 mg, about 0.5 and about 200 mg, about 0.5 and about 100 mg, or about 0.5 and about 50 mg.

[0200] The dose can be administered once per day or divided into sub-doses and administered in multiple doses, e.g., twice, three times, or four times per day. However, as wil be appreciated by a skiled artisan, depending on the route of administration diferent amounts can be administered at different times.

[0201] In some embodiments, the compounds are administered for about 1 to 31 days, or for about 1 to 12 months. In some embodiments, the compounds are administered for one or more weeks, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or more weeks. In some embodiments, the compounds are administered for one or more months, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more months.

[0202] Optimum dosages, toxicity, and therapeutic efficacy of such compounds may vary depending on the relative potency of individual compounds and can be determined by standard pharmaceutical procedures in experimental animals, for example, by determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeuticaly efective in 50% of the population). The dose ratio between toxic and therapeutic efects is the therapeutic index and can be expressed as the ratio, LD50 / ED50. Compounds that exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side-efects can be used, care should be taken to design a delivery system that targets such compounds to the afected site to minimize potential damage to normal cels and, thereby, reduce side-efects.

[0203] The dosage of a pharmaceutical composition or medicament of the present disclosure can be monitored and adjusted throughout treatment, depending on severity of symptoms, frequency of recurrence, and / or the physiological response to the therapeutic regimen. Those of skil in the art commonly engage in such adjustments in therapeutic regimens.

[0204] Single or multiple administrations of the pharmaceutical compositions or medicaments can be administered depending on the dosage and frequency as required and tolerated by the patient. In any event, the composition or medicament should provide a suficient quantity of the compounds of the disclosure to efectively treat the patient.Generaly, when treating cancer, the dose is sufficient to stop tumor growth or cause tumor regression without producing unacceptable toxicity or side-effects to the patient. VII. Intermediates

[0205] In some embodiments, the present disclosure provides intermediates useful in the preparation of compounds of Formula (I). Certain intermediates useful in the preparation of a compound of Formula (I) can be found, for example, in the Examples section of the curent disclosure.

[0206] In some embodiments, the intermediate is an External Building Block described herein. In some embodiments the intermediate is a compound produced in one of Methods A-D or Methods 1-14 for any one of the compounds exemplified herein. In some embodiments, the intermediate is one of Int.1-438. In some embodiments, the intermediate is one of Int.1-405. In some embodiments, the intermediate is one of Int.1-154.

[0207] In some embodiments, the intermediate is Int.7

[0208] In some embodiments, the intermediate is Int.30

[0209] In some embodiments, the intermediate is Int.142

[0210] In some embodiments, the intermediate is a combination of one or more convalently linked External Building Blocks. VIII. Kits

[0211] The present disclosure contemplates kits comprising a compound of Formula (I), (Ib), (Ib1), (Ic), (Ic1) (Id), or (Id1) described herein described herein, and pharmaceutical compositions thereof. The kits are generaly in the form of a physical structure housing various components, as described below, and can be utilized, for example, in practicing the methods described above.

[0212] A kit can include one or more of the compounds disclosed herein (provided in, e.g., a sterile container), which may be in the form of a pharmaceutical composition suitable for administration to a subject. The compounds described herein can be provided in a form that is ready for use (e.g., a tablet, capsule, syringe) or in a form requiring, for example, reconstitution or dilution (e.g., a powder) prior to administration. When the compounds described herein are in a form that needs to be reconstituted or diluted by a user, the kit may also include diluents (e.g., sterile water), bufers, pharmaceuticaly acceptable excipients, and the like, packaged with or separately from the compounds described herein. Each component of the kit can be enclosed within an individual container, and al of the various containers can be within a single package. A kit of the present disclosure can be designed for conditions necessary to properly maintain the components housed therein (e.g., refrigeration or freezing).

[0213] A kit may contain a label or packaging insert including identifying information for the components therein and instructions for their use (e.g., dosing parameters, clinical pharmacology of the active ingredient(s), including mechanism of action, pharmacokinetics and pharmacodynamics, adverse efects, contraindications, etc.). Labels or inserts can include manufacturer information such as lot numbers and expiration dates. The label or packaging insert may be, e.g., integrated into the physical structure housing the components,contained separately within the physical structure, or afixed to a component of the kit (e.g., an ampule, tube or vial).

[0214] Labels or inserts can additionaly include, or be incorporated into, a computer readable medium, such as a disk (e.g., hard disk, card, memory disk), optical disk such as CD- or DVD-ROM / RAM, DVD, MP3, magnetic tape, or an electrical storage media such as RAM and ROM or hybrids of these such as magnetic / optical storage media, FLASH media or memory-type cards. In some embodiments, the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g., via the internet, are provided. IX. Examples

[0215] The folowing examples ilustrate how various intermediates and exemplary compounds of Formula (I) are prepared. The folowing examples are ofered to ilustrate, but not to limit the curent disclosure. A. External Building Blocks

[0216] The compounds of Formula (I) described herein are prepared by covalently linking the external building blocks described in this section. The external building blocks of the present disclosure are identified in Table 1, below, by intermediate number (INT #), IUPAC name, and CAS number, if known. For those without a CAS number, an experimental write- up is provided herein. The order and details related to covalently linking these external building blocks are described in another section. Table 1: External Building Blocks of the Present Disclosure86Int.6: Preparation of (S)-2-(tert-butoxycarbonyl)(methyl)amino)-3-(2,5- dichlorophenyl)propanoic acidStep 1: Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-(2,5-dichlorophenyl)propanoate:

[0217] To a stired mixture of Zn (29.95 g, 458.06 mmol, 2.5 eq) and TMSCl (1.33 g, 12.28 mmol, 0.067 eq) in DMA was added methyl (2R)-2-[(tert-butoxycarbonyl)amino]-3- iodopropanoate (1.03 g, 3.11 mmol, 1.7 eq) dropwise below 45 ℃ under nitrogen atmosphere. The resulting mixture was stired for 16 h at rt under nitrogen atmosphere. The above mixture was added into a solution of 1,4- dichloro-2-iodo-benzene (50 g, 183.22 mmol, 1 eq), CuI (6.96 g, 36.64 mmol, 0.2 eq) and Pd(dppf)Cl2.CH2Cl2 (14.93 g, 18.32 mmol, 0.10 eq) at rt under nitrogen. The resulting mixture was stired for additional 16 h at 85 ℃. Desired product could be detected by LCMS. The reaction was quenched by the addition of water (1.5 L) at rt. The aqueous layer was extracted with EtOAc (3 x 500 mL). The combined organics were washed with (5 x 300 mL) of water and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (25:1) to aford methyl (2S)-2-[(tert- butoxycarbonyl)amino]-3-(2,5-dichlorophenyl)propanoate (40 g, 63 %) as a white solid. LCMS (ESI+): m / z 292.15 (M-56+).1H NMR (300 MHz, DMSO-d6): δ 1.11 – 1.47 (m, 12H), 2.89 (dd, 1H), 3.22 (dd, 1H), 3.64 (d, 4H), 3.91 – 4.37 (m, 1H), 6.87 – 7.89 (m, 4H). Step 2: Methyl (2S)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-(2,5- dichlorophenyl)propanoate:

[0218] To a stired solution of methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-(2,5- dichlorophenyl)propanoate (200 mg, 0.574 mmol, 1 eq) and methyl iodide (214.00 g, 1507.67 mmol, 15 eq) in DMF (350 mL) was added (argentiooxy)silver (93.17 g, 402.04 mmol, 4 eq) in portions at 25 ℃ under nitrogen atmosphere. The reaction mixture was stired for 16 h at 25 ℃. Desired product could be detected by LCMS. The resulting mixture was filtered, the filter cake was washed with EtOAc (3 x 100 mL). The filtrate was diluted water(500 mL) and extracted with EtOAc (3 x 300 mL). The combined organic layers were washed with water (4 x 200 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.05% TFA), 10% to 50% gradient in 10 min; detector, UV 220 nm. This resulted in methyl (2S)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-(2,5- dichlorophenyl)propanoate as a white solid. LCMS (ESI+): m / z 262.20 (M+Na+). Step 3: Int.6:

[0219] A solution of methyl (2S)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-(2,5- dichlorophenyl)propanoate (35 g, 96.62 mmol, 1 eq) and LiOH (4.63 g, 193.24 mmol, 2 eq) in THF (500 mL) / H2O (300 mg) was stired for 16 h at 25 ℃. Desired product could be detected by LCMS. The mixture was acidified to pH=4 with diluted HCl (aq.). The aqueous layer was extracted with EtOAc (3 x 500 mL). The combined organics was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% FA), 10% to 50% gradient in 10 min; detector, UV 220 nm. This resulted in Int.6 (25.26 g, 75.07%) as a light-yelow solid. LCMS (ESI+): m / z 346.00 (M-H-).1H NMR (400 MHz, DMSO-d6): δ 1.23 (d, 9H), 2.66 (d, 3H), 3.06 – 3.39 (m, 2H), 7.24 – 7.56 (m, 3H), 13.00 (s, 1H). Int.7: Preparation of (S)-2-(tert-butoxycarbonyl)(methyl)amino)-3-(5-chloro-2- cyclopropoxypyridin-3-yl)propanoic acidStep 1: 3-Bromo-5-chloro-2-cyclopropoxypyridine:

[0220] Into a 1000 mL round-botom flask were added 3-bromo-5-chloro-2-fluoropyridine (50 g, 237.61 mmol, 1 eq) in DMF (400 mL), Cs2CO3(232.97 g, 712.83 mmol, 3 eq) was added at rt under nitrogen atmosphere. The mixture was stired at rt for 50 min. cyclopropanol (9.94 g, 171.08 mmol, 1.2 eq) was added dropwise over 2 min at rt. The resulting mixture was stired at 80 °C for 16 h. The reaction was quenched with ice-water (700 mL) and extracted with EA (3 x 100 mL). The organic layer combined and washed with brine (300 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (0~20%).This resulted in 3-bromo-5-chloro-2-cyclopropoxypyridine (40 g, 68 %) as a colorless oil. LCMS (ESI+): m / z 249.95.1HNMR (400 MHz, DMSO-d6) δ 0.76 (ddd, J = 5.7, 4.5, 3.1 Hz, 2H) ,0.96 – 0.78 (m, 2H), 4.32 (t, J = 6.4, 3.1 Hz, 1H), 8.17 (d, J = 2.5 Hz, 1H), 8.26 (d, J = 2.4 Hz, 1H). Step 2: Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-(5-chloro-2-cyclopropoxypyridin- 3-yl)propanoate:

[0221] To a mixture of Zn (26.84 g, 410.46 mmol, 1.7 eq) in DMA (135 mL) was added 1,2-dibromoethane (6.80 g, 36.22 mmol, 0.15 eq) in one portion under N2. Then chlorotrimethylsilane (2.62 g, 24.15 mmol, 0.1 eq) was added slowly and the mixture was stired for 30 min at 25oC. A solution of methyl 2-[(tert-butoxycarbonyl)amino]-3- iodopropanoate (95.36 g, 289.74 mmol, 1.2 eq) in DMA (135mL) was added dropwise slowly (60 min) to maintain temperature below 50oC, the resulting mixture was stired at rt for 2 h and then added 1000 mL 3-necked round-botom flask a cannula to a solution of 3- bromo-5-chloro-2-cyclopropoxypyridine (60 g, 241.45 mmol, 1 eq), Pd(dppf)Cl2.CH2Cl2 (19.67 g, 24.14 mmol, 0.1 eq) and CuI (9.20 g, 48.29 mmol, 0.2 eq) in DMA (135 ml) under N, the color of the mixtur o 2 e turned brown, then the mixture was heated and stired at 80Cfor 2 h under N2. The mixture was quenched with ice-water (700 ml) and extracted with EA (3 x 500 ml). The organic layer was combined and washed with brine (300 ml), dried with anhydrous Na2SO4, filtered, and concentrated in vacuum to give the crude product. The crude product was purified by silica gel chromatography eluted with PE / EA (0~50%) to aford methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-(5-chloro-2-cyclopropoxypyridin-3- yl)propanoate (30 g, 34 %) as a white solid. LCMS (ESI+): m / z 371.10. Step 3: Methyl (2S)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-(5-chloro-2- cyclopropoxypyridin-3-yl)propanoate:

[0222] Into a 1000 mL round-botom flask were added methyl (2S)-2-[(tert- butoxycarbonyl)amino]-3-(5-chloro-2-cyclopropoxypyridin-3-yl)propanoate (25 g, 67.42 mmol, 1 eq) in DMF (400 mL), Ag2O (78.11 g, 337.08 mmol, 5 eq) was added at 0 °C under nitrogen atmosphere. The mixture was stired at 0 °C for 30 min, CH3I (95.69 g, 674.16 mmol, 10 eq) was added dropwise over 2 min at 0 °C. The resulting mixture was stired at rt for 16 h. The reaction was quenched with ice-water (500 mL) and extracted with EtOAc (3 x 500 mL). The organic layer was combined and washed with brine (300 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (7:1) to aford methyl (2S)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-(5-chloro-2- cyclopropoxypyridin-3-yl)propanoate (22 g, 85 %) as a colorless oil. LCMS (ESI+): m / z 385.10.1H NMR (400 MHz, DMSO-d6) δ 0.83 – 0.62(m, 2H), 1.19 (t, J = 7.1 Hz, 2H), 1.28 (s, 9H), 2.65 (d, J = 3.3 Hz, 3H), 2.95 (dd, J = 13.6, 10.4 Hz, 1H), 3.07(ddd, J = 14.2, 4.9, 1.9 Hz, 2H), 3.73 – 3.61 (m, 3H), 4.69 (dd, J = 10.5, 4.6 Hz, 1H), 8.12 (dd, J = 17.7, 2.6 Hz, 2H). Step 4: Int.7:

[0223] Into a 1000 mL round-botom flask were added methyl (2S)-2-[(tert- butoxycarbonyl)(methyl)amino]-3-(5-chloro-2-cyclopropoxypyridin-3-yl)propanoate (20 g, 51.97 mmol, 1 eq) in THF (250 ml) and NaOH (10.39 g, 259.84 mmol, 5 eq) in water (50 ml) was added dropwise at 0 °C under nitrogen atmosphere. The resulting mixture was stired at rt for 2 h. The solvent was removed by reduce pressure and the residue was purified by reverse flash chromatography with the folowing conditions: column, C18; mobile phase, ACN in water (0.5% FA), 0% to 100% gradient in 40 min; detector, UV 254 nm. This resulted in Int.7 (13.95 g, 72%) as a yelow oil. LCMS (ESI+): m / z 371.00.1H NMR (400 MHz, DMSO-d6) δ 0.79 – 0.61 (m, 4H), 1.21 (s, 9H), 2.95 – 2.84 (m, 2H), 3.00 (s, 3H), 3.09 – 3.01 (m, 1H), 4.86 (dd, J = 11.3, 4.6 Hz, 1H), 7.67 (d, J = 2.6 Hz, 1H), 8.11 (dd, J = 18.4, 2.6 Hz, 1H). Int.8: Preparation of (S)-2-(tert-butoxycarbonyl)(methyl)amino)-3-(5-chloro-2-(5- methyl-1,3,4-oxadiazol-2-yl)phenyl)propanoic acidStep 1: 4-chloro-2-iodobenzohydrazide:

[0224] Into a stirred mixture of 4-chloro-2-iodobenzoic acid (10 g, 35.40 mmol, 1 eq) and 2-methylpropyl carbonochloridate (4.84 g, 35.40 mmol, 1 eq) in THF (100mL) were added TEA (10.75 g, 106.21 mmol, 3 eq) and hydrazine (5.67 g, 177.02 mmol, 5 eq) dropwise at 0 ℃ under nitrogen atmosphere. The resulting mixture was stired for an additional 4 h at rt. Desired product could be detected by LCMS. The resulting mixture was diluted with water (100 mL). The resulting mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with 0.5N HCl solution (3 x 50 mL). The combined aqueous layers were basified to pH 8 with NaOH (0.5N). The resulting mixturewas extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in water (0.1% FA), 5% to 100% gradient in 30 min; detector, UV 254 nm. This resulted in 4-chloro-2-iodobenzohydrazide (7.5 g, 72 %) as a white solid. LCMS (ESI+): m / z 296.90 (M+H+). Step 2: 2-(4-chloro-2-iodophenyl)-5-methyl-1,3,4-oxadiazole:

[0225] Into a 200 mL vial were added 4-chloro-2-iodobenzohydrazide (8 g, 26.98 mmol, 1 eq) and triethyl orthoacetate (80 mL) at rt. The resulting mixture was stired overnight at 140 ℃. Desired product could be detected by LCMS. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in water (0.1% TFA), 5% to 100% gradient in 30 min; detector, UV 254 nm. This resulted in 2-(4-chloro-2-iodophenyl)-5-methyl-1,3,4-oxadiazole (10.2 g, 118 %) as a yelow solid. LCMS (ESI+): m / z 320.85 (M+H+). Step 3: methyl (2S)-2-[(tert-butoxycarbonyl) amino]-3-[5-chloro-2-(5-methyl-1,3,4- oxadiazol-2-yl) phenyl] propanoate:

[0226] Into a stirred solution of in Zn (3.84 g, 58.73 mmol, 2 eq) DMA (30 mL) were added 1,2-dibromoethane (0.55 g, 2.937 mmol, 0.1 eq) and TMSCl (0.21 g, 1.967 mmol, 0.067 eq) dropwise at rt under nitrogen atmosphere. To the above mixture was added methyl (2R)-2-[(tert-butoxycarbonyl) amino]-3-iodopropanoate (9.66 g, 29.37 mmol, 1 eq) in DMA (30 mL) dropwise. The resulting mixture was stired for an additional 3 h at rt. To a stired mixture of 2-(4-chloro-2-iodophenyl)-1,3,4-oxadiazole (9 g, 29.37 mmol, 1 eq) in DMA (30 mL) were added Pd(dppf)Cl2CH2Cl2(2.39 g, 2.94 mmol, 0.10 eq) and CuI(1.12 g, 5.87 mmol, 0.2 eq) in portions at rt under nitrogen atmosphere. Then, two mixtures were added together. The resulting mixture was stired for an additional 16h at rt. The resulting mixture was stired for additional 3 h at 80 ℃. Desired product could be detected by LCMS. The reaction was quenched with water 100 mL) at rt. The resulting mixture was filtered, and the filter cake was washed with EtOAc (3 x 150 mL). The filtrate was concentrated under reduced pressure. The resulting mixture was extracted with EtOAc (3 x 100mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reversed- phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in water (0.1% FA), 5% to 100% gradient in 30 min; detector, UV 254 nm. This resulted in methyl (2S)-2-[(tert-butoxycarbonyl) amino]-3-[5-chloro-2-(5-methyl-1,3,4- oxadiazol-2-yl) phenyl] propanoate (4.5 g, 39 %) as a yelow solid. LCMS (ESI+): m / z 396.1 (M+H+). Step 4: (2S)-2-[(tert-butoxycarbonyl) amino]-3-[5-chloro-2-(5-methyl-1,3,4-oxadiazol-2- yl) phenyl] propanoic acid:

[0227] A solution of methyl (2S)-2-[(tert-butoxycarbonyl) amino]-3-[5-chloro-2-(5-methyl- 1,3,4-oxadiazol-2-yl) phenyl] propanoate (5 g, 12.63 mmol, 1 eq) in THF (40 mL) and water (10 mL) was treated with LiOH (1.51 g, 63.16 mmol, 5 eq) for 4 h at rt. Desired product could be detected by LCMS. The mixture was diluted with water and EA. The water phase was acidified by diluted HCl (0.5N) and extracted with EA. The organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo. This resulted in (2S)-2-[(tert-butoxycarbonyl) amino]-3-[5-chloro-2-(5-methyl-1,3,4-oxadiazol-2-yl) phenyl] propanoic acid (4.5 g) as a light-yelow solid. LCMS (ESI+): m / z 404.0 (M+Na+). Step 5: methyl (2S)-3-[5-chloro-2-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]-2- [(isopropoxycarbonyl)(methyl)amino]propanoate:

[0228] A solution of (2S)-2-[(tert-butoxycarbonyl) amino]-3-[5-chloro-2-(5-methyl-1,3,4- oxadiazol-2-yl) phenyl] propanoic acid (4.5 g, 11.79 mmol, 1 eq) in DMF (50 mL) was treated with Ag2O (13.66 g, 58.93 mmol, 5 eq) for 20 min at rt under nitrogen atmosphere folowed by the addition of CH3I (25.09 g, 176.79 mmol, 15 eq) dropwise at rt. The resulting mixture was stired for 4 h at rt. The resulting mixture was diluted with water (50 mL). The resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (3 x 50 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in water (0.1% TFA), 5% to 100% gradient in 50 min; detector, UV 220 nm. This resulted in methyl (2S)-3-[5-chloro-2-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]-2- [(isopropoxycarbonyl)(methyl)amino]propanoate (3.7 g, 79 %) as a yelow solid. LCMS (ESI+): m / z 410.1 (M+H+). Step 6: Int.8:

[0229] A solution of methyl (2S)-2-[(tert-butoxycarbonyl) (methyl)amino]-3-[5-chloro-2- (5-methyl-1,3,4-oxadiazol-2-yl) phenyl] propanoate (2.6 g, 6.34 mmol, 1 eq) in THF (40mL) and H2O (10 mL) was treated with LiOH (1.08 g, 45.14 mmol, 5 eq) for 4 h at rt under nitrogen atmosphere. Desired product could be detected by LCMS. The resulting mixture was diluted with water (20 mL) and acidified to pH 6 with HCl (0.5mol / L). The mixture was concentrated under reduced pressure and extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate wasconcentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in water (0.1% TFA), 5% to 100% gradient in 30 min; detector, UV 254 nm. This resulted in Int.8 (3.4289 g, 96 %) as a yelow solid. LCMS (ESI+): m / z 390.10 (M+H+).1H NMR (300 MHz, DMSO-d6): δ 1.26 (s, 4H) , 1.39 (s, 5H) 2.67 (d, J = 1.9 Hz, 3H) , 2.84 (d, J = 8.8 Hz, 3H), 3.33 (ddd, J = 14.3, 10.9, 3.4 Hz, 1H), 3.91 (dt, J = 14.6, 2.9 Hz, 1H), 5.06 (ddd, J = 18.1, 10.8, 3.8 Hz, 1H), 7.34 – 7.26 (m, 1H), 7.40 (ddd, J = 8.5, 6.1, 2.1 Hz, 1H), 7.90 (dd, J = 8.4, 3.8 Hz, 1H), 10.00 (s, 1H). Int.9: Preparation of (S)-2-(tert-butoxycarbonyl)(methyl)amino)-3-(2-cyclopropoxy-5- fluoropyridin-3-yl)propanoic acidStep 1: 3-bromo-2-cyclopropoxy-5-fluoropyridine:

[0230] To a solution of cyclopropanol (15.55 g, 268.10 mmol, 1.3 eq) in THF (500 mL) was added sodium hydride (16.6 g, 691.67 mmol, 2 eq) portion wise at 0 °C under nitrogen atmosphere. The mixture was stired at 0 °C for 1 h.3-bromo-2,5-difluoropyridine (40 g, 206.21 mmol, 1 eq) was added dropwise over 30 min at 0 °C. The resulting mixture was stired at rt for 16 h. The reaction was quenched with ice-water (700 mL) and extracted with DCM (3 x 100 mL). The organic layer combined and washed with brine (300 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to aford 3-bromo-2-cyclopropoxy-5-fluoropyridine (34 g, crude) as a yelow oil. The crude product was used in the next step directly without further purification. LCMS (ESI+): m / z 233.90 (M+H+). Step 2: Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-(2-cyclopropoxy-5-fluoropyridin- 3-yl)propanoate:

[0231] To a mixture of Zn (15.94 g, 249.06 mmol, 1.7 eq) in DMA (80 mL) was added 1,2- dibromoethane (4.13 g, 21.98 mmol, 0.15 eq) in one portion under N2. Then chlorotrimethylsilane (1.58 g, 14.66 mmol, 0.1 eq) was added slowly and the mixture was stired for 30 min at 25oC. A solution of methyl 2-[(tert-butoxycarbonyl)amino]-3- iodopropanoate (57.86 g, 175.86 mmol, 1.2 eq) in DMA (80 mL) was added dropwise slowly (60 min) to maintain temperature below 50oC, the resulting mixture was stired at rt for 2 h and then added 250 mL 3-necked round-botom flask a cannula to a solution of 3-bromo-2- cyclopropoxy-5-fluoropyridine (34 g, 146.55 mmol, 1equiv), Pd(dppf)Cl2.CH2Cl2 (23.94 g, 29.31 mmol, 0.2 eq) and CuI (5.57 g, 29.31 mmol, 0.2 eq) in DMA (80 mL) under N2, the color of the mixture turned brown, then the mixture was heated and stired at 80oC for 2 h under N2. The mixture was quenched with ice-water (400 ml) and extracted with EA (3 x 500 ml). The organic layer was combined and washed with brine (300 ml), dried with anhydrous Na2SO4, filtered, and concentrated in vacuum to give the crude product. The crude product was purified by silica gel chromatography eluted with PE / EtOAc =0~50% to aford methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-(2-cyclopropoxy-5-fluoropyridin-3-yl)propanoate (11.2 g, 23 %) as a yelow oil. LCMS (ESI+): m / z 355.10 (M+H+). Step 3: Int.9:

[0232] Into a 1000 mL round-botom flask were added methyl (2S)-2-[(tert- butoxycarbonyl)amino]-3-(2-cyclopropoxy-5-fluoropyridin-3-yl)propanoate (11 g, 31.07 mmol, 1 eq) in DMF (150 mL), Ag2O (35.89 g, 155.37 mmol, 5 eq) was added at 0 °C under nitrogen atmosphere. The mixture was stired at 0 °C for 30 min, methyl iodide (44.12 g, 310.73 mmol, 10 eq) was added dropwise over 2 min at 0 °C. The resulting mixture wasstired at rt for 16 h. The reaction was quenched with ice-water (100 mL) and extracted with EtOAc (3 x 300 mL). The organic layer was combined and washed with brine (3 x 200 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (7:1) to aford Int.9 (10.8 g, 94 %) as a yelow oil. LCMS (ESI+): m / z 369.15 (M+H+).1H NMR (400 MHz, DMSO-d6): δ 8.06 (dd, J = 18.7, 3.0 Hz, 1H), 7.55 (ddd, J = 18.5, 8.7, 3.0 Hz, 1H), 4.68 (dd, J = 10.6, 4.5 Hz, 1H), 4.24 (ddt, J = 11.7, 8.6, 4.0 Hz, 1H), 3.68 (d, J = 7.6 Hz, 3H), 3.13 – 2.84 (m, 2H), 2.63 (d, J = 7.7 Hz, 3H), 1.24 (d, J = 18.3 Hz, 9H), 0.80 – 0.63 (m, 4H). Int.10: Preparation of (S)-2-(tert-butoxycarbonyl)(methyl)amino)-3-(5-chloro-2- isopropoxypyridin-3-yl)propanoic acidStep 1: 3-bromo-5-chloro-2-isopropoxypyridine:

[0233] To a stired mixture of 3-bromo-5-chloro-2-fluoropyridine (50 g, 237.61 mmol, 1 eq) and K2CO3 (98.52 g, 712.83 mmol, 3 eq) in IPA (500 mL, 5261.52 mmol, 22.14 eq) at 20 °C. The resulting mixture was stired for 48 h at 80 °C. The resulting mixture was concentrated under vacuum and the mixture was dissolved in DCM (300 mL). The resulting mixture was filtered, and the filter cake was washed with DCM (3 x 50 mL). The filtrate was concentrated under reduced pressure. This resulted in 3-bromo-5-chloro-2- isopropoxypyridine (50 g, 84.0%) as a yelow oil. LCMS (ESI+): m / z 252.05 (M+H+). Step 2: Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-(5-chloro-2-isopropoxypyridin-3- yl) propanoate:

[0234] To a stired mixture of 3-bromo-5-chloro-2-isopropoxypyridine (50 g, 199.59 mmol, 1 eq) and Pd(dppf)Cl2 DCM adduct (16.26 g, 19.96 mmol, 0.1 eq), CuI (7.60 g, 39.92 mmol, 0.2 eq) in DMA (500 mL) was added methyl (2S)-2-[(tert-butoxycarbonyl)amino]-2- (iodozincio)acetate (162.6 mL, 199.59 mmol, 10 eq) dropwise at 20 °C under nitrogen atmosphere. The resulting mixture was stired for 16 h at 80 °C under nitrogen atmosphere. The resulting mixture was filtered, the filter cake was washed with EtOAc (3 x 500 mL). The filtrate was extracted with EtOAc (3 x 800 mL). The combined organic layers were washed with H2O (3 x 1000 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH2Cl2 / PE (5:1) to aford methyl (2S)-2-[(tert- butoxycarbonyl)amino]-3-(5-chloro-2-isopropoxypyridin-3-yl)propanoate(110g) as a yelow oil. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% FA), 10% to 80% gradient in 35 min; detector, UV 280 nm. The resulting mixture was concentrated under vacuum. This resulted in methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-(5-chloro-2- isopropoxypyridin-3-yl) propanoate (53g, 77 %) as a white solid. LCMS (ESI+): m / z 373.25 (M+H+). Step 3: Methyl (2S)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-(5-chloro-2- isopropoxypyridin-3-yl)propanoate:

[0235] To a stired mixture of methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-(5-chloro-2- isopropoxypyridin-3-yl)propanoate (20 g, 53.64 mmol, 1 eq) and Ag2O (62.15 g, 268.21 mmol, 5 eq) in DMF (500 mL) was added MeI (77.66 g, 536.41 mmol, 10 eq) at 20 °C. The resulting mixture was stired for 16 h at 60 °C. The resulting mixture was filtered, the filter cake was washed with EtOAc (3 x 500 mL). The filtrate was dissolved in H2O (800 mL) andthe mixture was extracted with EtOAc (3 x 1000 mL). The combined organic layers were washed with H2O (4 x 1200 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to aford methyl (2S)-2-[(tert- butoxycarbonyl)(methyl)amino]-3-(5-chloro-2-isopropoxypyridin-3-yl)propanoate (20.5 g, 99 %) as a yelow oil. LCMS (ESI+): m / z 387.15 (M+H+). Step 4: Int.10:

[0236] To a stired mixture of methyl (2S)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-(5- chloro-2-isopropoxypyridin-3-yl)propanoate (20 g, 51.70 mmol, 1 eq) in EtOH (30 mL) and THF (60 mL) were added NaOH (6.20 g, 155.09 mmol, 3 eq) in H2O (120 mL) dropwise at 0 °C. The resulting mixture was stired for 16 h at 20 °C. The resulting mixture was extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with H2O (1 x 150 mL). The combined water phase was acidified to pH=6 with diluted citric acid(1N). The resulting mixture was extracted with EtOAc (2 x 200 mL). The combined organic layers were washed with H2O (1 x 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under vacuum to aford Int.10 (14.2 g, 74%) as a yelow oil. LCMS (ESI+): m / z 373.15 (M+H+). Int.11: Preparation of (S)-2-(tert-butoxycarbonyl)(methyl)amino)-3-(5-chloro-2- (pyrimidin-2-yloxy)phenyl)propanoic acidStep 1: 5-(2-bromo-4-chlorophenyl) pyrimidine:

[0237] To a stired solution of pyrimidin-5-ylboronic acid (10 g, 80.70 mmol, 1 eq) and 2- bromo-4-chloro-1-iodobenzene (25.61 g, 80.70 mmol, 1 eq) in 1,4-dioxane (80 mL) and H2O (20 mL) were added Pd(dppf)Cl2CH2Cl2 (6.57 g, 8.06 mmol, 0.10 eq) and Na2CO3 (25.66 g, 242.11 mmol, 3 eq) in portions at rt under nitrogen atmosphere. The resulting mixture was stired for additional 4 h at 80 ℃. Desired product could be detected by LCMS. The resulting mixture was filtered, and the filter cake was washed with EtOAc (3 x 10 mL). The resulting mixture was diluted with water and extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in water (0.1% TFA), 5% to 100% gradient in 30 min; detector, UV 220 nm. This resulted in 5-(2-bromo-4-chlorophenyl) pyrimidine (9.6 g, 44 %) as a brown oil. LCMS (ESI+): m / z 270.90 (M+H+). Step 2: Methyl (2S)-2-[(tert-butoxycarbonyl) amino]-3-[5-chloro-2-(pyrimidin-5-yl) phenyl] propanoate:

[0238] Into a stirred solution of Zn (6.31 g, 96.46 mmol, 2 eq) in DMA (30 mL) were added 1,2-dibromoethane (0.91 g, 4.82 mmol, 0.1 eq) and TMSCl (0.35 g, 3.23 mmol, 0.067 eq) dropwise at rt under nitrogen atmosphere. To the above mixture was added methyl (2R)- 2-[(tert-butoxycarbonyl) amino]-3-iodopropanoate (15.87 g, 48.23 mmol, 1 eq) in DMA (30 mL) dropwise. The resulting mixture was stired for additional 3 h at rt. To a stired solution of 5-(2-bromo-4-chlorophenyl) pyrimidine (13 g, 48.23 mmol, 1 eq) in DMA (40 mL) were added Pd(dppf)Cl2CH2Cl2 (3.93 g, 4.82 mmol, 0.1 eq) and CuI (1.84 g, 9.65 mmol, 0.2 eq) in portions at rt under nitrogen atmosphere. Then, the two mixtures were added together. Theresulting mixture was stired for additional 3 h at 80 ℃. Desired product could be detected by LCMS. The reaction was quenched by the addition of water (100 mL) at rt. The resulting mixture was filtered, and the filter cake was washed with EA (3 x 100 mL). The residue was diluted with water and EA. The organic phase was washed with brine (100 mL x 3), dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was purified by reverse flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in water (0.1% FA), 5% to 100% gradient in 30 min; detector, UV 220 nm. This resulted in methyl (2S)-2-[(tert-butoxycarbonyl) amino]-3-[5-chloro-2-(pyrimidin-5-yl) phenyl] propanoate (8 g, 42 %) as a yelow solid. LCMS (ESI+): m / z 392.05 (M+H+). Step 3: Methyl (S)-2-(tert-butoxycarbonyl)(methyl)amino)-3-(5-chloro-2-(pyrimidin-2- yloxy)phenyl)propanoate:

[0239] A solution of methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-[5-chloro-2- (pyrimidin-2-yloxy)phenyl]propanoate (1.3 g, 3.19 mmol, 1 eq) in DMF (15 mL) was treated with Ag2O (3.69 g, 15.94 mmol, 5 eq) at rt under nitrogen atmosphere folowed by the addition of CH3I (6.79 g, 47.81 mmol, 15 eq) dropwise at rt. The resulting mixture was stired for additional 3 h at rt. Desired product could be detected by LCMS. The resulting mixture was filtered, the filter cake was washed with DMF (30 mL). The filtrate was used in the next step directly without further purification. LCMS (ESI+): m / z 378.0 (M+H+). Step 4: Int.11:

[0240] A solution of methyl (2S)-2-[(tert-butoxycarbonyl) (methyl)amino]-3-[5-chloro-2- (pyrimidin-2-yloxy) phenyl] propanoate (3 g, 7.111 mmol, 1 eq) in DMF (45 mL) and H2O (10 mL) was treated with NaOH (0.85 g, 21.333 mmol, 3 eq) at rt. The resulting mixture was stired for additional 16 h at rt. Desired product could be detected by LCMS. The resulting mixture was diluted with water (40 mL). The resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (3 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in water (0.1% FA), 5% to 100% gradient in 10 min; detector, UV 220 nm. This resulted in Int.11 (1.86 g, 62 %) as a yelow solid. LCMS (ESI+): m / z 408.05 (M+H+). Int.12: Preparation of (S)-2-(tert-butoxycarbonyl)(methyl)amino)-3-(5-chloro-2- cyclobutoxypyridin-3-yl)propanoic acidStep 1: 3-Bromo-5-chloro-2-cyclobutoxypyridine:

[0241] To a suspension of NaH (6.35 g, 158.67 mmol, 1.2 eq, 60 % in oil) in THF (250 mL) was added cyclobutanol (10.49 g, 145.45 mmol, 1.1 eq) in THF (20 mL) at 0 °C dropwise. The resulting mixture was stired for 1 h at 0 °C under nitrogen atmosphere.3- bromo-2,5-dichloropyridine (30.0 g, 132.23 mmol, 1.0 eq) in THF (30 mL) was added and the mixture was stired for 16 h at 60 °C under nitrogen atmosphere. The reaction was quenched by the addition of sat. NH4Cl (aq.) (100 mL) at 0 °C. The resulting mixture was diluted with water (500 mL) and then extracted with EtOAc (3 x 150 mL). The combined organic layers were washed with brine (1 x 300 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified bysilica gel column chromatography, eluted with PE / EA (40:1) to aford 3-bromo-5-chloro-2- cyclobutoxypyridine (31.0 g, 89 %) as a colorless oil. LCMS (ESI+): m / z 262 (M+H+). Step 2: Methyl (2S)-2-[(tert-butoxycarbonyl) amino]-3-(5-chloro-2-cyclobutoxypyridin- 3-yl) propanoate:

[0242] To a stired mixture of 3-bromo-5-chloro-2-cyclobutoxypyridine (15 g, 57.14 mmol, 1.0 eq), Pd(dppf)Cl2.CH2Cl2 (2.33 g, 2.86 mmol, 0.05 eq) and CuI (1.09 g, 5.71 mmol, 0.1 eq) in N, N-dimethylacetamide (300 mL) was added methyl (2R)-2-[(tert-butoxycarbonyl) amino]-3-(iodozincio) propanoate (171.41 mL, 171.41 mmol, 3.00 eq) in one portion at rt under nitrogen atmosphere. The resulting mixture was stired for 16 h at 80 °C under nitrogen atmosphere. The resulting mixture was diluted with water (600 mL) and EtOAc (200 mL), and then filtered. The filter cake was washed with EtOAc (1 x 20 mL). The filtrate was separated, and the aqueous layer was extracted with EtOAc (2 x 200 mL). The combined organic layers were washed with sat. NH4Cl(aq.) (2 x 300 mL), brine (1 x 300 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in Water, 10% to 80% gradient in 20 min; detector, UV 220 nm. This resulted in methyl (2S)-2-[(tert-butoxycarbonyl) amino]- 3-(5-chloro-2-cyclobutoxypyridin-3-yl) propanoate (16.4 g, 75 %) as a colorless oil. LCMS (ESI+): m / z 385 (M+H+). Step 3: Methyl (2S)-2-[(tert-butoxycarbonyl) (methyl)amino]-3-(5-chloro-2- cyclobutoxypyridin-3-yl) propanoate:

[0243] To a stired mixture of methyl (2S)-2-[(tert-butoxycarbonyl) amino]-3-(5-chloro-2- cyclobutoxypyridin-3-yl) propanoate (16.4 g, 42.61 mmol, 1 eq) and Ag2O (39.50 g, 170.45 mmol, 4.0 eq) in DMF (200 mL) was added CH3I (96.8 g, 681.81 mmol, 16.0 eq) in one portion at rt under nitrogen atmosphere. The resulting mixture was stired for 16 h at 50 °C under nitrogen atmosphere. The starting material was transformed completely. The resulting mixture was diluted with water (500 mL) and EtOAc (200 mL) and was then filtered. The filter cake was washed with EtOAc (1 x 20 mL). The resulting mixture was separated, and the aqueous layer was extracted with EtOAc (2 x 150 mL). The combined organic layers were washed with sat. NH4Cl(aq.) (2 x 300 mL), brine (1 x 300 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (20:1) to aford methyl (2S)-2-[(tert-butoxycarbonyl) (methyl)amino]-3-(5-chloro-2-cyclobutoxypyridin-3-yl) propanoate (17.0 g, 95 %) as a colorless oil. Step 4: Int.12:

[0244] To a stired solution of methyl (2S)-2-[(tert-butoxycarbonyl) (methyl)amino]-3-(5- chloro-2-cyclobutoxypyridin-3-yl) propanoate (17 g, 42.62 mmol, 1 eq) in THF (300 mL) and H2O (100 mL) was added LiOH (3.06 g, 127.86 mmol, 3.00 eq) in H2O (100 mL) dropwise at 0 °C. The resulting mixture was stired for 16 h at rt. The resulting mixture was diluted with water (300 mL) and then acidified to pH 2 with HCl (2 M aq.). The resulting mixture was extracted with EtOAc (3 x 150 mL). The combined organic layers were washed with brine (1 x 300 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in Water, 10% to 60% gradient in 25 min; detector, UV 220 nm. This resulted in Int.12 (15.7 g, 95 %) as a white solid. LCMS (ESI+): m / z 385 (1.23 (d, J = 21.1 Hz, 9H), 1.54 – 1.88 (m, 2H), 1.93 – 2.20 (m, 2H), 2.28 – 2.47 (m, 2H), 2.68 (d, J = 1.4 Hz, 3H), 2.86 – 3.03 (m, 1H), 3.04 – 3.19 (m, 1H), 4.66 – 5.03 (m, 1H), 5.05 – 5.21 (m, 1H), 7.49 – 7.81 (m, 1H), 7.88 – 8.23 (m, 1H), 12.95 (s, 1H).Int.13: Preparation of (S)-2-(tert-butoxycarbonyl)(methyl)amino)-3-(5-chloro-2- methoxypyridin-3-yl)propanoic acidStep 1: 5-Chloro-2-methoxy-3-iodopyridine:

[0245] 2,5-dichloro-3-iodopyridine (5.0 g, 1 eq, 18 mmol) solution in THF (26 mL) was brought to 0 °C and added NaH (1.5 g, 60% Wt, 2 eq, 37 mmol) as a solid. Then MeOH was added dropwise and stired for 1 hour at 0 °C. Then the mixture was stired at 50 °C until LCMS analysis showed the complete consumption of starting material. The reaction was added into ice water 100 mL, then extracted with EtOAc (150 mL × 2), the combined organic layers were washed with brine, dried over MgSO4, and filtered. The filtrate was concentrated under reduced pressure to give crude product which was purified by column chromatography (SiO2, EtOAc:Hexanes; 0-60%) to yield 5-chloro-2-methoxy-3-iodopyridine (4.3 g, 16 mmol, 87 % yield) as yelow solid. Step 2: Methyl (S)-2-(tert-butoxycarbonyl)amino)-3-(5-chloro-2-methoxypyridin-3- yl)propanoate:

[0246] Zinc (2.4 g, 3 eq, 37 mmol) and DMF (15 mL) were added to a dry flask and degas with Ar. Then Boc-beta-iodo-Ala-OMe (4.0 g, 1 eq, 12 mmol) and iodine (0.47 g, 0.15 eq, 1.8 mmol) were added as solids. In a separate vial, 5-chloro-3-iodo-2-methoxypyridine (4.3g, 1.3 eq, 16 mmol) and 2-Dicyclohexylphosphino-2,6-Dimethoxy-1,1-Biphenyl (0.13 g, 0.025 eq, 0.31 mmol) were dissolved in DMF (15 mL) and degassed by Ar. Then Pd2dba3 (0.14 g, 0.013 eq, 0.15 mmol) was added. Transfer the first solution into the second solution and stir at rt until LCMS analysis showed the complete consumption of starting material. The reaction was added into ice water 50 mL, then extracted with EtOAc (100 mL × 2), the combined organic layers were washed with brine, dried over MgSO4, and filtered. The filtrate was concentrated under reduced pressure to give crude product which was purified by column chromatography (SiO2, EtOAc:Hexanes; 0-60%) to yield methyl (S)-2-(tert- butoxycarbonyl)amino)-3-(5-chloro-2-methoxypyridin-3-yl)propanoate (1.8 g, 8.1 mmol, 66 % yield) as white solid. LCMS (ESI+): m / z 345.3 (M+H+) Step 3: (S)-2-((tert-butoxycarbonyl)amino)-3-(5-chloro-2-methoxypyridin-3- yl)propanoic acid:

[0247] Methyl (S)-2-(tert-butoxycarbonyl)amino)-3-(5-chloro-2-methoxypyridin-3- yl)propanoate (2.8 g, 1 eq, 8.1 mmol) was dissolved into THF (20 mL), H2O (14 mL) and MeOH (6.8 mL) , then bring to 0 °C. Lithium hydroxide monohydrate (1.0 g, 0.68 mL, 3 eq, 24 mmol) was added and the mixture was stired at 25 °C until LCMS analysis showed the complete consumption of starting material. Then the 10% citric acid was added to the mixture at 0 °C until pH was acidic. The reaction mixture was concentrated via rotavapor and extracted with EtOAc (80 mL × 2), the combined organic layers were washed with brine, dried over MgSO4 and filtered. The filtrate was concentrated under reduced pressure to give crude product which was purified by column chromatography to give (S)-2-(tert- butoxycarbonyl)amino)-3-(5-chloro-2-methoxypyridin-3-yl)propanoic acid (2.3g, 7.0 mmol, 86 % yield). LCMS (ESI+): m / z 331.4 (M+H+) Step 4: Int.13:

[0248] (S)-2-(tert-butoxycarbonyl)amino)-3-(5-chloro-2-methoxypyridin-3-yl)propanoic acid (2.3 g, 1 eq, 7.0 mmol) solid was dissolved in THF (35 mL) and brought to 0 °C under Ar. Then NaH (0.56 g, 60% Wt, 2 eq, 14 mmol) was added as solid, and MeI (5.9 g, 2.6 mL, 6 eq, 42 mmol) was added dropwise. The mixture was stired for 1 hour at 0 °C. Then the mixture was stired at 25 °C until LCMS analysis showed the complete consumption of starting material. The reaction was quenched with ice water 100 mL and 10% citric acid was added to the mixture at 0 °C until pH was acidic. The reaction mixture was concentrated via rotavapor and extracted with EtOAc (80 mL × 2), the combined organic layers were washed with brine, dried over MgSO4, and filtered. The filtrate was concentrated under reduced pressure to give crude product which was purified by column chromatography to give Int.13 (2.3 g, 6.7 mmol, 96 % yield) as white solid. LCMS (ESI+): m / z 345.3 (M+H+). Int.14: (S)-2-((tert-butoxycarbonyl)(methyl)amino)-3-(5-chloro-2-ethoxypyridin-3- yl)propanoic acid:

[0249] This material was synthesized by folowing the procedure for Int.13 with ethanol as the starting alcohol. LCMS (ESI+): m / z 359.3 (M+H+) Int.15: (S)-2-((tert-butoxycarbonyl)(methyl)amino)-3-(5-chloro-2-isobutoxypyridin-3- yl)propanoic acid:

[0250] This material was synthesized by folowing the procedure for Int.13 with 2- methylpropan-1-ol as the starting alcohol. LCMS (ESI+): m / z 387.3 (M+H+) Int.16: Preparation of (S)-2-(tert-butoxycarbonyl)(methyl)amino)-3-(5-chloro-2-(5- cyclopropyl-1,3,4-oxadiazol-2-yl)phenyl)propanoic acidStep 1: 4-Chloro-N'-cyclopropanecarbonyl-2-iodobenzohydrazide:

[0251] To a stired solution of 4-chloro-2-iodobenzoic acid (1 g, 3.54 mmol, 1 eq) and NMI (0.87 g, 10.62 mmol, 3 eq) in ACN (40 mL) were added cyclopropanecarbohydrazide (354.45 mg, 3.540 mmol, 1 eq) and TCFH (1.19 g, 4.25 mmol, 1.2 eq) in portions at 0 °C. The resulting mixture was stired for 16 h at rt. The resulting mixture was diluted with water (20 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (1 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under vacuum. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, Acetonitrile in Water (0.1% FA), 0% to 60% gradient in 30 min; detector, UV 254 nm. This resulted in 4-chloro-N'-cyclopropanecarbonyl-2-iodobenzohydrazide (815 mg, 62%) as an of-white solid. LCMS (ESI+): m / z 364.80 (M+H+). Step 2: 2-(4-chloro-2-iodophenyl)-5-cyclopropyl-1,3,4-oxadiazole:

[0252] A solution of 4-chloro-N'-cyclopropanecarbonyl-2-iodobenzohydrazide (5 g, 13.72 mmol, 1 eq) in POCl3 (100 mL) was stired for 2 h at 85 °C. The resulting mixture wasconcentrated under vacuum and extracted with CH2Cl2 (3 x 200 mL). The combined organic layers were washed with NaHCO3(aq.) (1 x 200 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under vacuum to aford 2-(4-chloro-2-iodophenyl)-5- cyclopropyl-1,3,4-oxadiazole (4.5 g, 82 %) as a brown solid. The crude product was used in the next step directly without further purification. LCMS (ESI+): m / z 347.00 (M+H+). Step 3: Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-[5-chloro-2-(5-cyclopropyl-1,3,4- oxadiazol-2-yl)phenyl]propanoate:

[0253] To a stired solution of Zn (4.98 g, 76.18 mmol, 2.4 eq), 1,2-Dibromoethane (609.07 mg, 3.17 mmol, 0.1 eq) in DMA (20 mL) was added TMSCl (231.04 mg, 2.13 mmol, 0.067 eq) dropwise at 25 °C under nitrogen atmosphere. The resulting mixture was stired for 30 min and methyl (2R)-2-[(tert-butoxycarbonyl)amino]-3-iodopropanoate (20.89 g, 63.48 mmol, 2.00 eq) in DMA (20 mL) was added to the above solution. The temperature risen and kept it under 50 °C. After 30 min, the mixture was added to a solution of 2-(4-chloro-2- iodophenyl)-5-cyclopropyl-1,3,4-oxadiazole (11 g, 31.74 mmol, 1 eq), CuI (1.21 g, 6.35 mmol, 0.2 eq) and Pd(dppf)Cl2 (2.32 g, 3.174mmol, 0.1equiv.) in DMA (200 mL) dropwise and stired for 2 h at 80 °C. The reaction was quenched with sat. NH4Cl (aq.) at 0 °C. The resulting mixture was filtered, the filter cake was washed with CH2Cl2(500 mL) and the filtrate was extracted with CH2Cl2 (1000 mL). The combined organic layers were washed with brine (3 x 200 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under vacuum. The residue was purified by reverse flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, Acetonitrile in Water (0.1% FA), 0% to 100% gradient in 40 min; detector, UV 254 nm. This resulted in methyl (2S)-2- [(tert-butoxycarbonyl)amino]-3-[5-chloro-2-(5-cyclopropyl-1,3,4-oxadiazol-2- yl)phenyl]propanoate (7.2 g, 197 %) as a brown solid. LCMS (ESI+): m / z 422.20 (M+H+). Step 4: Methyl (2S)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-[5-chloro-2-(5- cyclopropyl-1,3,4-oxadiazol-2-yl)phenyl]propanoate:

[0254] To a stired solution of methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-[5-chloro-2- (5-cyclopropyl-1,3,4-oxadiazol-2-yl)phenyl]propanoate (7 g, 16.59 mmol, 1 eq) and Ag2O (15.38 g, 66.37 mmol, 4 eq) in DMF (140 mL) was added CH3I (23.55 g, 165.9 mmol, 10 eq) dropwise at 0 °C. The resulting mixture was stired for 72 h at rt. The resulting mixture was filtered, the filter cake was washed with EtOAc (3 x 100 mL) and the filtrate was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (3 x 200 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under vacuum. The crude product (7 g) was purified by Prep-HPLC with the folowing conditions (Column: XBridge C18 OBD Prep Column, 100Å 10 μm, 19 mm X 250 mm; Mobile Phase A: Water(10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 60% B to 60% B in 24 min; Wave Length: 220 nm; RT1(min): 18; Number Of Runs: 0) to aford methyl (2S)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-[5-chloro-2-(5-cyclopropyl- 1,3,4-oxadiazol-2-yl)phenyl]propanoate (3.6 g, 50 %) as a brown oil. LCMS (ESI+): m / z 565.60 (M+H+). Step 5: Int.16:

[0255] To a stired solution of methyl (2S)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-[5- chloro-2-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)phenyl]propanoate (2.6 g, 5.97 mmol, 1 eq) in THF (24 mL) / H2O (8 mL) was added NaOH (715.69 mg, 17.90 mmol, 3.00 eq) in water (10 mL) dropwise at 0 °C. The mixture was acidified to pH=5 with HCl (1N). The resulting mixture was extracted with EtOAc (3 x 200 mL). The combined organic layers were washed with brine (1 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under vacuum. The residue was purified by reversed-phase flashchromatography with the folowing conditions: column, C18 silica gel; mobile phase, Acetonitrile in Water (0.1% FA), 5% to 100% gradient in 30 min; detector, UV 254 nm. This resulted in Int.16 (2.73 g, 108 %) as an of-white solid. LCMS (ESI+): m / z 421.95 (M+H+). Int.17: Preparation of (S)-3-(2-((1-acetylpiperidin-4-yl)oxy)-5-chlorophenyl)-2-(tert- butoxycarbonyl)(methyl)amino)propanoic acid:Step 1: 1-(4-(4-chloro-2-iodophenoxy)piperidin-1-yl)ethan-1-one:

[0256] To a solution of 4-chloro-2-iodophenol (20 g, 78.60 mmol, 1 eq), 1-(4-hydroxy-1- piperidyl)ethanone (12.38 g, 86.46 mmol, 1.1 eq) and PPh3 (24.74 g, 94.32 mmol, 1.2 eq) in THF (200 mL) was added DIAD (19.07 g, 94.32 mmol, 18.34 mL, 1.2 eq) dropwise at 0 °C under N2 atmosphere. Then the reaction mixture was alowed to warm to 20 °C slowly and stired at 20 °C for 12 h. LCMS showed starting material was consumed completely and desired mass was detected. The reaction mixture was quenched by water (200 mL), extracted with EtOAc (150 mL x 2). The combined organics were washed with brine (150 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 330 g SepaFlash® Silica Flash Column, Eluent of 0~55% EtOAc / PE gradient @ 200 mL / min) to give 1-(4-(4-chloro-2- iodophenoxy)piperidin-1-yl)ethan-1-one (21.49 g, 39.55 mmol, 50 % yield, 70 % purity) as a light-yelow solid.Step 2: methyl (S)-3-(2-(1-acetylpiperidin-4-yl)oxy)-5-chlorophenyl)-2-(tert- butoxycarbonyl)amino)propanoate

[0257] A mixture of Zn (6.95 g, 106.34 mmol, 3.5 eq) in DMF (50 mL) was degassed and purged with N2 for 3 times, and the mixture was stired at 120 °C for 10 min under N2 atmosphere. Then I2 (2.31 g, 9.11 mmol, 1.84 mL, 0.3 eq) in DMF (10 mL) was added dropwise at 20 °C, methyl (R)-2-(tert-butoxycarbonyl)amino)-3-iodopropanoate (10 g, 30.38 mmol, 1 eq) in DMF (30 mL) was added dropwise, I2 (2.31 g, 9.11 mmol, 1.84 mL, 0.3 eq) in DMF (10 mL) was added dropwise, the reaction mixture was stired at 20 °C for 1 hr. TLC (PE:EtOAc = 5:1, Rf = 0.5) showed starting material was consumed completely and a new major spot was detected. The (R)-(2-(tert-butoxycarbonyl)amino)-3-methoxy-3- oxopropyl)zinc(I) iodide (11.99 g, crude) as a gray liquid was obtained, which was used into the next step without further purification.

[0258] To a solution of 1-(4-(4-chloro-2-iodophenoxy)piperidin-1-yl)ethan-1-one (5.58 g, 14.70 mmol, 1 eq), sPhos (603.43 mg, 1.47 mmol, 0.1 eq) and Pd2(dba)3 (673.00 mg, 734.95 umol, 0.05 eq) in DMF (50 mL) was degassed and purged with N23 times. Then (R)-(2- (tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)zinc(I) iodide (11.99 g, 30.39 mmol, 2.07 eq) in DMF was added dropwise. Then, the reaction mixture was stired at 65 °C for 12 h. LCMS showed starting material was consumed completely and desired mass was detected. The reaction mixture was cooled to rt and quenched by water (150 mL), extracted with EtOAc (100 mL x 2). The combined organics were washed with brine (150 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: 800g Agela C18; mobile phase: [water-ACN];B%: 20-50% 30min;50% 20min) to give methyl (S)-3-(2-(1-acetylpiperidin-4-yl)oxy)-5-chlorophenyl)-2- (tert-butoxycarbonyl)amino)propanoate (3.62 g, 7.66 mmol, 52 % yield, 96 % purity) as a white solid.Step 3: (S)-3-(2-(1-acetylpiperidin-4-yl)oxy)-5-chlorophenyl)-2-(tert- butoxycarbonyl)amino)propanoic acid:

[0259] To a solution of methyl (S)-3-(2-((1-acetylpiperidin-4-yl)oxy)-5-chlorophenyl)-2- (tert-butoxycarbonyl)amino)propanoate (3.62 g, 7.96 mmol, 1 eq) in THF (40 mL) was added a solution of LiOH.H2O (400.69 mg, 9.55 mmol, 1.2 eq) in H2O (20 mL). Then the reaction mixture was stired at 25 °C for 1 hr. LCMS showed starting material was consumed completely and desired mass was detected. The reaction mixture was concentrated under reduced pressure to remove THF. Then the mixture was acidified by 1N HCl to pH=2~3 at 0 °C and extracted with EtOAc (15 mL x 2). The combined organics were washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give compound (S)-3-(2-(1-acetylpiperidin-4-yl)oxy)-5-chlorophenyl)-2-((tert- butoxycarbonyl)amino)propanoic acid (3.35 g, 7.60 mmol, 95 % yield, 100% purity) as a white solid. Step 4: Int.17:

[0260] To a solution of (S)-3-(2-(1-acetylpiperidin-4-yl)oxy)-5-chlorophenyl)-2-((tert- butoxycarbonyl)amino)propanoic acid (3.35 g, 7.60 mmol, 1 eq) in THF (40 mL) was added NaH (759.71 mg, 18.99 mmol, 60% purity, 2.5 eq) at 0 °C under N2 atmosphere. The mixturewas stired at 20 °C for 30 min. Then MeI (14.02 g, 98.77 mmol, 6.15 mL, 13 eq) was added at 0 °C and the reaction mixture was stired at 20 °C for 12 hr. LCMS showed 38% of starting material remained and 26% of desired mass was detected. The reaction mixture was cooled to 0 °C and quenched by NH4Cl (40 mL), extracted with EtOAc (30 mL x 2). The combined organics were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The crude product was purified by reversed-phase HPLC (column: 800g Agela C18; mobile phase: [water (FA)-ACN]; B%: 25- 55% 30min; 55% 20min) to Int.17 (3.02 g, 6.41 mmol, 97 % purity) was obtained as a light- yelow solid. Spectrum:1H NMR (400 MHz, DMSO-d6) δ = 12.80 (br s, 1H), 7.28 - 6.99 (m, 3H), 4.90 - 4.60 (m, 2H), 3.73 - 3.54 (m, 2H), 3.39 (td, J = 3.8, 13.3 Hz, 2H), 3.18 (br dd, J = 3.8, 13.8 Hz, 1H), 2.95 - 2.82 (m, 1H), 2.66 (s, 3H), 2.01 (s, 3H), 1.97 - 1.80 (m, 2H), 1.74 - 1.50 (m, 2H), 1.30 - 1.15 (m, 9H) Int.18: Preparation of (S)-2-(tert-butoxycarbonyl)(methyl)amino)-3-(5-fluoro-2-(1- methyl-1H-pyrazol-4-yl)pyridine-3-yl)propanoic acidStep 1: 5-Fluoro-2-(1-methyl-1H-pyrazol-4-yl)pyridine-3-amine:

[0261] To a solution of 2-bromo-5-fluoropyridin-3-amine (12 g, 62.83 mmol, 1 eq) in dioxane (96 mL) and H2O (18 mL) was added, 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-pyrazole, Pd(dppf)Cl2 (2.30 g, 3.14 mmol, 0.05 eq) and K2CO3 (17.37 g, 125.65 mmol, 2 eq), the mixture was stired at 90 °C for 12 h under N2. The reaction was monitored by LCMS, which showed 2-bromo-5-fluoropyridin-3-amine was consumed and one of peak with desired mass was detected. Five other reactions of the same size were set up and al six reactions were combined to work up. After cooling to rt, the mixture was filtered.The filtrate was diluted with water (500 mL), extracted with EtOAc (200 mL x 3). The combined organics were washed with brine (300 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was dissolved in DCM (200 mL), and 250 g of silica gel was added. The resulting mixture was evaporated under reduced pressure to give a dry flowing solid, and then it was loaded to Biotage® using a 400 g Agela flash silica gel column, eluted with 0 % to 50 % EtOAc in PE with the flower rate of 75 mL / min. The product fraction was combined and concentrated to give 5-fluoro-2-(1- methyl-1H-pyrazol-4-yl)pyridine-3-amine (63 g, crude) as a yelow solid. Step 2: 5-Fluoro-3-iodo-2-(1-methyl-1H-pyrazol-4-yl)pyridine:

[0262] To a solution of 5-fluoro-2-(1-methyl-1H-pyrazol-4-yl)pyridine-3-amine (15.75 g, 81.95 mmol, 1 eq) in MeCN (450 mL) was added CuI (18.73 g, 98.34 mmol, 1.2 eq), KI (68.02 g, 409.75 mmol, 5 eq) and tert-butyl nitrite (42.25 g, 409.75 mmol, 48.73 mL, 5 eq), the mixture was stired at 60 °C for 12 h under N2. The reaction was monitored by LCMS, which showed 5-fluoro-2-(1-methyl-1H-pyrazol-4-yl)pyridine-3-amine as consumed and one of peak with desired mass was detected. Three other reactions of the same size were set up and al four reactions were combined and filtered, and the filter cake was rinsed with EtOAc (100 mL x 3). The combined filtrate were concentrated under reduced pressure to give a residue. The filtrate was diluted with water (200 mL), extracted with dichloromethane (80 mL x 3). The combined organics were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was dissolved in DCM (100 mL), and 200 g of silica gel was added. The resulting mixture was evaporated under reduced pressure to give a dry flowing solid, and then it was loaded to Biotage® using a 300 g Agela flash silica gel column, eluted with 0 % to 20 % EtOAc in PE with the flower rate of 75 mL / min. The product fraction was combined and concentrated to give 5-fluoro-3- iodo-2-(1-methyl-1H-pyrazol-4-yl)pyridine (30 g, 98.99 mmol, 60 % yield, 100% purity) as a yelow solid. Step 3: Methyl (S)-2-(tert-butoxycarbonyl)amino)-3-(5-fluoro-2-(1-methyl-1H-pyrazol- 4-yl)pyridine-3-yl)propanoate:

[0263] To a solution of 5-fluoro-3-iodo-2-(1-methyl-1H-pyrazol-4-yl)pyridine (30 g, 98.99 mmol, 1 eq), SPhos (4.06 g, 9.90 mmol, 0.1 eq) and Pd2(dba)3 (4.83 g, 5.28 mmol, 0.05 eq) in DMF (330 mL) was degassed and purged with N23 times. Then (R)-(2-(tert- butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)zinc(I) iodide (78.10 g, 197.97 mmol, 2 eq) in DMF (200 mL) was added dropwise. Then the reaction mixture was stired at 20 °C for 12 h. The reaction was monitored by LCMS, which showed 5-fluoro-3-iodo-2-(1-methyl-1H- pyrazol-4-yl)pyridine was consumed and one of peak with desired mass was detected. The mixture was filtered. The filtrate was diluted with water (200 mL), extracted with EtOAc (100 mL x 3). The combined organics were washed with brine (200 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Welch Xtimate C18250 x 100 mm#10 um; mobile phase: [water (NH4HCO3)-ACN];B%: 30%-60%,36 min) the HPLC fractions were combined, lyophilized. The product fraction was combined and concentrated to give methyl (S)-2-(tert- butoxycarbonyl)amino)-3-(5-fluoro-2-(1-methyl-1H-pyrazol-4-yl)pyridine-3-yl)propanoate (4.2 g, 11.10 mmol, 11 % yield, 100% purity) as a yelow solid. Step 4: (S)-2-((tert-butoxycarbonyl)amino)-3-(5-fluoro-2-(1-methyl-1H-pyrazol-4- yl)pyridine-3-yl)propanoic acid:

[0264] To a solution of methyl (S)-2-(tert-butoxycarbonyl)amino)-3-(5-fluoro-2-(1- methyl-1H-pyrazol-4-yl)pyridine-3-yl)propanoate (4.2 g, 11.10 mmol, 1 eq) in THF (60 mL) was added a solution of LiOH.H2O (558.93 mg, 13.32 mmol, 1.2 eq) in H2O (30 mL), the mixture was stired at 20 °C for 1 h. The mixture was acidified by adding hydrochloric acid (0.1 M, 10 mL) dropwise at 20 °C to pH = 5. The filtrate was diluted with water (30 mL),extracted with EtOAc (20 mL x 3). The combined organics were washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give (S)-2-(tert- butoxycarbonyl)amino)-3-(5-fluoro-2-(1-methyl-1H-pyrazol-4-yl)pyridine-3-yl)propanoic acid (3.7 g, 10.15 mmol, 91 % yield, 100 % purity) as a yelow solid. Step 5: Int.18:

[0265] To a solution of (S)-2-((tert-butoxycarbonyl)amino)-3-(5-fluoro-2-(1-methyl-1H- pyrazol-4-yl)pyridine-3-yl)propanoic acid (1.85 g, 5.08 mmol, 1 eq) in THF (76 mL) was added NaH (1.02 g, 25.39 mmol, 60% purity, 5 eq) at 0 °C, the mixture was stired at 0 °C for 1 h under N2. MeI (7.21 g, 50.77 mmol, 3.16 mL, 10 eq) was added to the reaction mixture, the mixture was stired at 20 °C for 12 h under N2. LCMS showed the (S)-2-((tert- butoxycarbonyl)(methyl)amino)-3-(5-fluoro-2-(1-methyl-1H-pyrazol-4-yl)pyridine-3- yl)propanoic acid was consumed and desired mass was detected. One other reaction of the same size was set up and al two reactions were combined to work up. The reaction was quenched by addition of saturated ammonium chloride aqueous solution (20 mL), acidified by adding hydrochloric acid (0.1 M, 10 mL) dropwise at 0 °C to pH = 5, extracted with EtOAc (20 mL x 3). The combined organics were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give Int.18 (2.5 g, 6.53 mmol, 64.3% yield, 99 % purity) as a yelow solid.1H NMR (400 MHz, MeOD -d4) δ = 8.34 (dd, J = 2.4, 15.3 Hz, 1H), 8.02 (d, J = 7.0 Hz, 1H), 7.84 (d, J = 3.1 Hz, 1H), 7.52 (dt, J = 2.6, 9.2 Hz, 1H), 4.74 - 4.62 (m, 1H), 4.02 - 3.92 (m, 3H), 3.64 - 3.54 (m, 1H), 3.28 - 3.12 (m, 1H), 2.66 (d, J = 6.9 Hz, 3H), 1.42 - 1.18 (m, 9H). Int.19: Preparation of (S)-2-(tert-butoxycarbonyl)(methyl)amino)-3-(5-chloro-2-(1- methyl-1H-pyrazol-4-yl)pyridine-3-yl)propanoic acidStep 1: 5-chloro-2-(1-methyl-1H-pyrazol-4-yl)pyridine-3-amine:

[0266] To a solution of 2-bromo-5-chloropyridin-3-amine (30 g, 144.61 mmol, 1 eq) and 1- methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (36.11 g, 173.53 mmol, 1.2 eq) in dioxane (720 mL) and H2O (120 mL) was added K2CO3 (39.97 g, 289.22 mmol, 2 eq) and Pd(dppf)Cl2(3.17 g, 4.34 mmol, 0.03 eq), the mixture was stired at 90 °C for 12 h under N2. The reaction was monitored by LCMS, which showed 2-bromo-5-chloropyridin-3- amine was consumed and one of peak with desired mass was detected. The reaction mixture was filtered, and the filter cake was washed with EtOAc (50 mL x 3) and diluted with water (10 mL), extracted with EtOAc (200 mL x 3). The combined organics were washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was dissolved in DCM (80 mL), and 40 g of silica gel was added. The resulting mixture was evaporated under reduced pressure to give a dry flowing solid, and then it was loaded to Biotage® using a 180 g Agela flash silica gel column, eluted with 0 % to 40 % EtOAc in PE with the flower rate of 75 mL / min. The product fraction was combined and concentrated to give 5-chloro-2-(1-methyl-1H-pyrazol-4-yl)pyridine-3-amine (30 g, 142.35 mmol, 98 % yield, 99% purity) as a brown solid. Step 2: 5-chloro-3-iodo-2-(1-methyl-1H-pyrazol-4-yl)pyridine:

[0267] To a solution of 5-chloro-2-(1-methyl-1H-pyrazol-4-yl)pyridine-3-amine (9 g, 43.14 mmol, 1 eq) in MeCN (300 mL) was added CuI (9.86 g, 51.76 mmol, 1.2 eq), KI (35.80 g, 215.68 mmol, 5 eq) and tert-butyl nitrite (22.24 g, 215.68 mmol, 25.65 mL, 5 eq), the mixture was stired at 60 °C for 12 h under N2. The reaction was monitored by LCMS, which showed 5-chloro-2-(1-methyl-1H-pyrazol-4-yl)pyridine-3-amine was consumed and one of peak with desired mass was detected. After cooling to rt, the solid was colected by filtration, washed with EtOAc (100 mL x 3) and dried under reduced pressure to give a brown solid. The solid was triturated with EtOAc at 20oC for 30 min. Then the crude product was triturated with ammonia water at 20oC for 30 min and filtered, the filter cake was concentrated to give 5- chloro-3-iodo-2-(1-methyl-1H-pyrazol-4-yl)pyridine (20.5 g, 50.04 mmol, 58 % yield, 78% purity) brown solid. Step 3: Methyl (S)-2-(tert-butoxycarbonyl)amino)-3-(5-chloro-2-(1-methyl-1H-pyrazol- 4-yl)pyridine-3-yl)propanoate:

[0268] To a solution of 5-chloro-3-iodo-2-(1-methyl-1H-pyrazol-4-yl)pyridine (20.5 g, 64.16 mmol, 1 eq) in DMF (200 mL) was added (R)-(2-(tert-butoxycarbonyl)amino)-3- methoxy-3-oxopropyl)zinc(I) iodide (50.62 g, 128.31 mmol, 2 eq), Pd2(dba)3 (2.94 g, 3.21 mmol, 0.05 eq) and sPhos (2.63 g, 6.42 mmol, 0.1 eq), the mixture was stired at 20 °C for 12 h under N2. The reaction was monitored by LCMS, which showed 5-chloro-3-iodo-2-(1- methyl-1H-pyrazol-4-yl)pyridine was consumed and one of peak with desired mass was detected. The reaction was quenched by addition of saturated ammonium chloride aqueous solution (200 mL) and extracted with EtOAc (100 mL x 3). The combined organics were washed with brine (100 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was dissolved in DCM (50 mL), and 40 g of silica gel was added. The resulting mixture was evaporated under reduced pressure to give a dry flowing solid, and then it was loaded to Biotage® using a 120 g Agela flash silica gel column, eluted with 0 % to 55 % EtOAc in PE with the flower rate of 75 mL / min. The product fraction was combined and concentrated to give methyl (S)-2-(tert-butoxycarbonyl)amino)-3-(5-chloro-2-(1-methyl-1H-pyrazol-4-yl)pyridine-3-yl)propanoate (8 g, 19.86 mmol, 31 % yield, 98% purity) as a yelow solid. Step 4: (S)-2-((tertbutoxycarbonyl)amino)-3-(5-chloro-2-(1-methyl-1H-pyrazol-4- yl)pyridine-3-yl)propanoic acid:

[0269] To a solution of methyl (S)-2-(tert-butoxycarbonyl)amino)-3-(5-chloro-2-(1- methyl-1H-pyrazol-4-yl)pyridine-3-yl)propanoate (8 g, 20.26 mmol, 1 eq) in THF (100 mL) was added a solution of LiOH.H2O (1.02 g, 24.31 mmol, 1.2 eq) in H2O (50 mL), the mixture was stired at 20 °C for 1 h. The reaction was monitored by LCMS, which showed methyl (S)-2-(tert-butoxycarbonyl)amino)-3-(5-chloro-2-(1-methyl-1H-pyrazol-4-yl)pyridine-3- yl)propanoate was consumed and one of peak with desired mass was detected. The mixture was extracted with EtOAc (100 mL). The aqueous phase was acidified by added hydrochloric acid (1 M, 50 mL) dropwise at 0 °C to pH = 4 and extracted with EtOAc (200 mL x 3). The combined organics were washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated to give (S)-2-(tertbutoxycarbonyl)amino)-3-(5-chloro-2-(1-methyl-1H-pyrazol- 4-yl)pyridine-3-yl)propanoic acid (7 g, 18.01 mmol, 89 % yield, 98% purity) as a yelow solid. Step 5: Int.19:

[0270] To a solution of (S)-2-((tertbutoxycarbonyl)amino)-3-(5-chloro-2-(1-methyl-1H- pyrazol-4-yl)pyridine-3-yl)propanoic acid (3.7 g, 9.72 mmol, 1 eq) in THF (100 mL) was added NaH (1.94 g, 48.58 mmol, 60% purity, 5 eq) at 0 °C, the mixture was stired at 0 °C for 1 h under N2. MeI (13.79 g, 97.16 mmol, 6.05 mL, 10 eq) was added to the reactionmixture, the mixture was stired at 20 °C for 12 h under N2. The reaction was monitored by LCMS, which showed (S)-2-((tertbutoxycarbonyl)amino)-3-(5-chloro-2-(1-methyl-1H- pyrazol-4-yl)pyridine-3-yl)propanoic acid was consumed and one of peak with desired mass was detected. The reaction mixture was cooled to 0 °C and quenched by NH4Cl (30 mL), extracted with EtOAc (50 mL x 2). The combined organics were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give Int.19 (3 g, 7.51 mmol, 77 % yield, 98 % purity) as a yelow solid.1H NMR (400 MHz, MeOD-d4)1H NMR (400 MHz, METHANOL-d4) δ = 8.48 - 8.32 (m, 1H), 8.08 (d, J = 6.8 Hz, 1H), 7.92 (s, 1H), 7.76 - 7.64 (m, 1H), 4.80 - 4.66 (m, 1H), 3.98 (s, 3H), 3.64 - 3.56 (m, 1H), 3.28 - 3.16 (m, 1H), 2.66 (d, J = 9.8 Hz, 3H), 1.24 (s, 9H) Int.20: Preparation of (S)-2-(tertbutoxycarbonyl)(methyl)amino)-3-(5-chloro-2-(1- methylcyclopropoxy)phenyl)propanoic acidStep 1: 4-chloro-1-(1-methylcyclopropoxy)-2-nitrobenzene:

[0271] To a solution of 4-chloro-1-fluoro-2-nitrobenzene (21 g, 119.63 mmol, 1 eq) and 1- methylcyclopropanol (11.16 g, 131.59 mmol, 85% purity, 1.1 eq) in DMF (150 mL) was added Cs2CO3 (58.47 g, 179.44 mmol, 1.5 eq). Then, the reaction mixture was stired at 75 °C for 3 h. HPLC showed starting material was consumed completely and a new major peak was detected. The reaction mixture was cooled to rt and quenched by water (200 mL), extracted with EtOAc (150 mL x 2). The combined organics were washed with water (100 mL x 3) and brine (150 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give 4-chloro-1-(1-methylcyclopropoxy)-2-nitrobenzene (25 g, 104.54 mmol, 87 % yield, 95.2 % purity) as a brown oil. Step 2: 5-chloro-2-(1-methylcyclopropoxy)aniline:

[0272] To a solution of 4-chloro-1-(1-methylcyclopropoxy)-2-nitrobenzene (25 g, 109.82 mmol, 1 eq) in EtOH (200 mL) and H2O (100 mL) was added NH4Cl (5.87 g, 109.82 mmol, 1 eq) and Fe (18.40 g, 329.46 mmol, 3 eq). Then, the reaction mixture was stired at 80 °C for 2 h. LCMS showed starting material was consumed completely and desired mass was detected. The resultant mixture was filtered, and the filter cake was rinsed with EtOH (100 mL x 3). Then the combined filtrates were concentrated under reduced pressure to remove EtOH. Then the aqueous phase was extracted with EtOAc (150 mL x 2). The combined organics were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give 5-chloro-2-(1-methylcyclopropoxy)aniline (20.9 g, 104.54 mmol, 95 % yield, 99 % purity) as a black, brown oil. Step 3: 4-chloro-2-iodo-1-(1-methylcyclopropoxy)benzene:

[0273] To a solution of 5-chloro-2-(1-methylcyclopropoxy)aniline (20.9 g, 105.74 mmol, 1 eq) in HCl (2.5 M, 209.00 mL, 4.94 eq) and ACN (100 mL) was added a solution of NaNO2 (8.02 g, 116.31 mmol, 1.1 eq) in H2O (100 mL) slowly at 0 °C. Then, a solution of KI (43.88 g, 264.34 mmol, 2.5 eq) in H2O (100 mL) was added slowly. Then the reaction mixture was alowed to warm to 25 °C and stired at 25 °C for 12 h. LCMS showed starting material was consumed completely and a new major spot was detected. The reaction mixture was adjusted pH = 7 by adding saturated NaHCO3 aqueous solution slowly at 0 °C, extracted with EtOAc (60 mL x 2). The combined organics were washed with brine (80 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 220 g SepaFlash® Silica Flash Column, Eluent of 0~0% EtOAc / PE gradient @ 150 mL / min) to give 4-chloro-2-iodo-1-(1- methylcyclopropoxy)benzene (23 g, 73.84 mmol, 70 % yield, 99.1% purity) as a light-yelow oil. Step 4: Methyl (S)-2-(tert-butoxycarbonylamino)-3-(5-chloro-2-(1- methylcyclopropoxy)phenyl)propanoate:

[0274] A mixture of 4-chloro-2-iodo-1-(1-methylcyclopropoxy)benzene (15 g, 48.62 mmol, 1 eq), sPhos (2.00 g, 4.86 mmol, 0.1 eq) and Pd2(dba)3 (2.23 g, 2.43 mmol, 0.05 eq) in DMF (50 mL) was degassed and purged with N23 times, then [(2R)-2-(tert- butoxycarbonylamino)-3-methoxy-3-oxo-propyl]-iodo-zinc (41.95 g, 106.34 mmol, 2.19 eq) was added to the mixture and then the mixture was stired at 65 °C for 12 h under N2 atmosphere. LCMS showed starting material was consumed completely and desired mass was detected. The reaction mixture was cooled to rt and quenched by water (300 mL), extracted with EtOAc (150 mL x 2). The combined organics were washed with water (200 mL x 2) and brine (200 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Welch Xtimate C18 250*70mm#10um; mobile phase: [water (NH4HCO3)-ACN]; B%: 50%-80%, 20min) to give methyl (S)-2-(tert-butoxycarbonylamino)-3-(5-chloro-2-(1- methylcyclopropoxy)phenyl)propanoate (15 g, 36.75 mmol, 76 % yield, 94.0 % purity) as a light-yelow solid. Step 5: (S)-2-((tert-butoxycarbonyl)amino)-3-(5-chloro-2-(1- methylcyclopropoxy)phenyl) propanoic acid:

[0275] To a solution of methyl(S)-2-(tert-butoxycarbonylamino)-3-(5-chloro-2-(1- methylcyclopropoxy)phenyl)propanoate (15 g, 39.08 mmol, 1 eq) in THF (200 mL) was added a solution of LiOH.H2O (2.46 g, 58.61 mmol, 1.5 eq) in H2O (100 mL) at 0~10 °C. Then the reaction mixture was stired at 20 °C for 0.5 hr. LCMS showed starting material was consumed completely and desired mass was detected. The reaction mixture was concentrated under reduced pressure to remove THF and extracted with EtOAc (80 mL x 2). The aqueous phase was acidified by adding hydrochloric acid (1N) dropwise at 0 °C to pH = 2~3. Theaqueous phase was extracted with EtOAc (100 mL x 2). The combined organics were washed with brine (150 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give (S)-2-((tert-butoxycarbonyl)amino)-3-(5-chloro-2-(1-methylcyclopropoxy)phenyl) propanoic acid (12.7 g, 33.65 mmol, 86 % yield, 98.1 % purity) as a light-yelow oil. Step 6: Int.20:

[0276] To a solution of (S)-2-((tert-butoxycarbonyl)amino)-3-(5-chloro-2-(1- methylcyclopropoxy)phenyl) propanoic acid (12.7 g, 34.34 mmol, 1 eq) in THF (400 mL) was added NaH (6.87 g, 171.70 mmol, 60% purity, 5 eq) at 0 °C under N2 atmosphere. The mixture was stired at 20 °C for 0.5 hr. Then MeI (48.74 g, 343.39 mmol, 21.38 mL, 10 eq) was added and the reaction mixture was stired at 20 °C for 12 h. LCMS showed starting material was consumed completely and desired mass was detected. The reaction mixture was cooled to 0 °C and quenched by NH4Cl (150 mL), acidified by adding hydrochloric acid (1 N) dropwise at 0 °C to pH = 2~3 and extracted with EtOAc (200 mL x 2). The combined organics were washed with brine (200 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give Int.20 (9.98 g, 26.00 mmol, 76 % yield, 100% purity) as a light-yelow solid.1NMR (400 MHz, DMSO-d6) δ = 7.28 - 7.04 (m, 3H), 4.83 - 4.39 (m, 1H), 3.15 - 2.97 (m, 1H), 2.89 - 2.71 (m, 1H), 2.61 (br d, J = 3.3 Hz, 3H), 1.49 (d, J = 11.1 Hz, 3H), 1.30 - 1.12 (m, 9H), 0.95 - 0.81 (m, 2H), 0.81 - 0.69 (m, 2H) Int.22: Preparation of (S)-3-(1’-acetyl-5-chloro-1’,2’,3’,6’-tetrahydro-[2,4’-bipyridin]-3- yl)-2-(tert-butoxycarbonyl)(methyl)amino)propanoic acidStep 1: 2-bromo-3-(bromomethyl)-5-chloropyridine:

[0277] To a stired mixture of 2-bromo-5-chloro-3-methylpyridine (25 g, 121.08 mmol, 1 eq.) and NBS (23706.05 mg, 133.19 mmol, 1.1 eq) in ACN (200 mL) was added AIBN (1988.33 mg, 12.11 mmol, 0.1 eq.) at rt under nitrogen atmosphere. The resulting mixture was stired overnight at 80 oC. The resulting mixture was concentrated in vacuo and diluted with water. The mixture was extracted with EtOAc (2 x 200 mL) and the combined organic layers were dried over anhydrous Na2SO4and filtered. The filtrate was concentrated under vacuum. This resulted in 2-bromo-3-(bromomethyl)-5-chloropyridine (30 g, 87 %) as a yelow oil. The crude product was used in the next step directly without further purification. LCMS (ESI+): m / z 282.4. Step 2: Tert-butyl (2S)-3-(2-bromo-5-chloropyridin-3-yl)-2- [(diphenylmethylidene)amino]propanoate:

[0278] To a stired mixture of 2-bromo-3-(bromomethyl)-5-chloropyridine (15 g, 52.57 mmol, 1 eq.), (2S,4S,5R)-1-[(anthracen-9-yl)methyl]-5-ethenyl-2-[(R)-(prop-2-en-1- yloxy)(quinolin-4-yl)methyl]-1-azabicyclo[2.2.2]octan-1-ium bromide (1591.69 mg, 2.63 mmol, 0.05 eq.) and isopropyl 2-[(diphenylmethylidene)amino]acetate (29578.95 mg, 105.13 mmol, 2 eq.) in DCM (100 mL) was added KOH (29.49 g, 525.65 mmol, 10 eq.) in H2O (30 mL) in portions at -10 oC under air atmosphere. The resulting mixture was stired for an additional 4 h at -10 oC. The resulting mixture was extracted with EtOAc (2 x 200 mL), and the combined organic layers were dried over anhydrous Na2SO4and filtered. The filtrate was concentrated under vacuum. The residue was purified by silica gel column chromatography,eluted with PE / EA (10:1) to aford tert-butyl (2S)-3-(2-bromo-5-chloropyridin-3-yl)-2- [(diphenylmethylidene)amino]propanoate (25 g, 95 %) as a yelow oil. LCMS (ESI+): m / z 501.1. Step 3: (S)-2-amino-3-(2-bromo-5-chloropyridin-3-yl)propanoic acid:

[0279] A mixture of tert-butyl (2S)-3-(2-bromo-5-chloropyridin-3-yl)-2- [(diphenylmethylidene)amino]propanoate (5 g, 10.0 mmol, 1 eq.) and HCl (6M) (30 mL) in THF (10 mL) was stired overnight at 55 oC. The resulting mixture was concentrated under vacuum. This resulted in (2S)-2-amino-3-(2-bromo-5-chloropyridin-3-yl)propanoic acid (2.6 g, 93 %) as a yelow oil. The crude product was used in the next step directly without further purification. LCMS (ESI+): m / z 278.9. Step 4: (2S)-3-(2-bromo-5-chloropyridin-3-yl)-2-[(tert-butoxycarbonyl)amino]propanoic acid:

[0280] To a stired mixture of (2S)-2-amino-3-(2-bromo-5-chloropyridin-3-yl)propanoic acid (9 g, 32.20 mmol, 1 eq.) and Na2CO3 (10.24 g, 96.59 mmol, 3 eq.) in H2O (60 mL) was added Boc2O (14.05 g, 64.40 mmol, 2 eq.) in portions at rt under air atmosphere. The resulting mixture was stired overnight at rt. The mixture was acidified to pH=6 with diluted HCl (aq.1N). The resulting mixture was extracted with EtOAc (2 x 100 mL), and the combined organic layers were dried over anhydrous Na2SO4and filtered. The filtrate was concentrated under vacuum. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% FA), 10% to 100% gradient in 30 min; detector, UV 210 nm. This resulted in (2S)-3-(2-bromo-5-chloropyridin-3-yl)-2-[(tert-butoxycarbonyl)amino]propanoic acid (12 g, 98 %) as a white solid. LCMS (ESI+): m / z 380.90. Step 5: (2S)-3-(2-bromo-5-chloropyridin-3-yl)-2-[(tert- butoxycarbonyl)(methyl)amino]propanoic acid:

[0281] NaH (6.32 g, 263.41 mmol, 10 eq.) was added into a stired mixture of (2S)-3-(2- bromo-5-chloropyridin-3-yl)-2-[(tert-butoxycarbonyl)amino]propanoic acid (10 g, 26.34 mmol, 1 eq.) in THF (100 mL) portion wise at 0oC under nitrogen and the resulting mixture was stired for 1 h at 0oC. MeI (56.08 g, 395.12 mmol, 15 eq.) was added dropwise at 0 oC under nitrogen atmosphere. The resulting mixture was stired overnight at rt. The reaction was quenched with water at 0oC. The mixture was acidified to pH= 6 with HCl (aq.). The resulting mixture was extracted with EtOAc (2 x 120 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% FA), 10% to 100% gradient in 30 min; detector, UV 220 nm. This resulted in (2S)-3-(2-bromo-5-chloropyridin-3-yl)-2-[(tert- butoxycarbonyl)(methyl)amino]propanoic acid (7.3 g, 70 %) as a yelow oil. Step 6: Int.22:

[0282] To a stired mixture of (2S)-3-(2-bromo-5-chloropyridin-3-yl)-2-[(tert- butoxycarbonyl)(methyl)amino]propanoic acid (2.5 g, 6.35 mmol, 1 eq.) and 1-[4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridin-1-yl]ethanone (2392.26 mg, 9.53 mmol, 1.5 eq.) in dioxane (20 mL) was added Na2CO3 (2019.28 mg, 19.05 mmol, 3 eq.)and Pd(dppf)Cl2.DCM Adduct (517.34 mg, 0.635 mmol, 0.1eq) in portions at rt under nitrogen atmosphere. The resulting mixture was stired for an additional 3 h at 80 oC. The mixture was acidified to pH=6 with HCl (aq.1N). The resulting mixture was extracted with EtOAc (2 x 60 mL), and the combined organic layers were dried over anhydrous Na2SO4and filtered. The filtrate was concentrated under vacuum. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% FA), 10% to 100% gradient in 30 min; detector, UV 254 nm. This resulted in Int.22 (1.94 g, 66 %) as a brown solid. LCMS (ESI+): m / z 438.2.1H NMR (400 MHz, DMSO-d6) δ 12.99 (s, 1H), 8.45 (dd, J = 15.5, 2.4 Hz, 1H), 7.81 (dd, J = 53.7, 2.4 Hz, 1H), 5.86 (d, J = 33.1 Hz, 1H), 4.85 – 4.50 (m, 1H), 4.09 (t, J = 30.1, 13.7 Hz, 2H), 3.90 – 3.47 (m, 2H), 3.42 – 3.24 (m, 2H), 3.11 (dt, J = 26.2, 13.1 Hz, 1H), 2.58 – 2.37 (m, 4H), 2.41 – 2.15 (m, 1H), 2.05 (dd, J = 12.3, 2.5 Hz, 3H), 1.23 (dd, J = 31.0,3.0 Hz, 9H). Int.23: Preparation of (S)-2-(tert-butoxycarbonyl)(methyl)amino)-3-(5-chloro-2- cyclopropoxyphenyl)propanoic acidStep 1: 4-chloro-1-cyclopropoxy-2-nitrobenzene:

[0283] To a solution of 4-chloro-1-fluoro-2-nitrobenzene (40 g, 227.86 mmol, 1 eq) in DMF (400 mL) was added cyclopropanol (19.85 g, 341.79 mmol, 1.5 eq) and Cs2CO3 (111.36 g, 341.79 mmol, 1.5 eq), the mixture was stired at 75 °C for 12 h under N2. The reaction was monitored by LCMS, which showed 4-chloro-1-fluoro-2-nitrobenzene was consumed and one of peak with desired mass was detected. After cooling to rt, the filtrate was diluted with water (400 mL), extracted with EtOAc (200 mL x 3). The combined organics were washed with brine (400 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue.4-chloro-1-cyclopropoxy-2-nitrobenzene (35 g, crude) was obtained as a black, brown oil.Step 2: 5-chloro-2-cyclopropoxyaniline:

[0284] To a solution of 4-chloro-1-cyclopropoxy-2-nitrobenzene (35 g, 163.84 mmol, 1 eq) in H2O (280 mL) and ethanol (280 mL) was added Fe (45.75 g, 819.22 mmol, 5 eq) and NH4Cl (4.38 g, 81.92 mmol, 0.5 eq), the mixture was stired at 80 °C for 1 h. The reaction was monitored by LCMS, which showed 4-chloro-1-cyclopropoxy-2-nitrobenzene was consumed and one of peak with desired mass was detected. After cooling to rt, the reaction mixture was filtered, and the filter cake was rinsed with EtOAc (100 mL x 3). Then the combined filtrates were concentrated under reduced pressure to give a residue, 5-chloro-2- cyclopropoxyaniline (26 g, 115.93 mmol, 71 % yield, 82% purity) was obtained as a yelow oil. Step 3: 4-chloro-1-cyclopropoxy-2-iodobenzene:

[0285] To a solution of 5-chloro-2-cyclopropoxyaniline (20 g, 108.91 mmol, 1 eq) in H2O (216 mL) was added hydrogen chloride (12 M, 27.23 mL, 3 eq) dropwise at 0 °C adjusted pH to 2, the mixture was stired at 0 °C for 0.5 hr, a solution of NaNO2 (8.27 g, 119.80 mmol, 1.1 eq) in H2O (36 mL) was added to the mixture dropwise at 0 °C and stired for 1 hr. Then the reaction mixture was added to a solution of KI (54.24 g, 326.74 mmol, 3 eq) in H2O (200 mL), the mixture was stirred at 20 °C for 12 hr. The reaction was monitored by LCMS, which showed 5-chloro-2-cyclopropoxyaniline was consumed and one of peak with desired mass was detected. The mixture was filtered, and filtrate was diluted with water (300 mL), extracted with EtOAc (150 mL x 3). The combined organics were washed with brine (150 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give residue. The residue was dissolved in DCM (100 mL), and 60 g of silica gel was added. The resulting mixture was evaporated under reduced pressure to give a dry flowing solid, and then it was loaded to Biotage® using a 120 g agela flash silica gel column, eluted with 0 % to 12 % EtOAc in PE with the flower rate of 75 mL / min. The product fraction was combined and evaporated.4-chloro-1-cyclopropoxy-2-iodobenzene (20 g, 65.46 mmol, 60 % yield, 96.4% purity) was obtained as a black, brown oil.Step 4: Methyl (S)-2-(tert-butoxycarbonyl)amino)-3-(5-chloro-2- cyclopropoxyphenyl)propanoate:

[0286] A mixture of Zn (34.77 g, 531.70 mmol, 3.5 eq) in DMF (210 mL) was degassed and purged with N2 for 3 times, and the mixture was stired at 120 °C for 10 min under N2 atmosphere. Then I2 (11.57 g, 45.57 mmol, 9.18 mL, 0.3 eq) in DMF (120 mL) was added dropwise at 20 °C, methyl (R)-2-(tert-butoxycarbonyl)amino)-3-iodopropanoate (50 g, 151.92 mmol, 1 eq) in DMF (40 mL) was added dropwise, I2 (11.57 g, 45.57 mmol, 9.18 mL, 0.3 eq) in DMF (40 mL) was added dropwise, the reaction mixture was stired at 20 °C for 1 hr. The reaction was monitored by TLC (PE: EtOAc = 5:1, Rf = 0.5) showed starting material was consumed completely and a new major spot was detected. The crude product was used into the next step without further purification. (R)-(2-(tert-butoxycarbonyl)amino)-3- methoxy-3-oxopropyl)zinc(I) iodide (59.93 g, crude) was obtained as a grey liquid. The zincate was used without further purification.

[0287] To a solution of 4-chloro-1-cyclopropoxy-2-iodobenzene (20 g, 67.91 mmol, 1 eq), sPhos (4.18 g, 10.19 mmol, 0.15 eq) and Pd2(dba)3 (6.22 g, 6.79 mmol, 0.1 eq) in DMF (400 mL) was degassed and purged with N2 for 3 times. Then (R)-(2-(tert- butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)zinc(I) iodide (53.58 g, 135.82 mmol, 2 eq) in DMF was added dropwise. Then the reaction mixture was stired at 20 °C for 12 hr. The reaction was monitored by LCMS, which showed 4-chloro-1-cyclopropoxy-2-iodobenzene was consumed and one of peaks with desired mass was detected. The reaction was quenched by addition of saturated ammonium chloride aqueous solution (200 mL) and filtered, the filtrate was diluted with water (100 mL), extracted with EtOAc (100 mL x 3). The combined organics were washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Waters Xbridge BEH C18250 x 70 mm x10 um; mobile phase: [water (NH4HCO3)- ACN]; B%:50%-80%,18 min) the HPLC fractions were combined, lyophilized. Methyl (S)-2- (tert-butoxycarbonyl)amino)-3-(5-chloro-2-cyclopropoxyphenyl)propanoate (8 g, 19.53 mmol, 29 % yield, 98% purity) was obtained as a yelow oil.Step 5: (S)-2-((tert-butoxycarbonyl)amino)-3-(5-chloro-2- cyclopropoxyphenyl)propanoic acid:

[0288] To a solution of methyl (S)-2-(tert-butoxycarbonyl)amino)-3-(5-chloro-2- cyclopropoxyphenyl)propanoate (8 g, 21.63 mmol, 1 eq) in THF (112 mL) was added LiOH.H2O (1.09 g, 25.96 mmol, 1.2 eq) in H2O (56 mL), the mixture was stired at 20 °C for 1 hr. The reaction was monitored by LCMS, which showed methyl (S)-2-((tert- butoxycarbonyl)amino)-3-(5-chloro-2-cyclopropoxyphenyl)propanoate was consumed and one of peak with desired mass was detected. The mixture was acidified pH = 5 by adding hydrochloric acid (0.1 M, 15 mL) dropwise at 0 °C. The residue was diluted with water (100 mL), extracted with EtOAc (40 mL x 3). The combined organics were washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. (S)-2-(tert- butoxycarbonyl)amino)-3-(5-chloro-2-cyclopropoxyphenyl)propanoic acid (5 g, 13.77 mmol, 64 % yield, 98% purity) was obtained as a yelow solid. Step 6: Int.23:

[0289] To a solution of (S)-2-((tert-butoxycarbonyl)amino)-3-(5-chloro-2- cyclopropoxyphenyl)propanoic acid (5 g, 14.05 mmol, 1 eq) in THF (50 mL) was added NaH (2.81 g, 70.26 mmol, 60% purity, 5 eq) at 0 °C, the mixture was stired at 0 °C for 1 h under N2, MeI (19.95 g, 140.52 mmol, 8.75 mL, 10 eq) was added to the reaction mixture, the mixture was stired at 20 °C for 12 h. The reaction was monitored by LCMS, which showed (S)-2-(tert-butoxycarbonyl)amino)-3-(5-chloro-2-cyclopropoxyphenyl)propanoic acid was consumed and one of peak with desired mass was detected. The reaction was quenched by addition of saturated ammonium chloride aqueous solution (20 mL), the mixture was acidified pH = 5 by adding hydrochloric acid (0.1 M, 10 mL) dropwise at 0 °C. The residuewas extracted with EtOAc (20 mL x 3). The combined organics were washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue Int.23 (3 g, 7.71 mmol, 54 % yield, 95% purity) was obtained as a yelow oil.1H NMR (400 MHz, DMSO-d6) 1H NMR (400 MHz, DMSO-d6) δ = 7.31 - 7.08 (m, 3H), 4.85 - 4.52 (m, 1H), 3.91 - 3.80 (m, 1H), 3.12 - 2.99 (m, 1H), 2.94 - 2.80 (m, 1H), 2.65 - 2.55 (m, 3H), 1.24 (br d, J = 19.6 Hz, 9H), 0.87 - 0.58 (m, 4H) Int.24: Preparation of (2S)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-[5-chloro-2- (morpholin-4-yl)phenyl]propanoic acidStep 1: (2S)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-[5-chloro-2-(morpholin-4- yl)phenyl]propanoate

[0290] A solution of methyl (2S)-3-(2-bromo-5-chlorophenyl)-2-[(tert- butoxycarbonyl)(methyl)amino]propanoate (3 g, 7.376 mmol, 1 equiv.), Cs2CO3 (7232.46 mg, 22.128 mmol, 3 equiv.), morpholine (771.18 mg, 8.851 mmol, 1.2 equiv.), SPhos (605.66 mg, 1.475 mmol, 0.2 equiv.) and Pd2(dba)3 (675.48 mg, 0.738 mmol, 0.1 equiv.) in dioxane (50 mL) was stired for 3 h at 80 oC under nitrogen atmosphere. The residual Cs2CO3 was removed by filtration. The residue was purified by silica gel column chromatography, eluted with PE / EA (5:1) to aford methyl (2S)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-[5- chloro-2-(morpholin-4-yl)phenyl]propanoate (1.15 g, 38 %) as a brown oil. LCMS (ESI+): m / z 413 (M+H+). Step 2: Int.24:

[0291] To a stired solution of methyl (2S)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-[5- chloro-2-(morpholin-4-yl)phenyl]propanoate (1.2 g, 2.906 mmol, 1 equiv.) in tetrahydrofuran (15 mL) was added caustic soda (0.58 g, 14.530 mmol, 5 equiv.) in water (5 mL) dropwise at 0 °C. The resulting mixture was stired for 16 h at rt. The resulting mixture was concentrated under reduced pressure and then diluted with water (20 mL). The resulting mixture was acidified to pH=3 with diluted citric acid (1N) and then extracted with EtOAc (3x100 mL). The combined organic layers were washed with brine (1x100 mL) and dried over anhydrous Na2SO4. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% FA), 10% to 50% gradient in 10 min; detector, UV 220 nm. After filtration, the filtrate was concentrated under reduced pressure. This resulted in Int.24 (0.81 g, 70 %) as a Brown yelow solid. LCMS (ESI+): m / z 399 (M+H+). Int.25: Preparation of (S)-2-(tert-butoxycarbonyl)(methyl)amino)-3-(5-chloro-2- morpholinopyridin-3-yl)propanoic acidStep 1: 4-(3-bromo-5-chloropyridin-2-yl)morpholine:

[0292] A solution of 3-bromo-5-chloro-2-fluoropyridine (10 g, 47.52 mmol, 1 eq) in DMF (600 mL) was treated with Cs2CO3 (46.45 g, 142.57 mmol, 3 eq) at rt under nitrogen atmosphere folowed by the addition of morpholine (6.21 g, 71.28 mmol, 1.5 eq.) in portionsat rt. The resulting mixture was stired for 16 h at rt under nitrogen atmosphere. Desired product could be detected by LCMS. The resulting mixture was diluted with ice water (1 L) and extracted with EtOAc (2 x 1L). The combined organic layers were washed with brine (500mL x 3) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% FA), 10% to 100% gradient in 40 min; detector, UV 200.210 nm. This resulted in 4-(3- bromo-5-chloropyridin-2-yl)morpholine (3 g, 23 %) as a light-yelow solid. LCMS (ESI+): m / z 279.00. Step 2: Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-[5-chloro-2-(morpholin-4- yl)pyridin-3-yl]propanoate:

[0293] A solution of 4-(3-bromo-5-chloropyridin-2-yl)morpholine (3.3 g, 11.89 mmol, 1 eq.) in DMA (30 mL) was treated with CuI (0.45 g, 2.38 mmol, 0.2 eq.) and Pd(dppf)Cl2.CH2Cl2(0.87g, 1.19 mmol.0.1 eq.) at rt under nitrogen atmosphere folowed by the addition of methyl (2R)-2-[(tert-butoxycarbonyl)amino]-3-(iodozincio)propanoate (33 mL) at rt. The resulting mixture was stired for 16 h at 80 °C under nitrogen atmosphere. Desired product could be detected by LCMS. The reaction was quenched with water (200 mL) and diluted with EA (200 mL). The precipitated solids were removed by filtration and washed with EtOAc (2 x 200 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% FA), 10% to 100% gradient in 40 min; detector, UV 200.210 nm. The residue was purified by Prep-TLC (PE / EA 2:1) to aford methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-[5-chloro-2-(morpholin-4-yl)pyridin-3- yl]propanoate (1 g, 21 %) as a light-yelow oil. LCMS (ESI+): m / z 400.15. Step 3: Methyl (2S)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-[5-chloro-2-(morpholin- 4-yl)pyridin-3-yl]propanoate:

[0294] A solution of methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-[5-chloro-2- (morpholin-4-yl)pyridin-3-yl]propanoate (700 mg, 1.75 mmol, 1 eq.) in DMF (10 mL, 129.22 mmol) was treated with Ag2O (2 g, 8.76 mmol, 5 eq.) at rt under nitrogen atmosphere folowed by the addition of CH3I (2.4 g, 17.51 mmol, 10 eq.) at rt. The resulting mixture was stired for 16 h at rt under nitrogen atmosphere. Desired product could be detected by LCMS. The resulting mixture was extracted with EtOAc (2 x 100 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-TLC (PE / EA 2:1) to aford methyl (2S)- 2-[(tert-butoxycarbonyl)(methyl)amino]-3-[5-chloro-2-(morpholin-4-yl)pyridin-3- yl]propanoate (500 mg, 69 %) as a light-yelow oil. LCMS (ESI+): m / z 414.15.1H NMR (400 MHz, DMSO-d6)： δ 1.15 – 1.34 (m, 8H), 2.61 (d, J = 8.9 Hz, 2H), 2.94 – 3.13 (m, 4H), 3.23 (dd, J = 14.7, 4.5 Hz, 1H), 3.66 – 3.75 (m, 5H), 7.69 (dd, J = 34.4, 2.6 Hz, 1H), 8.22 (dd, J = 13.9, 2.6 Hz, 1H). Step 4: Int.25:

[0295] A solution of methyl (2S)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-[5-chloro-2- (morpholin-4-yl)pyridin-3-yl]propanoate (660 mg, 1.60 mmol, 1 eq.) in THF (10 mL) was treated with NaOH (318.89 mg, 7.98 mmol, 5 eq.) in water (10 mL) at 0 °C. The resulting mixture was stired for 2 h at rt. Desired product could be detected by LCMS. The mixture neutralized to pH=2 with diluted HCl(1N). The resulting mixture was extracted with EtOAc (2 x 50 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silicagel; mobile phase, MeCN in Water (0.1% FA), 10% to 100% gradient in 40 min; detector, UV 200.210 nm. This resulted in Int.25 (423 mg, 66 %) as a white solid. LCMS (ESI+): m / z 400.15.1H NMR (400 MHz, DMSO-d6): δ 1.26 (s, 9H), 2.61 (d, J = 8.7 Hz, 3H), 3.00 (tq, J = 13.5, 8.6, 7.2 Hz, 4H), 3.63 – 3.78 (m, 4H), 5.03 (ddd, J = 148.8, 11.4, 4.2 Hz, 1H), 7.67 (dd, J = 35.8, 2.6 Hz, 1H), 8.21 (dd, J = 14.5, 2.6 Hz, 1H), 12.91 (s, 1H). Int.26: Preparation of (S)-2-(tert-butoxycarbonyl)(methyl)amino)-3-(7-chloro-2,3- dihydrobenzo[b][1,4]dioxin-5-yl)propanoic acidStep 1: 5-chloro-2-hydroxy-3-nitrophenyl acetate:

[0296] Add TFAA (409.17 g, 1.95 mol, 270.97 mL, 10 eq.) to a three-necked flask, add H2O2 (110.44 g, 974.07 mmol, 93.59 mL, 30% purity, 5 eq.) dropwise at -10 °C. After 10 min, add a solution of 1-(5-chloro-2-hydroxy-3-nitrophenyl)ethan-1-one (42 g, 194.81 mmol, 1 eq) in DCM (250 mL) dropwise. The reaction mixture was stired at 20 °C for 12 h. The reaction was monitored by LCMS, which showed starting material was consumed and one of peak with desired mass was detected. The reaction mixture was diluted with water (100 mL), extracted with DCM (300 mL x 3). The combined organics were washed with sodium sulfite aqueous solution (100 mL, 1M) and brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give 5-chloro-2-hydroxy-3-nitrophenyl acetate (30 g, 124.36 mmol, 64 % yield, 96% purity) as a yelow solid. LCMS (ESI+): m / z 230.0 (M+H+). Step 2: 5-chloro-3-nitrobenzene-1,2-diol:

[0297] To a solution of 5-chloro-2-hydroxy-3-nitrophenyl acetate (30 g, 129.54 mmol, 1 eq) in EtOH (300 mL) was added NaOH (12.95 g, 129.54 mmol, 40 mL, 40% purity in H2O, 1 eq), the mixture was stired at 20 °C for 2 h. The reaction was monitored by LCMS, which showed starting material was consumed and one of peak with desired mass was detected. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was acidified pH = 4 by adding hydrochloric acid (1 M, 50 mL) dropwise at 0 °C. The mixture was extracted with EtOAc (200 mL x 3). The combined organics were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give 5-chloro-3- nitrobenzene-1,2-diol (22 g, 113.74 mmol, 87.80% yield, 98% purity) as a yelow solid. LCMS (ESI+): m / z 188.0 (M+H+). Step 3: 7-chloro-5-nitro-2,3,-dihydrobenzo[b][1,4]dioxine:

[0298] To a solution of 5-chloro-3-nitrobenzene-1,2-diol (10 g, 52.76 mmol, 1 eq) in DMF (100 mL) was added 1,2-dibromoethane (9.91 g, 52.76 mmol, 3.98 mL, 1 eq) and K2CO3 (14.58 g, 105.51 mmol, 2 eq) at 20 °C. Then the mixture was stired at 80 °C for 12 h. The reaction was monitored by LCMS, which showed starting material was consumed and one of main peak was detected. The reaction mixture was cooled to rt and diluted by water (100 mL), extracted with EtOAc (60 mL x 3). The combined organics were washed with water (100 mL x 2). Then the combined organics were washed with brine (200 mL), dried over Na2SO4, filtered and the reaction mixture was concentrated under reduced pressure to give 7- chloro-5-nitro-2,3,-dihydrobenzo[b][1,4]dioxine (11 g, 51.0 mmol, 97 % yield) as a black, brown oil. Step 4: 7-chloro-2,3-dihydrobenzo[b][1,4]dioxin-5-amine:

[0299] To a solution of 7-chloro-5-nitro-2,3,-dihydrobenzo[b][1,4]dioxine (16 g, 74.21 mmol, 1 eq) in EtOH (80 mL) and H2O (80 mL) were added Fe (20.72 g, 371.07 mmol, 5 eq) and NH4Cl (19.85 g, 371.07 mmol, 5 eq) at 20 °C. The reaction was stired at 80 °C for 2 h. The reaction was monitored by LCMS, which showed starting material was consumed and one of main peak with desired mass was detected. The reaction mixture was filtered through a pad of celite and the celite was rinsed with EtOAc (100 mL). The filtrate was diluted with water (100 mL), extracted with EtOAc (120 mL x 3). The combined organics were washed with brine (200 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was dissolved in DCM (200 mL), and 50 g of silica gel was added. The resulting mixture was evaporated under reduced pressure to give a dry flowing solid, and then it was loaded to Biotage® using an 80 g Agela flash silica gel column, eluted with 30 % to 40 % EtOAc in PE with the flower rate of 75 mL / min. The product fraction was combined and evaporated to give 7-chloro-2,3-dihydrobenzo[b][1,4]dioxin-5-amine (8.6 g, 43.84 mmol, 30 % yield, 94 % purity) as a brown oil. LCMS (ESI+): m / z 186.3 (M+H+). Step 5: 7-chloro-5-iodo-2,3-dihydrobenzo[b][1,4]dioxine:

[0300] To a solution of 7-chloro-2,3-dihydrobenzo[b][1,4]dioxin-5-amine (4.6 g, 24.78 mmol, 1 eq) in MeCN (24 mL) was added hydrogen chloride (2.5 M, 49.57 mL, 5 eq) at 0 °C. The mixture was stired at 0 °C for 0.5 h. Then a solution of NaNO2 (1.88 g, 27.26 mmol, 1.1 eq) in H2O (20 mL) was added to the reaction mixture, the mixture was stirred at 0 °C for 0.5 h. Then a solution of KI (12.34 g, 74.35 mmol, 3 eq) in H2O (100 mL) was added to the reaction mixture, the reaction mixture was stired at 0 °C for 2 h. The reaction was monitored by LCMS, which showed starting material was consumed and one of main peak with desired mass was detected. The mixture was adjusted pH = 7-8 by adding saturated NaHCO3 aqueous solution slowly at 0 °C. Then the mixture was extracted with EtOAc (50 mL x 3). The combined organics were washed with brine (100 mL), dried over Na2SO4, filtered, andconcentrated under reduced pressure to give a residue. The residue was dissolved in DCM (50 mL), and 20 g of silica gel was added. The resulting mixture was evaporated under reduced pressure to give a dry flowing solid, and then it was loaded to Biotage® using a 40 g Agela flash silica gel column, eluted with 15 % to 20 % EtOAc in PE with the flower rate of 75 mL / min. The product fraction was combined and evaporated to give 7-chloro-5-iodo-2,3- dihydrobenzo[b][1,4]dioxine (6.5 g, 21.71 mmol, 88 % yield, 99 % purity) as a black, purple solid. LCMS (ESI+): m / z 298.1(M+H+). Step 6: methyl (S)-2-(tertbutoxycarbonyl)amino)-3-(7-chloro-2,3- dihydrobenzo[b][1,4]dioxin-5-yl)propanoate:

[0301] A mixture of Zn (13.91 g, 212.68 mmol, 3.5 eq) in DMF (100 mL) was degassed and purged with N2 for 3 times, and the mixture was stired at 120 °C for 10 min under N2 atmosphere. Then I2 (4.63 g, 18.23 mmol, 3.7 mL, 0.3 eq) in DMF (40 mL) was added dropwise at 20 °C, methyl (2R)-2-(tert-butoxycarbonylamino)-3-iodo-propanoate (20 g, 60.77 mmol, 1 eq) in DMF (30 mL) was added dropwise, I2 (4.63 g, 18.23 mmol, 3.67 mL, 0.3 eq) in DMF (30 mL) was added dropwise, the reaction mixture was stired at 20 °C for 1 hr. The zincate was used into the next step without further purification. [(2R)-2-(tert- butoxycarbonylamino)-3-methoxy-3-oxo-propyl]-iodo-zinc (23.95 g, 60.71 mmol, 99.9% yield) was obtained as a gray liquid. To a solution of 7-chloro-5-iodo-2,3- dihydrobenzo[b][1,4]dioxine (9 g, 30.36 mmol, 1 eq) in DMF (90 mL) was added [(2R)-2- (tert-butoxycarbonylamino)-3-methoxy-3-oxo-propyl]-iodo-zinc (23.95 g, 60.71 mmol, 2 eq), Pd2(dba)3 (1.39 g, 1.52 mmol, 0.05 eq) and SPhos (1.25 g, 3.04 mmol, 0.1 eq) at 20 °C. Then the mixture was stired at 20 °C for 12 h. The reaction was monitored by LCMS, which showed starting material was consumed and one of main peak with desired mass was detected. The reaction mixture was diluted by water (90 mL), extracted with EtOAc (100 mL x 3). The combined organics were washed with water (150 mL x 2). Then the combined organics were washed with brine (200 mL), dried over Na2SO4, filtered and the reaction mixture was concentrated under reduced pressure to give a residue. The residue wasdissolved in DCM (30 mL), and 18 g of silica gel was added. The resulting mixture was evaporated under reduced pressure to give a dry flowing solid, and then it was loaded to Biotage® using a 40 g Agela flash silica gel column, eluted with 0 % to 20 % EtOAc in PE with the flower rate of 75 mL / min. The product fraction was combined and evaporated to give methyl (S)-2-(tertbutoxycarbonyl)amino)-3-(7-chloro-2,3-dihydrobenzo[b][1,4]dioxin- 5-yl)propanoate (6 g, 15.55 mmol, 51% yield, 96 % purity) a yelow oil. Step 7: (S)-2-((tert-butoxycarbonyl)amino)-3-(7-chloro-2,3-dihydrobenzo[b][1,4]dioxin- 5-yl)propanoic acid:

[0302] To a solution of methyl (S)-2-(tertbutoxycarbonyl)amino)-3-(7-chloro-2,3- dihydrobenzo[b][1,4]dioxin-5-yl)propanoate (5.5 g, 14.79 mmol, 1 eq) in THF (36 mL) was added a solution of LiOH.H2O (744.89 mg, 17.75 mmol, 1.2 eq) in H2O (18 mL) at 0 °C. The mixture was stired at 20 °C for 2 h. The reaction was monitored by LCMS, which showed starting material was consumed and one of main peak with desired mass was detected. The mixture was acidified by adding hydrochloric acid (1 M) dropwise at 0 °C to pH = 3. The mixture was extracted with EtOAc (50 mL x 3). The combined organics were washed with brine (80 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was dissolved in DCM (30 mL), and 10 g of silica gel was added. The resulting mixture was evaporated under reduced pressure to give a dry flowing solid, and then it was loaded to Biotage® using a 40 g Agela flash silica gel column, eluted with 0 % to 35 % EtOAc in PE with the flower rate of 75 mL / min. The product fraction was combined and evaporated to give (S)-2-(tert-butoxycarbonyl)amino)-3-(7-chloro-2,3- dihydrobenzo[b][1,4]dioxin-5-yl)propanoic acid (5.2 g, 14.53 mmol, 98 % yield, 100% purity) as a yelow oil. LCMS (ESI+): m / z 380.2 (M+Na+). Step 8: Int.26:

[0303] To a solution of (S)-2-((tert-butoxycarbonyl)amino)-3-(7-chloro-2,3- dihydrobenzo[b][1,4]dioxin-5-yl)propanoic acid (2.6 g, 7.27 mmol, 1 eq.) in THF (60 mL) was added NaH (1.45 g, 36.33 mmol, 60% purity, 5 eq) at 0 °C, the mixture was stired at 0 °C for 1 h under N2. MeI (10.31 g, 72.67 mmol, 4.52 mL, 10 eq.) was added to the reaction mixture, the mixture was stired at 20 °C for 12 h under N2. (Batch 2) The reaction was monitored by LCMS, which showed starting material was consumed and one of main peaks with desired mass was detected. The reaction was quenched by saturated ammonium chloride (30 mL) at 0 °C, extracted with EtOAc (60 mL x 2). The combined organics were washed with brine (50 mL), dried over Na2SO4, filtered and the reaction mixture was concentrated under reduced pressure to give Int.26 (3.9 g, 10.0 mmol, 69 % yield, 96 % purity) as a pale- yelow solid.). LCMS (ESI+): m / z 394.1 (M+Na+).1H NMR (400 MHz, CHLOROFORM- d). δ ppm 1.40 (d, J=10.8 Hz, 9 H) 2.67 - 2.82 (m, 3 H) 3.00 - 3.13 (m, 1 H) 3.15 - 3.35 (m, 1 H) 4.18 - 4.34 (m, 4 H) 4.61 - 4.91 (m, 1 H) 6.68 (d, J=11.6 Hz, 1 H) 6.79 (d, J=2.0 Hz, 1 H). Int.27: Preparation of (S)-2-(tert-butoxycarbonyl)(methyl)amino)-3-(5-chloro-2- methylpyridin-3-yl)propanoic acid

[0304] NaBH4(6.11 g, 161.63 mmol, 3 eq.) was added into a mixture of methyl 5-chloro-2- methylpyridine-3-carboxylate (10 g, 53.88 mmol, 1 eq.) in MeOH (200 mL) at 0 oC under air atmosphere. The mixture was stired overnight at rt. Then the reaction wasquenched with water (100 mL) and concentrated in vacuo. The residual water phase was extracted with EtOAc (2 x 200 mL). The combined organic layers were dried over anhydrous Na2SO4and filtered. The filtrate was concentrated under vacuum. The residue was purified by silica gel column chromatography, eluted with PE / EA (10:1) to aford (5-chloro- 2-methylpyridin-3-yl)methanol (6.1 g, 72 %) as a yelow oil. LCMS (ESI+): m / z 158.0. Step 2: 3-(bromomethyl)-5-chloro-2-methylpyridine:

[0305] PBr3 (31431.18 mg, 116.12 mmol, 3 eq.) was added into a mixture of (5-chloro-2- methylpyridin-3-yl)methanol (6.1 g, 38.71 mmol, 1 eq.) in DCM (50 mL) dropwise at 0 oC under nitrogen atmosphere. The mixture was stired for 3 h at 0oC. The resulting mixture was quenched with water (50 mL) at 0oC and extracted with EtOAc (2 x 100 mL). The combined organic layers were dried over anhydrous Na2SO4and filtered. The filtrate was concentrated under vacuum. This resulted in 3-(bromomethyl)-5-chloro-2-methylpyridine (7 g, 82 %) as a yelow oil. The crude product was used in the next step directly without further purification. LCMS (ESI+): m / z 222.1. Step 3: Tert-butyl (2S)-3-(5-chloro-2-methylpyridin-3-yl)-2- [(diphenylmethylidene)amino]propanoate:

[0306] To a stired mixture of 3-(bromomethyl)-5-chloro-2-methylpyridine (6.1 g, 27.67 mmol, 1 eq.) and tert-butyl 2-[(diphenylmethylidene)amino]acetate (12257.90 mg, 41.50 mmol, 1.5 eq.) in DCM (60 mL) was added KOH (15521.82 mg, 276.66 mmol, 10 eq.) in H2O (15 mL) in portions at -10 oC under air atmosphere. The resulting mixture wasstired overnight at -10oC. The resulting mixture was extracted with DCM (2 x 100 mL) and the combined organic layers were dried over anhydrous Na2SO4and filtered. The filtrate was concentrated under vacuum. The residue was purified by silica gel column chromatography, eluted with PE / EA (10:1) to aford tert-butyl (2S)-3-(5-chloro-2-methylpyridin-3-yl)-2- [(diphenylmethylidene)amino]propanoate (6.4 g, 53 %) as a yelow oil. LCMS (ESI+): m / z 435.0. Step 4: (S)-2-amino-3-(5-chloro-2-methylpyridin-3-yl)propanoic acid:

[0307] A mixture of tert-butyl (2S)-3-(5-chloro-2-methylpyridin-3-yl)-2- [(diphenylmethylidene)amino] propanoate (300 mg, 0.69 mmol, 1 eq.) and HCl (6M) (100.00 mL, 3291.28 mmol, 119.30 eq.) in THF (10 mL) was stired overnight at 55 oC under air atmosphere. The resulting mixture was concentrated under vacuum. This resulted in (2S)-2-amino-3-(5-chloro-2-methylpyridin-3-yl) propanoic acid (5 g, 84.43%) as a yelow oil. The crude product was used in the next step directly without further purification. LCMS (ESI+): m / z 215.0. Step 5: (2S)-2-[(tert-butoxycarbonyl)amino]-3-(5-chloro-2-methylpyridin-3- yl)propanoic acid:

[0308] To a stired mixture of (2S)-2-amino-3-(5-chloro-2-methylpyridin-3-yl)propanoic acid (4 g, 18.64 mmol, 1 eq.) and Boc2O (12.20 g, 55.91 mmol, 3.00 eq.) in H2O (100 mL) was added Na2CO3 (5.93 g, 55.91 mmol, 3 eq.) in portions at rt under air atmosphere. The resulting mixture was stired overnight at rt. The mixture was acidified to pH=6 with diluted HCl (aq.1N). The resulting mixture was stired overnight at 0 oC. The resulting mixture was extracted with EtOAc (2 x 100 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% TFA), 10% to 100% gradient in 35 min; detector,UV 220 nm. This resulted in (2S)-2-[(tert-butoxycarbonyl)amino]-3-(5-chloro-2- methylpyridin-3-yl)propanoic acid (5.6 g, 95 %) as a white solid. LCMS (ESI+): m / z 315.10. NMR (400 MHz, DMSO-d6): δ12.82 (s, 1H), 8.33 (d, J = 2.4 Hz, 1H), 7.65 (d, J = 2.5 Hz, 1H), 7.21 (d, J = 8.8 Hz, 1H), 4.28 – 4.10 (m, 1H), 3.11 (dd, J = 14.3, 4.4 Hz, 1H), 2.81 (dd, J = 14.4, 11.0 Hz, 1H), 2.47 (s, 3H), 1.30 (s, 9H). Step 6: Int.27:

[0309] NaH (1.19 g, 49.56 mmol, 6 eq.) was added into a stired mixture of (2S)-2-[(tert- butoxycarbonyl)amino]-3-(5-chloro-2-methylpyridin-3-yl)propanoic acid (2.6 g, 8.26 mmol, 1 eq.) in THF (25 mL) portion wise at 0oC under nitrogen. Then the mixture was stired for 1 h at 0oC. MeI (11.72 g, 82.60 mmol, 10 eq.) was added into the above solution at 0 oC under nitrogen atmosphere. The resulting mixture was stired overnight at rt. The reaction was quenched by the addition of sat. NHCl (a o 4 q.) (20 mL) at 0C. The mixture was acidified to pH=6 with diluted HCl (aq.1N). The resulting mixture was extracted with EtOAc (2 x 50mL), and the combined organic layers were dried over anhydrous Na2SO4and filtered. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% FA), 10% to 100% gradient in 35 min; detector, UV 210 nm. This resulted in Int.27 (3.71 g, 133 % mass recovery) as a yelow solid. LCMS (ESI+): m / z 329.10.1H NMR (400 MHz, DMSO-d6): δ 12.98 (s, 1H), 8.34 (dd, J = 16.6, 2.4 Hz, 1H), 7.59 (dd, J = 21.9, 2.4 Hz, 1H), 4.72 (ddd, J = 53.9, 11.2, 4.4 Hz, 1H), 3.27 – 2.92 (m, 2H), 2.65 (d, J = 2.0 Hz, 3H), 2.50 (s, 3H), 1.25 (d, J = 34.2 Hz, 9H). Int.28: Preparation of (S)-2-(tert-butoxycarbonyl)(methyl)amino)-3-(5-chloro-2-((1- methyl-1H-pyrazol-4-yl)oxy)pyridine-3-yl)propanoic acidStep 1: 5-chloro-3-iodo-2-(1-methyl-1H-pyrazol-4-yl)oxy)pyridine:

[0310] To a solution of 2,5-dichloro-3-iodopyridine (10 g, 36.51 mmol, 1 eq) in DMF (140 mL) was added Cs2CO3 (23.79 g, 73.02 mmol, 2 eq) and 1-methylpyrazol-4-ol (4.30 g, 43.81 mmol, 1.2 eq). The mixture was stired at 80 °C for 1 hr. LCMS showed 2,5-dichloro-3- iodopyridine was consumed completely and desired mass was detected. After cooling to rt, the reaction mixture was diluted with water (200 mL), extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The resulting crude product was purified by flash chromatography on silica gel (0 – 22 % EtOAc in PE).5-chloro-3-iodo-2- (1-methyl-1H-pyrazol-4-yl)oxy)pyridine (10.9 g, 29.59 mmol, 81 % yield, 91 % purity) was obtained as a yelow solid. Step 2: methyl (S)-2-(tert-butoxycarbonyl)amino)-3-(5-chloro-2-((1-methyl-1H-pyrazol- 4-yl)oxy)pyridine-3-yl)propanoate

[0311] A mixture of Zn (18.08 g, 276.49 mmol, 3.5 eq) in DMF (150 mL) was degassed and purged with N2 for 3 times, and the mixture was stired at 120 °C for 10 min under N2atmosphere. Then I2 (6.01 g, 23.70 mmol, 4.77 mL, 0.3 eq) in DMF (20 mL) was added dropwise at 20 °C, methyl (R)-2-(tert-butoxycarbonyl)amino)-3-iodopropanoate(26 g, 79.00 mmol, 1 eq) in DMF (70 mL) was added dropwise, I2 (6.01 g, 23.70 mmol, 4.77 mL, 0.3 eq) in DMF (20 mL) was added dropwise, the reaction mixture was stired at 20 °C for 1 hr. The zincate was used directly.

[0312] To a solution of 5-chloro-3-iodo-2-((1-methyl-1H-pyrazol-4-yl)oxy)pyridine (9.9 g, 29.51 mmol, 1 eq) in DMF (260 mL) was added Pd2(dba)3 (1.35 g, 1.48 mmol, 0.05 eq) and sPhos (1.21 g, 2.95 mmol, 0.1 eq) under N2 atmosphere, and then was added dropwise, (R)- (2-(tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)zinc(I) iodide (24.33 g in DMF, 61.67 mmol, 2.09 eq), under N2 atmosphere and the reaction was stired at 65 °C for 12 hr under N2. LCMS showed 5-chloro-3-iodo-2-(1-methyl-1H-pyrazol-4-yl)oxy)pyridine was consumed completely and desired mass was detected. The mixture was quenched by NH4Cl (200 mL) and extracted with EtOAc (200 mL x 3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The resulting crude product was purified by flash chromatography on silica gel (0 – 21 % EtOAc in PE) to give methyl (S)-2-(tert-butoxycarbonyl)amino)-3-(5-chloro- 2-(1-methyl-1H-pyrazol-4-yl)oxy)pyridine-3-yl)propanoate (5.6 g, 11.97 mmol, 41 % yield, 87.8% purity) as a pale-yelow gum. Step 3: (S)-2-((tert-butoxycarbonyl)amino)-3-(5-chloro-2-((1-methyl-1H-pyrazol-4- yl)oxy)pyridine-3-yl)propanoic acid:

[0313] To a solution of methyl (S)-2-(tert-butoxycarbonyl)amino)-3-(5-chloro-2-(1- methyl-1H-pyrazol-4-yl)oxy)pyridine-3-yl)propanoate (4.6 g, 11.20 mmol, 1 eq) in THF (40 mL) was added LiOH.H2O (704.75, 16.79 mol, 1499.99 eq) in H2O (20 mL) at 0 °C and the reaction was stired at 25 °C for 0.5 hr. LCMS showed methyl (S)-2-(tert- butoxycarbonyl)amino)-3-(5-chloro-2-((1-methyl-1H-pyrazol-4-yl)oxy)pyridine-3- yl)propanoate was consumed completely and desired mass was detected. The reactionmixture was washed with MTBE (10 mL x 2), then the aqueous phase was adjusted pH to 3-4 with 1M HCl, extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue, (S)-2-(tert-butoxycarbonyl)amino)-3-(5-chloro-2-(1-methyl-1H-pyrazol-4- yl)oxy)pyridine-3-yl)propanoic acid (4 g, 9.37 mmol, 84 % yield, 93% purity) was obtained as a pale yelow gum without purification. Step 4: Int.28:

[0314] To a solution of (S)-2-((tert-butoxycarbonyl)amino)-3-(5-chloro-2-(1-methyl-1H- pyrazol-4-yl)oxy)pyridine-3-yl)propanoic acid (3 g, 7.56 mmol, 1 eq) in THF (90 mL) was added NaH (1.51 g, 37.80 mmol, 60% purity, 5 eq) at 0 °C under N2 atmosphere, the mixture was stired at 0 °C for 30 min then was added MeI (10.73 g, 75.60 mmol, 4.71 mL, 10 eq). The mixture was warmed to 25 °C and stired at 25 °C for 12 hr. LCMS showed (S)-2-(tert- butoxycarbonyl)amino)-3-(5-chloro-2-((1-methyl-1H-pyrazol-4-yl)oxy)pyridine-3- yl)propanoic acid was consumed completely and desired mass was detected. The reaction mixture was quenched with NH4Cl (100 mL), adjusted pH to 3-4 with 1M HCl, extracted with EtOAc (30 mL x 4). The combined organics were washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was diluted with MeOH (50 mL) and washed with PE (20 mL x 4). The residue was concentrated under reduced pressure to give pale yelow solid. Int.28 (2.6 g, 6.10 mmol, 81 % yield, 92.8 % purity) was obtained as a pale-yelow solid without purification. Int.29: (S)-3-(2-(1-acetylazetidin-3-yl)oxy)-5-chloropyridin-3-yl)-2-(tert- butoxycarbonyl)(methyl)amino)propanoic acid:

[0315] This material was synthesized by folowing the procedure for Int.13 with 1-(3- hydroxyazetidin-1-yl)ethan-1-one as the starting alcohol. LCMS (ESI+): m / z 428.1 (M+H+) Int.30: Preparation of (S)-3-(2-bromo-5-chlorophenyl)-2-(tert- butoxycarbonyl)(methyl)amino)propanoic acidStep 1: (2S,5R)-2-(2-bromo-5-chlorobenzyl)-3,6-diethoxy-5-isopropyl-2,5- dihydropyrazine:

[0316] To a solution of (R)-3,6-diethoxy-2-isopropyl-2,5-dihydropyrazine (151 g, 711 mmol, 1.00 eq) in THF (1500 mL) was added n-BuLi (2.5 M, 285 mL, 1.00 eq) at -70 °C under N2, then to the above solution was added 1-bromo-2-(bromomethyl)-4-chlorobenzene (222.5 g, 782 mmol, 1.10 eq) in THF (220 mL) at -70 °C. The mixture was stired at 25 °C for 12 hours. TLC indicated 1-bromo-2-(bromomethyl)-4-chlorobenzene was remained, and some new spots was detected. The reaction was poured into sat. NH4Cl (aq.) 6000 mL, the reaction mixture was partitioned between water phase 6000 mL and THF 6000 mL. The organic phase was separated and dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, PE / EtOAc=100 / 0 to 1 / 1) to give desired (2S,5R)-2-(2-bromo-5-chlorobenzyl)-3,6-diethoxy- 5-isopropyl-2,5-dihydropyrazine (620 g, 1.48 mol, 104 % yield, 99.3% purity) as a yelow gum. LCMS (ESI+): m / z 415 / 417 (M+H+)Step 2: Ethyl (S)-2-amino-3-(2-bromo-5-chlorophenyl)propanoate:

[0317] To a solution of (2S,5R)-2-(2-bromo-5-chlorobenzyl)-3,6-diethoxy-5-isopropyl-2,5- dihydropyrazine (100 g, 240 mmol, 1.00 eq) in ACN (1500 mL) was added HCl (0.20 M, 1.40 L, 1.16 eq) at 0 °C, then was stired at 25 °C for 48 hours. TLC indicated (2S,5R)-2-(2- bromo-5-chlorobenzyl)-3,6-diethoxy-5-isopropyl-2,5-dihydropyrazine was consumed completely. The reaction mixture was concentrated under reduced pressure to remove ACN and extracted with DCM 4000 mL (2000 mL x 2), the organic layers was concentrated under reduced pressure to give a residue. Then the water phase was basified with sat.aq. NaHCO3 to pH=7 and extracted with DCM 4.00 L (2.00 L x 2). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give desired ethyl (S)-2-amino-3-(2-bromo-5-chlorophenyl)propanoate (143 g, 466 mmol, 49 % yield) as a white solid and to give (2S,5R)-2-(2-bromo-5-chlorobenzyl)-3,6-diethoxy-5-isopropyl-2,5- dihydropyrazine (200 g, crude) was obtained as a yelow gum. Step 3: (S)-2-amino-3-(2-bromo-5-chlorophenyl)propanoic acid:

[0318] To a solution of ethyl (S)-2-amino-3-(2-bromo-5-chlorophenyl)propanoate (143 g, 466 mmol, 1.00 eq) in THF (715 mL) and EtOH (715 mL) was added LiOH.H2O (58.7 g, 1.40 mol, 3.00 eq) at 0 °C, then the reaction was stired at 25 °C for 12 hours. TLC indicated ethyl (S)-2-amino-3-(2-bromo-5-chlorophenyl)propanoate was consumed completely. The reaction mixture was concentrated under reduced pressure at 30 °C to remove half of solvent. It was added into a saturated solution of citric acid (1.50 L) at 5-10 °C, to keep al the progress worked under acid condition. Some solid precipitated, then the suspension was filtered, the filter cake was washed with MTBE (1.00 L). The filter cake was colected and dried in vacuum to give desired (S)-2-amino-3-(2-bromo-5-chlorophenyl)propanoic acid (130g, crude) as yelow solid which was confirmed by LCMS and SFC, then was used to the next step without further purification. Step 4: (S)-3-(2-bromo-5-chlorophenyl)-2-(tert-butoxycarbonyl)amino)propanoic acid:

[0319] To a mixture of (2S)-2-amino-3-(2-bromo-5-chloro-phenyl)propanoic acid (70.00 g, 251.32 mmol, 1 eq) in THF (750 mL) and NaOH (1 N, 750 mL) was added Boc2O (109.70 g, 502.64 mmol, 115.47 mL, 2 eq) at 0 °C, the mixture was stired at 20 °C for 12 h. The LCMS showed that the reactant 1 was consumed completely, and the desired product was detected. The mixture was poured into sat. Citric acid (4 L) and extracted with EtOAc (1 L x 3). The organic layer was washed with water (2 L) and brine (2 L), dried over Na2SO4, filtered, and concentrated. The mixture was suspended in PE (1 L) and stired at 20 °C for 0.5 h. Then the mixture was filtered, and the white solid was colected and dried to dryness to give compound 2 (2S)-3-(2-bromo-5-chloro-phenyl)-2-(tert-butoxycarbonylamino)propanoic acid (124 g, 320.9 mmol, 64 % yield, 98% purity) as a white solid.1H NMR: ET53616-98-P1Z (400 MHz, MeOD) δ 7.54 (d, J = 8.4 Hz, 1H), 7.33 (d, J = 2.4 Hz, 1H), 7.17-7.15 (m, 1H), 4.49 (dd, J = 4.4, 10.4 Hz, 1H), 3.39 (br dd, J = 4.4, 9.6 Hz, 1H), 2.94 - 2.88 (m, 1H), 1.36 - 1.28 (m, 9H). LCMS (ESI+): m / z 277.9 / 279.9 (M+H+) Step 5: Int.30:

[0320] To a mixture of (2S)-3-(2-bromo-5-chloro-phenyl)-2-(tert- butoxycarbonylamino)propanoic acid (3.00 g x 10, 7.92 mmol, 1 eq) in THF (90 mL x 10) was added NaH (1.58 g x 10, 39.61 mmol, 60% purity, 5 eq) at 0 °C, the mixture was stired at 0 °C for 0.5 h. Then MeI (11.25 g x 10, 79.23 mmol, 4.93 mL, 10 eq) was added at 0 °C, the mixture was stired at 15 °C for 12 h. The LCMS showed that the (2S)-3-(2-bromo-5-chloro-phenyl)-2-(tert-butoxycarbonylamino)propanoic acid was consumed completely, and the desired product was detected. The mixture was quenched by sat. Citric acid (1.5 L), extracted with EtOAc (1.5 Lx2). The organic layer was washed with brine (1.5 L), dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography (SiO2, PE / EtOAc / THF=20 / 1 / 0 to 6 / 1 / 1) to give crude product. The mixture was combined with ET53616-100,104. The residue was dissolved in DCM (1 L) and concentrated under reduced pressure to give the desired product Int.30 (114.0 g, 285.70 mmol, 98 % purity) as a yelow solid.1H NMR: ET53616-105-P1Z2 (400 MHz, CHLOROFORM-d) δ 11.44 (brs, 1H), 7.50 - 7.47 (m, 1H), 7.20 - 7.19 (m, 1H), 7.13 - 7.11 (m, 1H), 4.83 - 4.71 (m, 1H), 3.48- 3.43 (m, 1H), 3.31 - 3.06 (m, 1H), 2.81 - 2.70 (m, 3H), 1.44 - 1.37 (m, 9H). LCMS (ESI+): m / z 291.9 / 293.9 (M+H+). Int.31: (S)-3-(2-bromo-5-fluorophenyl)-2-(tert- butoxycarbonyl)(methyl)amino)propanoic acid:

[0321] This material was synthesized by folowing the procedure for Int.30 acid using 1- bromo-2-(bromomethyl)-4-fluorobenzene as the starting material. Int.33: (2S,4R)-4-fluoro-1-(1-(trifluoromethyl)cyclopropane-1-carbonyl)pyrrolidine-2- carbonyl)glycine:

[0322] This material was synthesized in an identical way to Int.34 using commercialy available FMOC protected amino acids. LCMS (ESI+): m / z 327.1 (M+H+). Int.34: Preparation of ((S)-2-(1-(trifluoromethyl)cyclopropane-1- carboxamido)butanoyl)-L-alanine

[0323] A mix of TEA (7.61 g, 10.5 mL, 6 Eq, 75.2 mmol) and ((9H-fluoren-9- yl)methoxy)carbonyl)-L-alanine (3.90 g, 1 Eq, 12.5 mmol) in DCM (50 mL) was added to a pre-sweled 2-Chlorotrityl chloride resin (5 g). The reaction was agitated for 1 h, then filtered. The loaded resin was washed with DMF (3 x 50 mL). Next, piperidine 20% in DMF (50 mL) was added to the resin and stired for 1 h, then washed with DMF (3 x 50 mL).The freshly deprotected resin was next subjected to a pre-activated solution of Fmoc-protected amino acid consisting of (S)-2-((9H-fluoren-9-yl)methoxy)carbonyl)amino)butanoic acid (4.08 g, 1 eq, 12.5 mmol), HATU (5.24 g, 1.1 Eq, 13.8 mmol) DIPEA (13.0 g, 17.5 mL, 8 Eq, 100 mmol) in DMF (50 mL). The Resin was agitated for 1 h, then washed with DMF (3 x 50 mL). The deprotection was repeated with the addition of piperidine 20% in DMF (50 mL). The resin was agitated for 1 h, then washed with DMF (3 x 50 mL). The final coupling wasperformed by adding another preactivated carboxylic acid solution, consisting of 1- (trifluoromethyl)cyclopropane-1-carboxylic acid (1.93 g, 1 Eq, 12.5 mmol), HATU (5.24 g, 1.1 Eq, 13.8 mmol), and DIPEA (13.0 g, 17.5 mL, 8 Eq, 100 mmol) in DMF (50 mL), to the resin. This was agitated for 1 h, then washed with DMF (3 x 50 mL), Methanol (3 x 50 mL), then DCM (3 x 50 mL). The tripeptide was then cleaved by agitating the resin with a HFIP / DCM mixture (1:1, 2 x 50 mL). The combined cleavage filtrate was concentrated and the crude residue was purified by FCC (SiO2, MeOH in DCM 0 to 20% over 10 min.). Int. 34 (500 mg, 80% based on 0.5 mmol / resin loading) was isolated as a white solid. LCMS (ESI+): m / z 311.1 (M+H+). Int.35: (S)-2-((2S,4R)-4-fluoro-1-(1-trifluoromethyl)cyclopropane-1- carbonyl)pyrrolidine-2-carboxamido)butanoic acid:

[0324] This material was synthesized in an identical way to Int.34 using commercialy available FMOC protected amino acids. LCMS (ESI+): m / z 355.4 (M+H+). Int.39: preparation of (2S,4R)-4-fluoro-1-(2-(trifluoromethyl)tetrahydro-2H-pyran-2- carbonyl)pyrrolidine-2-carboxylic acid:

[0325] Int.39 was synthesized in accordance with Int.148 and 149, but without separating the diastereomers. Int.40: Preparation of 1-(4-((4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2- yl)methylene)piperidin-1-yl)ethan-1-oneStep 1: Int.40:

[0326] tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)piperidine-1- carboxylate (1.0 g, 1 Eq, 3.1 mmol) was dissolved in 10 mL of DCM / TFA (3:1) and was stired until the consumption of starting material (monitored by LCMS). The volatile solvent was completely removed and residual TFA was removed via co-evaporation with toluene. The deprotected amine was used directly without further purification. The crude material from above was dissolved in DCM (20 mL) and cooled to 0 °C and TEA (0.94 g, 1.3 mL, 3 eq, 9.3 mmol) and AcCl (0.29 g, 0.26 mL, 1.2 eq, 3.7 mmol) were added subsequently and stired at 0 °C. Upon completion, the volatile solvent was removed, and the resulting solid was placed under high vacuum overnight. The resulting solid Int.40 (750 mg, 2.83 mmol, 91 %) was used in subsequent reactions with no additional purification. LCMS (ESI+): m / z 266.1 (M+H+). Int.41: Preparation of (S)-2-(tert-butoxycarbonyl)(ethyl)amino)pent-4-enoic acidStep 1: (2S)-2-(ethylamino) pent-4-enoic acid:

[0327] Into a stirred solution of (2S)-2-aminopent-4-enoic acid (5 g, 43.43 mmol, 1 eq) in MeOH (50 mL) was added NaBH3CN (3.41 g, 54.29 mmol, 1.25 eq) at 0 °C under nitrogen atmosphere. The resulting solution was stired for 10 min at 0 °C. Acetaldehyde (10.97 mL, 195.43 mmol, 1.5 eq) was added and the resulting solution was stired for 1 h at 0 °C. After warming to rt, the mixture was stired for 16 h at rt. The resulting mixture was quenched with water at 0 °C and extracted with EtOAc (2 x 10 mL). This resulted in (2S)-2-(ethylamino) pent-4-enoic acid (15 g, 76 %) and the crude resulting mixture was used in the next step directly without further purification. LCMS (ESI+): m / z 144.09 (M+H+). Step 2: Int.41:

[0328] Into a stirred solution of (2S)-2-(ethylamino) pent-4-enoic acid (15 g, 104.76 mmol, 1 eq) and NaOH (29.33 g, 733.31 mmol, 7 eq) in dioxane (150 mL) / H2O (150 mL) was added BocO (45.73 g, 209.52 mmol, 2 eq) a o 2 t 0C under nitrogen atmosphere. The resulting solution was stired for 16 h at rt. The reaction mixture was concentrated in vacuo to remove dioxane. The aqueous layer was acidified with 1 N HCl to pH=5. The aqueous layer was extracted with EtOAc (3 x 200 mL). The combined organic layers were washed with brine, dried over Na2SO4 and filtered. The filtrate was concentrated in vacuo and the residue was purified by reverse flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% FA), 0% to 100% gradient in 40 min; detector, UV 210 nm. This resulted in Int.41 (11.9 g, 46 %) as a white solid. LCMS (ESI+): m / z 244.15 (M+H+).1H NMR (400 MHz, DMSO-d6): δ 1.05 (dt, J = 7.0, 7.0, 14.3 Hz, 3H), 1.38 (d, J = 14.8 Hz, 9H), 2.51 – 2.69 (m, 2H), 3.03 (dq, J = 6.8, 6.8, 6.8, 18.6 Hz, 1H), 3.26 (ddq, J = 6.9, 7.0, 7.0, 14.0, 28.9 Hz, 1H), 4.18 (ddd, J = 5.1, 9.9, 114.9 Hz, 1H), 4.97 – 5.18 (m, 2H), 5.64 – 5.90 (m, 1H), 12.52 (s, 1H). Int.42: Preparation of (S)-2-(tert-butoxycarbonyl)(methyl)amino)hex-5-enoic acidStep 1: (S)-1-[(2R)-1-benzylpyrrolidine-2-carbonyl]-5-(but-3-en-1-yl)-7-phenyl-5H- benzo[d]1-oxa-3,7-diaza-2-nickelacyclononan-4-one:

[0329] A solution of 1-[(2R)-1-benzylpyrolidine-2-carbonyl]-7-phenyl-5H-benzo[d]1-oxa- 3,7-diaza-2-nickelacyclononan-4-one (75.31 g, 151.17 mmol, 1 eq) and NaOH (60.46 g, 1511.67 mmol, 10 eq) in DMF (600 mL) was stired for 15 min at rt under nitrogen atmosphere.4-bromo-1-butene (20 g, 148.14 mmol, 0.98 eq) was added to the solution dropwise and stired for 1.5 h at rt. The mixture was acidified to pH=6 with HOAc (5%) and extracted with EtOAc (3 x 1 L). The combined organic layers were washed with NH4Cl (aq.) (3 x 1 L) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under vacuum and purified by silica gel column chromatography, eluted with CH2Cl2 / MeOH (20:1) to aford crude product (5S)-1-[(2R)-1-benzylpyrolidine-2-carbonyl]-5-(but-3-en-1- yl)-7-phenyl-5H-benzo[d]1-oxa-3,7-diaza-2-nickelacyclononan-4-one (80 g, 86 %) as a red solid. LCMS (ESI+): m / z 552.3 (M+H+).1H NMR (400 MHz, DMSO-d6): δ 1.19 (t, J = 7.1 Hz, 7H), 1.59 (dtd, J = 13.3, 6.6, 3.3 Hz, 1H), 1.99 (s, 5H), 2.07 (s, 6H), 2.02 – 2.25 (m, 3H), 2.48 (s, 1H), 3.33 (s, 4H), 3.34 – 3.48 (m, 1H), 3.48 – 3.62 (m, 2H), 3.64 (td, J = 10.6, 9.7, 3.7 Hz, 1H), 3.99 – 4.13 (m, 5H), 4.82 (dd, J = 10.2, 1.9 Hz, 1H), 4.85 – 4.97 (m, 1H), 5.49 (s, 1H), 5.95 (s, 1H), 6.55 (dd, J = 8.2, 1.7 Hz, 1H), 6.61 – 6.74 (m, 1H), 7.03 – 7.16 (m, 2H), 7.13 – 7.27 (m, 1H), 7.36 (t, J = 7.7 Hz, 2H), 7.39 – 7.49 (m, 1H), 7.45 – 7.53 (m, 1H), 7.50 – 7.64 (m, 3H), 7.98 (dd, J = 8.7, 1.2 Hz, 1H), 8.32 – 8.43 (m, 2H). Step 2: (2S)-2-aminohex-5-enoic acid:

[0330] A solution of (5S)-1-[(2R)-1-benzylpyrolidine-2-carbonyl]-5-(but-3-en-1-yl)-7- phenyl-5H-benzo[d]1-oxa-3,7-diaza-2-nickelacyclononan-4-one (100 g, 181.06 mmol, 1eq) and HCl (600 mL, 3N) in THF (600 mL) was stired for 2 h at 80 °C. The mixture was basified to pH=7 with NaOH / Na2CO3.The resulting mixture was extracted with CH2Cl2 (3 x 500 mL). (2S)-2-aminohex-5-enoic acid (25 g, 427 %) was in water layer was used in the next step directly without further purification. LCMS (ESI+): m / z 130.15 (M+H+). Step 3: (2S)-2-[(tert-butoxycarbonyl)amino]hex-5-enoic acid:

[0331] To the above water solution (1.5 L) including (2S)-2-aminohex-5-enoic acid (25 g, 193.56 mmol, 1eq) was added Boc2O (84.50 g, 387.12 mmol, 2 eq) was stired for 16 h at rt. The mixture was acidified to pH =6 with citric acid and extracted with CH2Cl2 (3 x 500 mL). The combined organic layers were washed with brine (1 x 200 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under vacuum. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, Acetonitrile in Water, 5% to 100% gradient in 30 min; detector, UV 210 nm. This resulted in (2S)-2-[(tert-butoxycarbonyl)amino]hex-5-enoic acid (12 g, 135 %) as a light-yelow oil. LCMS (ESI+): m / z 130.15 (M+H+).1HNMR (400 MHz, DMSO-d6): δ 1.18 (t, J = 7.1 Hz, 1H), 1.35 (s, 1H), 1.39 (s, 8H), 1.57 – 1.69 (m, 1H), 1.66 – 1.78 (m, 1H), 1.91 (s, 2H), 1.99 (s, 1H), 2.06 (dq, J = 13.9, 7.2 Hz, 2H), 3.88 (ddd, J = 9.5, 8.1, 4.7 Hz, 1H), 4.03 (q, J = 7.1 Hz, 1H), 4.94 – 5.06 (m, 2H), 5.78 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H), 7.08 (d, J = 8.1 Hz, 1H), 12.26 (s, 2H). Step 4: methyl (S)-2-(tert-butoxycarbonyl)(methyl)amino)hex-5-enoate:

[0332] To a stired solution of (2S)-2-[(tert-butoxycarbonyl)amino]hex-5-enoic acid (6 g, 26.17 mmol, 1 eq) and Ag2O (24.26 g, 104.68 mmol, 4 eq) in DMF (90 mL) was added CH3I (55.72 g, 392.54 mmol, 15 eq) dropwise at 0oC. The resulting mixture was stired overnight at rt. The resulting mixture was filtered, the filter cake was washed with DMF (3 x 50 mL). The filtrate was used in the next step directly without further purification. LCMS (ESI+): m / z 258.20 (M+H+). Step 5: Int.42:

[0333] To a stired solution of methyl (2S)-2-[(tert-butoxycarbonyl)(methyl)amino]hex-5- enoate (20 g, 77.72 mmol, 1 eq) in H2O (500 mL) / DMF (500 mL) was added and NaOH (18.65 g, 466.33 mmol, 6 eq) in portions at 0oC .The resulting mixture was stired for 16 h at rt and acidified to pH 6 with HCl (3N).The mixture was extracted with CH2Cl2 (3 x 0.5 L). The combined organic layers were washed with brine (3 x 300 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under vacuum and purified by reversed- phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, Acetonitrile in Water, 5% to 50% gradient in 30 min; detector, UV 200 nm. This resulted in racemic product (20 g) which was purified by Prep-CHIRAL-HPLC with the folowing conditions (Column: CHIRALPAK IC-3, 4.6 x 50mm, 3μm; Mobile Phase A: Hex(0.1%TFA): IPA=98: 2; Flow rate: 1 mL / min; Gradient: 0% B to 0% B; Injection Volume: 5ul mL) to aford Int.42 (15.78 g, 83 %) as a light yelow oil. LCMS (ESI+): m / z 242.10 (M+H+).1H NMR (300 MHz, DMSO-d6) δ 1.38 (d, J = 13.4 Hz, 17H), 1.71 – 1.86 (m, 1H), 1.89 (s, 1H), 1.94 (d, J = 4.9 Hz, 1H), 1.94 – 2.12 (m, 3H), 2.72 (s, 6H), 4.26 (dd, J = 10.4, 4.6 Hz, 1H), 4.50 (dd, J = 10.8, 4.4 Hz, 1H), 4.93 – 5.05 (m, 3H), 5.02 – 5.10 (m, 1H), 5.81 (ddd, J = 16.9, 10.2, 3.6 Hz, 1H), 12.73 (s, 2H). Int.43: Preparation of (S)-2-(tert-butoxycarbonyl)(methyl)amino)hept-6-enoic acidStep 1: (5S)-1-[(2S)-1-benzylpyrrolidine-2-carbonyl]-5-(pent-4-en-1-yl)-7-phenyl-5H- benzo[d]1-oxa-3,7-diaza-2-nickelacyclononan-4-one:

[0334] To a solution of NaOH (80.51 g, 2013.0 mmol, 10 eq.) in DMF (270 mL),1-[(2S)-1- benzylpyrolidine-2-carbonyl]-7-phenyl-1H,4H,5H-benzo[d]1-oxa-3,7-diaza-2- nickelacyclononan-4-one (102.29 g, 205.33 mmol, 1.02 eq) was added in at 25 °C under nitrogen atmosphere. The reaction was stired for 15 min at 25 °C.5-bromopent-1-ene (30 g, 201.30 mmol, 1 eq) was dropwise below 25 °C. The reaction was stired for 5 hours at 25 °C. The reaction was purified together with Page EB2141275-183 and EB2141275-184. The mixture was acidified to pH=3 with acetic acid (5%), The resulting mixture was extracted with EtOAc (2 x 250 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH2Cl2 / MeOH (20:1) to aford (5S)-1- [(2S)-1-benzylpyrolidine-2-carbonyl]-5-(pent-4-en-1-yl)-7-phenyl-5H-benzo[d]1-oxa-3,7- diaza-2-nickelacyclononan-4-one (88 g, 77 %) as a yelow oil. LCMS (ESI+): m / z 566 (M+H+).MHz, DMSO-d6): δ 1.54 (dddd, 2H), 1.76 – 2.04 (m, 3H), 2.12 – 2.34 (m, 3H), 2.45 (t, 2H), 3.32 (d, 2H), 3.50 – 3.71 (m, 3H), 4.07 (d, 1H), 4.85 – 5.09 (m, 2H), 5.76 (ddt, 1H), 6.53 (dd, 1H), 6.66 (ddd, 1H), 7.01 – 7.24 (m, 3H), 7.36 (t, 2H), 7.45 – 7.66 (m, 4H), 7.91 – 8.09 (m, 1H), 8.27 – 8.46 (m, 2H). Step 2: (S)-2-aminohept-6-enoic acid:

[0335] To a solution of (5S)-1-[(2S)-1-benzylpyrrolidine-2-carbonyl]-5-(pent-4-en-1-yl)-7- phenyl-5H-benzo[d]1-oxa-3,7-diaza-2-nickelacyclononan-4-one (88 g, 155.39 mmol, 1 eq.) in THF (880.0 g, 12204.1 mmol, 78.54 eq) was added HCl (517.96 mL, 1553.87 mmol, 10 eq) at 25 °C. The reaction was stired for 2 hours at 60 °C. The resulting mixture was diluted with water (1500 mL). The mixture was basified to pH= 8 with NaOH (aq., 2N). The resulting mixture was extracted with EtOAc (2 x 500 mL). The aqueous phase(including about 22g product) was used in next step without further purification. LCMS (ESI+): m / z 144 (M+H+). Step 3: (2S)-2-[(tert-butoxycarbonyl)amino]hept-6-enoic acid:

[0336] To a solution of (2S)-2-aminohept-6-enoic acid (22 g, 153.65 mmol, 1 eq), Na2CO3 (97.71 g, 921.88 mmol, 6 eq) in water (2000 mL) was added Boc2O (100.60 g, 460.94 mmol, 3 eq) at 25 °C. The reaction was stired for 6 hours at 25 °C. The mixture was acidified to pH=6 with diluted citric acid. The resulting mixture was extracted with EtOAc (3 x 150 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH2Cl2 / MeOH (20:1) to aford (2S)-2-[(tert- butoxycarbonyl)amino]hept-6-enoic acid (30 g, 80 %) as a yelow oil. LCMS (ESI+): m / z 266 (M+Na+).1H NMR (400 MHz, DMSO-d6): δ 1.38 (s, 11H), 1.50 – 1.59 (m, 1H), 1.66 (dddd, 1H), 2.74 (s, 1H), 2.90 (s, 1H), 3.86 (ddd, 1H), 4.95 (ddt, 1H), 5.00 (dt, 1H), 5.68 – 5.88 (m, 1H), 7.07 (d,1H), 12.38 (s, 1H). Step 4: Methyl (S)-2-(tert-butoxycarbonyl)(methyl)amino)hept-6-enoate:

[0337] MeI (175.02 g, 1233.03 mmol, 10 eq) was added into a solution of (2S)-2-[(tert- butoxycarbonyl)amino]hept-6-enoic acid (30 g, 123.30 mmol, 1 eq) and Ag2O (142.87 g, 616.52 mmol, 5 eq) in DMF (200 mL). The reaction was stired for 6 hours at 25 °C. Desired product could be detected by LCMS. The resulting mixture was filtered, the filter cake was washed with DMF (2 x 5 mL). The filtrate was used in next step without further purification (about 35 g). LCMS (ESI+): m / z 172 (M+H-Boc+). Step 5: Int.43:

[0338] NaOH (25.79 g, 644.91 mmol, 5 eq) in water (350.00 mL, 19428.41 mmol, 150.63 eq) was added into a solution of methyl (2S)-2-[(tert-butoxycarbonyl)(methyl)amino]hept-6- enoate (35 g, 128.98 mmol, 1 eq) in DMF (20 mL) at 25 °C. The reaction was stired for 5 hours at 25 °C. Desired product could be detected by LCMS. The reaction was purified with Page EB2206983-001 and EB2206983-002 and EB2206983-003 and EB2206983-004. The resulting mixture was diluted with water (500 mL). The mixture was acidified to pH=6 with HCl (aq.2N). The resulting mixture was extracted with EtOAc (3 x 1000 mL). The combined organic layers were washed with saturated ammonium chloride (2 x 500 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography with the folowing conditions: column, C18 silica gel; mobile phase, MeCN in Water, 10% to 60% gradient in 20 min; detector, UV 254 nm to aford (2S)-2-[(tert-butoxycarbonyl)(methyl)amino]hept-6-enoic acid (31 g, 93.40%) as a light yelow oil. The compound was further purified by PREP_CHIRAL_HPLC with the folowing conditions: Column: CHIRAL ART Celulose- SC, 2*25 cm, 5 μm; Mobile Phase A: Hex (0.1% FA)-HPLC, Mobile Phase B: IPA--HPLC; Flow rate: 20 mL / min; Gradient: 2% B to 2% B in 17 min; Wave Length: 220 / 254 nm; RT1(min): 6.939; RT2(min): 12.248; Sample Solvent: EtOH—HPLC to aford Int.43 (21.4 g, 66 %) as a light yelow oil. LCMS (ESI+): m / z 280 (M+Na+).1H NMR (400 MHz,DMSO-d6): δ 1.39 (d, 11H), 1.56 – 1.88 (m, 2H), 2.05 (qp, 2H), 2.70 (s, 3H), 4.41 (ddd, 1H), 4.92 – 5.09 (m, 2H), 5.71 – 5.88 (m, 1H), 12.65 (s, 1H). Int.44: 1-(methylsulfonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydro- 1H-pyrrole:

[0339] This material was synthesized according to the procedure for Int.40 with tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydro-1H-pyrole-1-carboxylate and methanesulfonyl chloride as starting materials. LCMS (ESI+): m / z 274.2 (M+H+). Int.45: 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-8-azabicyclo[3.2.1]oct-2-en-8- yl)ethan-1-one:

[0340] This material was synthesized according to the procedure for Int.40 with tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate as the starting material LCMS (ESI+): m / z 278.2 (M+H+). Int.122: 1-(3,3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6- dihydropyridin-1(2H)-yl)ethan-1-one:

[0341] Int.122 was synthesized according to the procedure Int.40 with tert-butyl 3,3- dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)- carboxylate as starting material. LCMS (ESI+): m / z 280.5 (M+H+).Int.127: (S)-2-cyclopropyl-2-(2S,4R)-1- -difluoro-1-(trifluoromethyl)cyclobutene-1- carbonyl)-4-fluoropyrrolidine-2-carboxamido)acetic acid:

[0342] This material was synthesized in an identical way to Int.34 using commercialy available FMOC protected amino acids. LCMS (ESI+): m / z 417.1 (M+H+). Int.129: (S)-2-cyclopropyl-2-(2S,4R)-4-fluoro-1-(1-(trifluoromethyl)cyclopropane-1- carbonyl)pyrrolidine-2-carboxamido)acetic acid:

[0343] This material was synthesized in an identical way to Int.34 using commercialy available FMOC protected amino acids. LCMS (ESI+): m / z 367.4 (M+H+). Int.140: Preparation of (2S,4R)-4-fluoro-1-(1-(trifluoromethyl)cyclopropane-1- carbonyl)pyrrolidine-2-carboxylic acid

[0344] This compound was prepared folowing the general synthetic sequence described for the preparation of Int.141 With 1-(trifluoromethyl)cyclopropane-1-carboxylic acid as the starting material. LCMS (ESI+): m / z 417.99 (M+H+). Int.141: Preparation of (2S,4R)-1-(3,3-difluoro-1-(trifluoromethyl)cyclobutane-1- carbonyl)-4-fluoropyrrolidine-2-carboxylic acidStep 1: Methyl (2S,4R)-4-fluoropyrrolidine-2-carboxylate:

[0345] A solution of 1-tert-butyl 2-methyl (2S,4R)-4-fluoropyrolidine-1,2-dicarboxylate (150 g, 101.1 mmol, 1 eq) and HCl(gas) in 1,4-dioxane (758.29 mL, 505.53 mmol, 5 eq) was stired for 0.5 h at rt and then concentrated under vacuum to aford methyl (2S,4R)-4- fluoropyrolidine-2-carboxylate (110 g, yield, 99%, purity 80%) as a white solid. The crude product was used in the next step directly without further purification. LCMS (ESI+): m / z 148.15 (M+H+). Step 2: Methyl (2S,4R)-1-[3,3-difluoro-1-(trifluoromethyl)cyclobutanecarbonyl]-4- fluoropyrrolidine-2-carboxylate:

[0346] To a stired solution of methyl (2S,4R)-4-fluoropyrolidine-2-carboxylate (110 g, 103.3 mmol, 1 eq, 80%), 3,3-difluoro-1-(trifluoromethyl)cyclobutane-1-carboxylic acid (122.06 g, 103.3 mmol, 1 eq) and TCFH (251.69 g, 154.95 mmol, 1.5 eq) in ACN (1100 mL) was added NMI (245.51 g, 516.49 mmol, 5 eq) dropwise in 45 min at 0 °C. The mixture was slowly warmed up to rt and stired overnight at rt. The mixture was concentrated under vacuum at 28oC and diluted with EtOAc (900 mL) and washed with HCl (0.5N,1400 mL x 1). The aqueous layer was extracted again with EtOAc (1x500 mL). The combined organic layers were washed with saturated NaHCO3(1000 mL x1). The aqueous layer was extractedwith EtOAc (300mL x1) again. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under vacuum to aford methyl (2S,4R)-1-[3,3-difluoro-1-(trifluoromethyl)cyclobutanecarbonyl]-4- fluoropyrolidine-2-carboxylate 180 g, 81 %) as a light-yelow solid. The crude product was used in the next step directly without further purification. LCMS (ESI+): m / z 334.15 (M+H+). Step 3: Int.141:

[0347] To a stired solution of methyl (2S,4R)-1-[3,3-difluoro-1- (trifluoromethyl)cyclobutanecarbonyl]-4-fluoropyrrolidine-2-carboxylate (180 g, 82.15 mmol, 1 eq, 90%) in MeOH (1400 mL) was added dropwise NaOH (58.33 g, 246.45 mmol, 3 eq) in H2O (400 mL) in 30 min at 0-20oC. The mixture was stired for 2 h at rt. MeOH was evaporated out under vacuum. The residue was diluted with water (2500 mL) and acidified with HCl (3N,400 mL) at 0-20oC. Then the precipitated solids were colected by filtration and washed with water (3x200 mL). The filtrate was added HCl (3N,100 mL). The precipitated solids were colected by filtration and washed with water (3x100 mL). The combined solids were dried in an oven for 16 h at 40oC. This resulted in aford Int.40 (150.7 g, 97 %) as a white solid. LCMS (ESI+): m / z 319.95 (M+H+). Int.142: Preparation of (2S,4R)-4-fluoro-1-(R)-3,3,3-trifluoro-2-hydroxy-2- methylpropanoyl)pyrrolidine-2-carboxylic acid

[0348] This compound was prepared folowing the general synthetic sequence described for the preparation of Int.141. With (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoic acid as the starting material. LCMS (ESI+): m / z 421.08Int.143: Preparation of (2S,4R)-4-fluoro-1-(2-(trifluoromethyl)spiro[3.3]heptane-2- carbonyl)pyrrolidine-2-carboxylic acid

[0349] This compound was prepared folowing the general synthetic sequence described for the preparation of Int.141 with 2-(trifluoromethyl)spiro[3.3]heptane-2-carboxylic acid as the starting material. LCMS (ESI+): m / z 323.11 (M+H+). Int.144: Preparation of (2S,4R)-4-fluoro-1-(1-(trifluoromethyl)cyclobutane-1- carbonyl)pyrrolidine-2-carboxylic acid

[0350] This compound was prepared folowing the general synthetic sequence described for the preparation of Int.141 with 1-(trifluoromethyl)cyclobutane-1-carboxylic acid as the starting material. LCMS (ESI+): m / z 283.08 (M+H+). Int.145: Preparation of (1-(trifluoromethyl)cyclobutane-1-carbonyl)-L-proline:

[0351] This compound was prepared folowing the general synthetic sequence described for the preparation of Int.141 with (tert-butoxycarbonyl)-L-proline and 1- (trifluoromethyl)cyclobutane-1-carboxylic acid as the starting materials. LCMS (ESI+): m / z 266.1 (M+H+). Int.146: (3,3-difluoro-1-(trifluoromethyl)cyclobutane-1-carbonyl)-L-proline:

[0352] This compound was prepared folowing the general synthetic sequence described for the preparation of Int.141 with (tert-butoxycarbonyl)-L-proline as the starting material. LCMS (ESI+): m / z 302.2 (M+H+). Int.147: Preparation of (2S,4R)-1-(1-cyanocyclobutane-1-carbonyl)-4- fluoropyrrolidine-2-carboxylic acid

[0353] This compound was prepared folowing the general synthetic sequence described for the preparation of Int.141 with 1-cyanocyclobutane-1-carboxylic acid as the starting material. LCMS (ESI+): m / z 240.09 (M+H+). Int.148 and 149: Preparation of (2S,4R)-4-fluoro-1-((R)-2-(trifluoromethyl)tetrahydro- 2H-pyran-2-carbonyl)pyrrolidine-2-carboxylic acid and (2S,4R)-4-fluoro-1-((S)-2- (trifluoromethyl)tetrahydro-2H-pyran-2-carbonyl)pyrrolidine-2-carboxylic acidStep 1: Methyl (2S,4R)-4-fluoropyrrolidine-2-carboxylate:

[0354] A mixture of 1-(tert-butyl) 2-methyl (2S,4R)-4-fluoropyrolidine-1,2-dicarboxylate (20 g, 80.9 mmol, 1 eq) in HCl / EtOAc (200 mL) (4 M) was stired at 25 °C for 2 h. LC-MSshowed starting material was consumed and one main peak with desired mass was detected. The reaction mixture was concentrated to give methyl (2S,4R)-4-fluoropyrolidine-2- carboxylate (15 g, crude, HCl) as a light-yelow solid. This was taken on to the next reaction without further purification. Step 2: (2S,4R)-4-fluoro-1-(R)-2-(trifluoromethyl)tetrahydro-2H-pyran-2- carbonyl)pyrrolidine-2-carboxylate and (2S,4R)-4-fluoro-1-(S)-2- (trifluoromethyl)tetrahydro-2H-pyran-2-carbonyl)pyrrolidine-2-carboxylate:

[0355] To a solution of 2-(trifluoromethyl)tetrahydro-2H-pyran-2-carboxylic acid (13 g, 65.61 mmol, 1 eq) in DCM (200 mL) was added DIEA (8.48 g, 65.61 mmol, 11.43 mL, 1 eq), and the mixture was stired for 10 min, then BOP-Cl (18.37 g, 72.17 mmol, 1.1 eq), methyl (2S,4R)-4-fluoropyrolidine-2-carboxylate, and DIEA (16.96 g, 131.22 mmol, 22.86 mL, 2 eq) were added. The mixture was stired at 25 °C for 12 h. LC-MS showed one main peak with desired mass was detected. The reaction mixture was concentrated under reduced pressure to remove DCM, and then EtOAc (30 mL) was added. The solution was washed three times with 5% NaHCO3 solution (15 mL) and once consecutively with water (15 mL), 2M HCl solution (15 mL), water (15 mL) and saturated brine (15 mL). The organic layer was dried over anhydrous Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, PE:EtOAc = 10:1 to 2:1) to give methyl (2S,4R)-4-fluoro-1-(R)-2- (trifluoromethyl)tetrahydro-2H-pyran-2-carbonyl)pyrolidine-2-carboxylate (10.7 g, 31.7 mmol, 48 % yield, 96.8% purity) as a light yelow oil and to give methyl (2S,4R)-4-fluoro-1- (S)-2-(trifluoromethyl)tetrahydro-2H-pyran-2-carbonyl)pyrolidine-2-carboxylate (11 g, 32.0 mmol, 49 % yield, 95.2% purity) as a light yelow oil. Step 3: (2S,4R)-4-fluoro-1-(R)-2-(trifluoromethyl)tetrahydro-2H-pyran-2- carbonyl)pyrrolidine-2-carboxylic acid:

[0356] To a solution of methyl (2S,4R)-4-fluoro-1-(R)-2-(trifluoromethyl)tetrahydro-2H- pyran-2-carbonyl)pyrolidine-2-carboxylate (10.7 g, 31.66 mmol, 96.83% purity, 1 eq) in THF (100 mL) and H2O (100 mL) was added LiOH.H2O (2.66 g, 63.32 mmol, 2 eq). Then the mixture was stired at 25 °C for 1 hr. LC-MS showed methyl (2S,4R)-4-fluoro-1-(R)-2- (trifluoromethyl)tetrahydro-2H-pyran-2-carbonyl)pyrolidine-2-carboxylate was consumed and one main peak with desired mass was detected. The mixture was acidified at 0 °C with HCl (1 N) until pH = 2~3. Then the mixture was extracted with EtOAc 300 mL (100 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, PE:EtOAc = 10:1 to 2:1) to give (2S,4R)-4-fluoro-1-((R)-2- (trifluoromethyl)tetrahydro-2H-pyran-2-carbonyl)pyrolidine-2-carboxylic acid (8.9 g, 28.33 mmol, 89 % yield, 99 % purity) as a white solid. LCMS (ESI+): m / z 314.0 (M+H+). Step 4: Int.149:

[0357] The same hydrolysis procedure was performed on methyl (2S,4R)-4-fluoro-1-(S)- 2-(trifluoromethyl)tetrahydro-2H-pyran-2-carbonyl)pyrolidine-2-carboxylate to provide the desired product Int.149 (9.1 g, 28.97 mmol, 90.5 % yield, 99.7% purity) as a white solid. LCMS (ESI+): m / z 314.0 (M+H+). Int.150: Preparation of (2S,4R)-4-fluoro-1-(3,3,3-trifluoro-2,2- dimethylpropanoyl)pyrrolidine-2-carboxylic acid

[0358] Int.150 was prepared folowing the general synthetic sequence described for the preparation of Int.141. LCMS (ESI+): m / z 271.08 (M+H+). Int.154: Preparation of tert-butyl (S)-2-((9H-fluoren-9- yl)methoxy)carbonyl)(methyl)amino)pent-4-enoateStep 1: Int.154:

[0359] To a solution of Int.152 (250 g, 1.09 mol, 1 eq) in HCl / EtOAc (2500 mL). The mixture was stired at 25 °C for 12 hour. The reaction mixture was concentrated under reduced pressure to remove solvent to give the deprotected HCl salt (180.5 g, crude, HCl) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 14.33-13.58 (m, 1H), 10.10-8.94 (m, 2H), 5.84-5.69 (m, 1H), 5.31-5.11 (m, 2H), 3.99 (br t, J = 5.2 Hz, 1H), 2.68 (br t, J = 6.4 Hz, 2H), 2.60-2.52 (m, 3H).

[0360] To a solution of the crude HCl salt (170 g, 1.03 mol, 1 eq) in H2O (860 mL) and dioxane (1140 mL) was added FmocOSu (346 g, 1.03 mol, 1 eq) and DIEA (398 g, 3.08 mol, 536 mL, 3 eq). The mixture was stired until the LCMS showed consumption of starting material. The reaction was quenched with citric acid solution (800 mL) at 25 °C, and then extracted with EtOAc (500 mL x 4). The combined organic layers were washed with brine (500 mL x 2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Eluent of 0~40% EtOAc / PE) to give (S)-2-((9H-fluoren-9- yl)methoxy)carbonyl)(methyl)amino)pent-4-enoic acid (290 g, 815 mmol, 80 % yield, 99% purity) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.13-12.72 (m, 1H), 7.89 (dd, J= 3.7, 7.2 Hz, 2H), 7.63 (br d, J = 7.6 Hz, 2H), 7.45-7.27 (m, 4H), 5.73-5.46 (m, 1H), 5.17- 4.95 (m, 2H), 4.67-4.44 (m, 1H), 4.40-4.21 (m, 3H), 2.80-2.70 (m, 3H), 2.53 (br s, 1H), 2.48- 2.32 (m, 1H). Step 2: Int.154:

[0361] Dissolve (S)-2-((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)pent-4-enoic acid (10 g, 1 Eq, 28 mmol) in DCM (20 mL), bring to 0 °C under argon. Add DCC (6.5 g, 1.1 Eq, 31 mmol) and DMAP (0.35 g, 0.1 Eq, 2.8 mmol) as solids. Add tert-butanol (8.4 g, 11 mL, 4 Eq, 0.11 mol) by syringe. Stir at rt overnight. Dilute in water and DCM, extract 3X DCM. Wash combined organic layers with water and brine, dry over MgSO4, filter, concentrate. Purify by normal phase chromatography (0 to 100% EtOAc in hexanes) to yield Int.154 (9.8 g, 24 mmol, 85 %) as a pale oil. Int.162: Preparation of (S)-1-(3, 3-difluoro-1-(trifluoromethyl) cyclobutane-1- carbonyl)-4, 4-difluoropyrrolidine-2-carboxylic acidStep 1: 2-benzyl 1-(tert-butyl) (S)-4, 4-difluoropyrrolidine-1, 2-dicarboxylate:

[0362] To a solution of (S)-1-(tert-butoxycarbonyl)-4, 4-difluoropyrolidine-2-carboxylic acid (2.50 g, 9.95 mmol, 1.0 Equiv.) in DMF (50 mL) was added Na2CO3 (2.11 g, 19.9 mmol, 2.0 Equiv.) and stired at room temperature for 0.5 hrs. The reaction mixture was then cooled to 0°C and BnBr (1.87 g, 10.9 mmol, 1.30 mL, 1.1 Equiv.) was added. The mixture was stired at 0°C for another 2.5 hrs. Water (80 mL) was added, and the aqueous phase was extracted with EtOAc (30 mL×3), the combined organic layer was washed by brine (30 mL),dried over Na2SO4, filtered and the filtrate was concentrated to give a residue. The residue was purified by silica gel column chromatography (Pet. Ether / EtOAc, 30:1) to aford 2- benzyl 1-(tert-butyl) (S)-4, 4-difluoropyrolidine-1, 2-dicarboxylate (2.80 g, 8.20 mmol, 82.4% yield) as a clear oil.1H NMR (400 MHz, DMSO-d6): δ7.37 (d, J = 4.8 Hz, 5H), 5.23- 5.10 (m, 2H), 4.59-4.50 (m, 1H), 3.83-3.70 (m, 2H), 3.02-2.87 (m, 1H), 2.59-2.50 (m, 1H), 1.41-1.25 (m, 9H). Step 2: benzyl (S)-4, 4-difluoropyrrolidine-2-carboxylate:

[0363] To a solution of 2-benzyl 1-(tert-butyl) (S)-4, 4-difluoropyrolidine-1, 2- dicarboxylate (2.00 g, 5.86 mmol, 1.0 Equiv.) in EtOAc (10 mL) was added HCl / EtOAc (4 M, 40 mL, 27.3 Equiv.) and stired at 20°C for 1 hr. The reaction mixture was concentrated to aford benzyl (S)-4, 4-difluoropyrolidine-2-carboxylate (2.14 g, crude) as a white solid. 1H NMR (400 MHz, DMSO-d6): δ10.78-10.59 (m, 1H), 7.48-7.33 (m, 5H), 5.30-5.22 (m, 2H), 4.86 (t, J = 8.8 Hz, 1H), 3.83-3.64 (m, 2H), 2.97-2.85 (m, 1H), 2.75 (dq, J = 8.8, 14.8 Hz, 1H). Step 3: benzyl (S)-1-(3, 3-difluoro-1-(trifluoromethyl) cyclobutane-1-carbonyl)-4, 4- difluoropyrrolidine-2-carboxylate

[0364] To a solution of benzyl (S)-4,4-difluoropyrolidine-2-carboxylate (1.90 g, 7.88 mmol, 1.0 Equiv.) in DMF (30 mL) was added DIPEA (3.05 g, 23.6 mmol, 4.12 mL, 3.0 Equiv.), 3, 3-difluoro-1-(trifluoromethyl)cyclobutanecarboxylic acid (2.41 g, 11.8 mmol, 1.5 Equiv.) and HATU (4.49 g, 11.8 mmol, 1.5 Equiv.), the mixture was stired at 20°C for 2 hrs. Water (60 mL) was added and the aqueous phase was extracted with EtOAc (20 mL ×3). Then the organic layers was washed with brine (30 mL), dried over Na2SO4, filtered and the filtrate was concentrated to give a residue. The residue was purified by silica gel columnchromatography, eluted with Pet. Ether / EtOAc (10:1 to 3:1) to aford benzyl (S)-1-(3, 3- difluoro-1-(trifluoromethyl) cyclobutane-1-carbonyl)-4, 4-difluoropyrrolidine-2-carboxylate (2.30 g, 5.38 mmol, 68.3% yield) as a yelow oil.1H NMR (400 MHz, DMSO-d6): δ7.41- 7.32 (m, 5H), 5.15 (s, 2H), 4.83 (dd, J = 4.4, 10.0 Hz, 1H), 4.13-4.00 (m, 2H), 3.34-3.20 (m, 4H), 2.99-2.83 (m, 1H), 2.59-2.51 (m, 1H). Step 4: Int.162

[0365] To a solution of benzyl (S)-1-(3,3-difluoro-1-(trifluoromethyl)cyclobutane-1- carbonyl)-4,4-difluoropyrolidine-2-carboxylate (2.30 g, 5.38 mmol, 1.0 Equiv.) in MeOH (30 mL) was added 10% Pd / C (572 mg, 538 μmol, 0.1 Equiv.) under Ar atmosphere. The suspension was degassed and purged with H2.The mixture was stired under H2 (15 Psi) at 20°C for 2 hrs. The reaction is filtered with diatomaceous earth and the filter cake was rinsed with MeOH (10 mL x 3). Then the combined filtrates were concentrated under reduced pressure. The resulting residue was purified by reversed-phase flash chromatography (C18, MeCN in Water (0.2% formic acid), 35%-65% gradient over 10 min) to give Int.162 (1.08 g, 3.03 mmol, 56.2% yield, 94.5% purity) as a white solid after lyophilization. LCMS: m / z 336.0 (M-H+).1H NMR (400 MHz, DMSO-d6): δ13.03 (s, 1H), 4.68-4.61 (m, 1H), 3.99 (t, J = 11.6 Hz, 2H), 3.33-3.23 (m, 4H), 2.94-2.80 (m, 1H), 2.50-2.40 (m, 1H).17 (s, 12H), 1.12 (s, 6H). Int.172: Preparation of 1-methyl-5'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3'H- spiro[azetidine-3,1'-isobenzofuran]:Step 1: 5'-bromo-3'H-spiro[azetidine-3,1'-isobenzofuran]:

[0366] Tert-butyl 5'-bromo-3'h-spiro[azetidine-3,1'-isobenzofuran]-1-carboxylate (300 mg, 1 Equiv., 882 μmol) was dissolved in 3 mL 3N HCl in MeOH and stired at 50 °C until the deprotection was complete (monitored via LCMS). The volatile solvent was completely removed to afford the crude deprotection product as the HCl salt. The material can be used without any further purification in the next reaction. LCMS (ESI+): m / z 240.37 (M+H). Step 2: 5'-bromo-1-methyl-3'H-spiro[azetidine-3,1'-isobenzofuran]:

[0367] Crude 5'-bromo-3'H-spiro[azetidine-3,1'-isobenzofuran] hydrochloride, formaldehyde (98.2 mg, 90.1 μL, 37% Wt, 1.5 Equiv., 1.21 mmol) and DIPEA (313 mg, 421 μL, 3 Equiv., 2.42 mmol) were dissolved in THF (8.67 mL) stired at 25 °C for 15 mins. Then, NaBH(OAc)3 (305 mg, 2 Equiv., 1.61 mmol) was added portion-wise to the reaction mixture. The reaction was stired at room temperature until the starting material was completely consumed (monitored by LCMS). The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layer was washed with brine, dried over MgSO4, filtered, and concentrated. The crude mixture was purified by silica gel column chromatography, eluted with^DCM / MeOH^(95:5). The solvent was removed to afford^5'-bromo-1-methyl-3'H-spiro[azetidine-3,1'-isobenzofuran] (185 mg, 728 μmol, 90.3 %) as white solid. LCMS (ESI+): m / z 253.96 (M+H).^ Step 3: Int.172:

[0368] In a sealed tube were placed 5'-bromo-1-methyl-3'H-spiro[azetidine-3,1'- isobenzofuran] (185 mg, 1 Equiv., 544 μmol), Potassium acetate (213 mg, 136 μL, 4 Equiv., 2.18 mmol) and Bis(pinacolato)diborane (414 mg, 3 Equiv., 1.63 mmol) in Dioxane (2.72 mL). The reaction was degassed for 15 min with Ar and then [1,1'- Bis(diphenylphosphino)ferocene]dichloropaladium(I) Dichloro (22.2 mg, 0.05 Equiv., 27.2 μmol) was added. The reaction was sealed and heated to 80 °C until the complete consumption of starting material (monitored by LCMS). Then the reaction was cooled to room temperature, quenched with water, and the organic layers were extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with water (2 x 10 mL) and brine (10 mL), dried (Na2S04), concentrated, and purified by flash column chromatography, (DCM:MeOH, 95:5) and concentrated. This resulted in Int.172 (149 mg, 495 μmol, 68.0 %) as brown solid. LCMS (ESI+): m / z 387.52 (M+H).^ Int.174: (2S,4R)-1-(1-(difluoromethyl)-3,3-difluorocyclobutane-1-carbonyl)-4- fluoropyrrolidine-2-carboxylic acidStep 1: Isopropyl 1-formyl-3,3-dimethoxycyclobutane-1-carboxylate:

[0369] To a stired solution of 1,1-disopropyl 3,3-dimethoxycyclobutane-1,1- dicarboxylate (10 g, 34.681 mmol, 1 Equiv.) in DCM (100 mL) was added DIBAL (69.36 mL, 69.362 mmol, 2 Equiv., 1M in DCM) dropwise at -78°C under argon atmosphere. The resulting mixture was stired for 4hr at -78°C under argon atmosphere. The desired product could be detected by GCMS. The reaction was quenched with 2 N HCl (aq.) at 0°C. The aqueous layer was extracted with CH2Cl2 (50 mL x2). The combined organics were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with Pet. Ether / EtOAc (5:1) to aford isopropyl1-formyl-3,3-dimethoxycyclobutane-1-carboxylate (2.1 g, 25.0%) as a colorless oil. GCMS: (EIC): m / z 230.00 (M). Step 2: Isopropyl 1-formyl-3-oxocyclobutane-1-carboxylate:

[0370] A mixture of isopropyl 1-formyl-3,3-dimethoxycyclobutane-1-carboxylate (2.1 g, 9.120 mmol, 1 Equiv.) in 6N HCl (25 mL) was stired overnight at room temperature. Desired product could be detected by GCMS. The aqueous layer was extracted with CH2Cl2 (50 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. This resulted in isopropyl 1-formyl-3-oxocyclobutane- 1-carboxylate (1.0 g, 53.6%) as a colorless oil which was used in the next reaction without further purification. GCMS (EIC): m / z 184.00 (M). Step 3: Isopropyl 1-(difluoromethyl)-3,3-difluorocyclobutane-1-carboxylate:

[0371] To a stired solution of isopropyl 1-formyl-3-oxocyclobutane-1-carboxylate (1 g, 5.429 mmol, 1 Equiv.) in DCM (20 mL) was added DAST (4.81 g, 29.860 mmol, 5.5 Equiv.) dropwise at 0°C under atmosphere of argon. The resulting mixture was stired overnight at room temperature. Desired product could be detected by GCMS. The reaction was quenched by the addition of sat. NaHCO3 (aq.) (100 mL) at 0°C. The organics were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH2Cl2 to aford isopropyl 1- (difluoromethyl)-3,3-difluorocyclobutane-1-carboxylate (1 g, 72.65%) as a colorless oil. GCMS (EIC): m / z 228.00 (M). Step 4: 1-(difluoromethyl)-3,3-difluorocyclobutane-1-carboxylic acid:

[0372] To a stired solution of isopropyl 1-(difluoromethyl)-3,3-difluorocyclobutane-1- carboxylate (1.5 g, 6.574 mmol, 1 Equiv.) in THF (20 mL) was added dropwise NaOH (0.79 g, 19.722 mmol, 3 Equiv.) in H2O (20 mL) at 0oC. The resulting mixture was stired overnight at room temperature. Desired product could be detected by LCMS. The resulting mixture was diluted with water (20mL) and acidified with HCl (aq.) to pH ~4. The aqueous layer was extracted with EtOAc (2x30 mL). The combined organics were dried over anhydrous Na2SO4 and concentrated under reduced pressure. This resulted in 1- (difluoromethyl)-3,3-difluorocyclobutane-1-carboxylic acid (730 mg, 56.69%) as a colorless oil. The material was used directly in the next step without further purification. LCMS (ESI): m / z 185.00 (M-H-). Step 5: Methyl (2S,4R)-1-(1-(difluoromethyl)-3,3-difluorocyclobutane-1-carbonyl)-4- fluoropyrrolidine-2-carboxylate:

[0373] Into a solution of 1-(difluoromethyl)-3,3-difluorocyclobutane-1-carboxylic acid (1 g, 5.373 mmol, 1 Equiv.), TCFH (2.26 g, 8.06 mmol, 1.5 Equiv.) and methyl (2S,4R)-4- fluoropyrolidine-2-carboxylate (0.87 g, 5.910 mmol, 1.1 Equiv.) in MeCN (20 mL) was added NMI (3.31 g, 40.297 mmol, 7.5 Equiv.) dropwise at 0 °C under nitrogen atmosphere. The mixture was stired for 16 h at room temperature. The reaction solution was concentrated in vacuo. The residue was purified by reverse \chromatography (20 g C18; MeCN in Water +0.1% formic acid; 10% to 50% gradient in 40 min). This resulted in methyl (2S,4R)-1-[1- (difluoromethyl)-3,3-difluorocyclobutanecarbonyl]-4-fluoropyrolidine-2-carboxylate (300 mg, 15.94%) as a brown solid upon removal of solvents. LCMS (ESI): m / z 315.24 (M+H+). 1H NMR (400 MHz, DMSO-d6): δ 2.11 (dddd, J = 4.0, 8.9, 14.7, 39.8 Hz, 1H), 2.51 – 2.67(m, 2H), 2.85 – 3.24 (m, 4H), 3.31 – 3.46 (m, 1H), 3.66 – 3.99 (m, 3H), 4.55 (t, J = 8.7, 8.7 Hz, 1H), 5.41 (dt, J = 3.3, 3.3, 52.6 Hz, 1H), 6.47 (t, J = 55.2, 55.2 Hz, 1H). Step 6: Int 174:

[0374] Into a solution of methyl (2S,4R)-1-[1-(difluoromethyl)-3,3- difluorocyclobutanecarbonyl]-4-fluoropyrrolidine-2-carboxylate (600 mg, 1.903 mmol, 1 Equiv.) in THF (10 mL) was added LiOH (136.75 mg, 5.709 mmol, 3 Equiv.) in H2O (10 mL) at 0 °C. The resulting solution was stired for 16hr at room temperature. The reaction mixture was concentrated in vacuo to remove THF. The aqueous layer was acidified with 1 N HCl to pH ~4 and extracted with EtOAc (3x20 mL). The combined organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo. This resulted in Int.174 (0.496 g, 84.8%) as a white solid. LCMS (ESI): m / z 302.21 (M+H+).1H NMR (400 MHz, CD3OD): δ 2.07 – 2.27 (m, 1H), 2.59 – 2.75 (m, 1H), 2.91 – 3.16 (m, 3H), 3.20 – 3.31 (m, 1H), 3.73 (ddd, J = 2.7, 12.6, 36.6 Hz, 1H), 3.95 (ddd, J = 2.3, 12.6, 17.7 Hz, 1H), 4.63 (t, J = 8.8, 8.8 Hz, 1H), 5.35 (dd, J = 3.4, 52.1 Hz, 1H), 6.24 (t, J = 55.6, 55.6 Hz, 1H). Int.176: 2-(1S,6R)-3-oxabicyclo[4.1.0]heptan-6-yl)-5-(4,4,5,5-tetraethyl-1,3,2- dioxaborolan-2-yl)pyridineStep 1: 5-bromo-2-(3,6-dihydro-2H-pyran-4-yl)pyridine:

[0375] To a stired solution of 5-bromo-2-iodopyridine (5 g, 17.612 mmol, 1 Equiv.) and 2- (3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4.44 g, 21.134 mmol, 1.2 Equiv.) in dioxane (100 mL) and H2O (50 mL) were added PdCl2(Dppf)•CH2Cl2 (1.43 g, 1.761 mmol, 0.1 Equiv.) and K2CO3 (4.87 g, 35.224 mmol, 2 Equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was stired for 6hr at 80°C under nitrogen atmosphere. The resulting mixture was diluted with water (50mL). The aqueous layer was extracted with EtOAc (3x100 mL). The combined organics were dried over anhydrous Na2SO4 and concentrated under vacuum. The residue was purified by flash chromatography (PE / EtOAc 3:1) to aford 5-bromo-2-(3,6-dihydro-2H-pyran-4-yl)pyridine (2.8 g, 66.2%) as a light yelow solid. LCMS: (ESI): m / z 240.10 (M+H+).1H NMR (400 MHz, DMSO-d6): δ 2.61 (dddq, J = 5.6, 3.9, 2.8, 1.4 Hz, 2H), 3.94 (t, J = 5.5 Hz, 2H), 4.36 (q, J = 2.8 Hz, 2H), 6.70 (t, J = 3.1, 1.6 Hz, 1H), 7.28 (d, J = 8.4 Hz, 1H), 7.78 (dd, J = 8.5, 2.4 Hz, 1H), 8.61 (d, J = 2.4 Hz, 1H). Step 2: 2-(3-oxabicyclo[4.1.0]heptan-6-yl)-5-bromopyridine:

[0376] To a stired mixture of trimethylsulfoxonium chloride Th(3.00 g, 23.324 mmol, 2.00 Equiv.) and NaH (0.93 g, 23.324 mmol, 2.00 Equiv., 60%) in DMSO (30 mL) was added 5- bromo-2-(3,6-dihydro-2H-pyran-4-yl)pyridine (2.8 g, 11.662 mmol, 1 Equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was stired for overnight at 65°C under nitrogen atmosphere. The reaction was quenched with sat. NH4Cl (aq.) at 0°C and extracted with EtOAc (3x100 mL). The combined organics were dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by reversed-phase flashchromatography (C18 silica gel; mobile phase, MeCN in Water with 10mmol / L NH4HCO3, 5% to 95) This resulted in 2-(3-oxabicyclo[4.1.0]heptan-6-yl)-5-bromopyridine (1.1 g, 37.12%) as a light yelow oil. LCMS (ESI): m / z 254.0 (M+H+).1H NMR (400 MHz, Chloroform-d): δ 1.08 (dd, J = 6.3, 4.2 Hz, 1H), 1.27 (dd, J = 9.1, 4.2 Hz, 1H), 1.69 (dddd, J = 9.1, 6.1, 4.3, 1.5 Hz, 1H), 2.11 (ddd, J = 14.2, 8.9, 5.6 Hz, 1H), 2.44 (dt,J = 13.9, 4.9 Hz, 1H), 3.46 (ddd, J = 11.6, 8.9, 5.1 Hz, 1H), 3.64 (dt, J = 11.6, 5.2 Hz, 1H), 3.91 – 4.09 (m, 2H), 7.12 (d, J = 8.3 Hz, 1H), 7.71 (dd, J = 8.5, 2.4 Hz, 1H), 8.53 (d, J = 2.4 Hz,1H). Step 3: 2-(1S,6R)-3-oxabicyclo[4.1.0]heptan-6-yl)-5-bromopyridine:

[0377] The 2-(3-oxabicyclo[4.1.0]heptan-6-yl)-5-bromopyridine (800 mg, 3.148 mmol, 1 Equiv.) was purified by Prep-Chiral-HPLC with the folowing conditions (Column: CHIRALPAK IG, 2x25 cm, 5 μm; Mobile Phase A: Hex(0.5% 2M NH3-MeOH), Mobile Phase B: MeOH: DCM=1: 1-HPLC; Flow rate: 20 mL / min; Gradient: 10% B) to aford 2- (1S,6R)-3-oxabicyclo[4.1.0]heptan-6-yl)-5-bromopyridine (250 mg, 31.25%) as a colorless oil. LCMS (ESI): m / z 254.00 (M+H+). Step 4: Int.176:

[0378] To a stired solution of 2-(1S,6R)-3-oxabicyclo[4.1.0]heptan-6-yl)-5- bromopyridine (240 mg, 0.944 mmol, 1 Equiv.), KOAc (278.06 mg, 2.83 mmol, 3 Equiv.) and 4,4,5,5-tetraethyl-2-(4,4,5,5-tetraethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (414.97 mg, 1.133 mmol, 1.2 Equiv.) in dioxane (10 mL) was added Pd(dppf)Cl2•CH2Cl2 (76.93 mg, 0.094 mmol, 0.1 Equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was stired for 2h at 80°C under nitrogen atmosphere. The resulting mixturewas concentrated under vacuum. The residue was purified by Prep-TLC (Pet. Ether / EtOAc 7:1) to aford Int.176 as a colorless oil. LCMS (ESI): m / z 358.15 (M+H+).1H NMR (400 MHz, DMSO-d6): δ 0.91 (t, J = 7.4 Hz, 12H), 1.03 (dd, J = 6.3, 3.9 Hz, 1H), 1.27 (dd, J = 9.0, 3.8 Hz, 1H), 1.58 (q, J = 7.5 Hz, 2H), 1.63 – 1.78 (m, 9H), 1.98 (ddd, J = 13.8, 8.6, 5.4 Hz, 1H), 2.53 – 2.62 (m, 1H), 3.35 – 3.44 (m, 1H), 3.53 (dt, J = 11.1, 5.3 Hz, 1H), 3.81 (d, J = 11.3 Hz, 1H), 3.92 (dd, J = 11.3, 4.6 Hz, 1H), 7.35 (d, J = 8.0 Hz, 1H), 7.92 (dd, J = 8.1, 1.8 Hz, 1H), 8.66 (s, 1H). Int.178: Preparation of 8-methyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl)-3,8-diazabicyclo[3.2.1]octaneStep 1: tert-butyl 3-phenyl-3,8-diazabicyclo[3.2.1]octane-8-carboxylate:

[0379] To a solution of bromobenzene (5 g, 31.85 mmol, 3.35 mL, 1 Equiv.) in dioxane (25 mL) was added t-BuONa in dioxane (2 M, 31.85 mL, 2 ), tert-butyl 3,8- diazabicyclo[3.2.1]octane-8-carboxylate (7.44 g, 35.03 mmol, 1.1 Equiv.) and RuPhos Pd G4 (2.71 g, 3.18 mmol, 0.1 Equiv.) under N2. The mixture was stired at 90 °C for 12 hr under N2. LCMS showed starting material was consumed desired mass was detected. The reaction mixture was cooled to room temperature and diluted with water (50 mL), extracted with EtOAc (2 x 50 mL). The combined organics were washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated under reduced. The resulting residue was purified by flash silica gel chromatography (Pet. Ether / EtOAc, 5:1) to aford tert-butyl 3-phenyl-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (9 g, 31.2 mmol, 97%) as a white solid. LCMS (ESI+): m / z 289.3 (M+H+).1H NMR (400 MHz, CDCl3): δ 7.32 - 7.28 (m, 2H), 6.90 - 6.81 (m, 3H), 4.49 - 4.30 (m, 2H), 3.44 (dd, J = 1.9, 11.1 Hz, 2H), 3.02 (br s, 2H), 2.02 - 1.85 (m, 4H), 1.51 (s, 9H). Step 2: tert-butyl 3-(4-bromophenyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate:

[0380] To a solution of tert-butyl 3-phenyl-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (9 g, 31.21 mmol, 1 Equiv.) ethanol (540 mL)was added tetrabutylammonium;bromide (10.06 g, 31.21 mmol, 1 Equiv.) and dibromocopper (10.46 g, 46.81 mmol, 2.19 mL, 1.5 Equiv.) under N2. The mixture was stired at 25 °C for 12 hrs. LCMS showed starting material was consumed and desired mass was detected. The reaction mixture was filtered, and the filter cake was rinsed with EtOAc (3 x 20 mL). Then the combined filtrates were concentrated under reduced pressure. The resulting residue was purified by flash silica gel chromatography (Pet. Ether / EtOAc, 5:1) to aford tert-butyl 3-(4-bromophenyl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (5.0 g, 13.6 mmol, 44%) as a white solid. LCMS (ESI+): m / z 367.1 (M+H+).1H NMR (400 MHz, CDCl3): δ 7.33 (d, J = 9.0 Hz, 2H), 6.70 (br d, J = 9.0 Hz, 2H), 4.36 (br s, 2H), 3.40 - 3.30 (m, 2H), 2.97 (br s, 2H), 2.02 - 1.79 (m, 4H), 1.48 (s, 9H). Step 3: tert-butyl 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate:

[0381] To a solution of tert-butyl 3-(4-bromophenyl)-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (4 g, 10.89 mmol, 1 Equiv.) dioxane (40 mL) was added bis(pinacolato)diboron (4.15 g, 16.34 mmol, 1.5 Equiv.), potassium acetate (3.21 g, 32.67 mmol, 3 Equiv.) and Pd(dppf)Cl2 (796.89 mg, 1.09 mmol, 0.1 Equiv.) under N2. The mixture was stired at 80 °C for 12 hrs under N2. LCMS showed starting material was consumed and desired mass was detected. The reaction mixture was filtered, and the filter cake was rinsed with EtOAc (45 mL). Then the combined filtrates were concentrated under reduced pressure. The resulting residue was purified by flash silica gel chromatography, eluted with Pet. Ether / EtOAc (4:1) to aford a yelow solid. The yelow solid was triturated with Pet. Ether (30 mL) at 25oC for 30 min, filtered. The filter cake was concentrated to give tert-butyl 3-(4-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)phenyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (3.4 g, 8.21 mmol, 75%) as a white solid. LCMS (ESI+): m / z 415.2 (M+H+).1HNMR (400 MHz, CDCl3): δ 7.71 (d, J = 8.5 Hz, 2H), 6.82 (d, J = 8.5 Hz, 2H), 4.48 - 4.27 (m, 2H), 3.49 (dd, J = 1.8, 11.3 Hz, 2H), 3.04 (s, 2H), 2.00 - 1.80 (m, 4H), 1.48 (s, 9H), 1.38 - 1.30 (m, 12H). Step 4: 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3,8-diazabicyclo[3.2.1]octane:

[0382] To a solution of tert-butyl 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (4.1 g, 9.90 mmol, 1 Equiv.) in EtOAc (20 mL) was added HCl / EtOAc (4 M, 40 mL, 16.17 Equiv.) dropwise. The mixture was stired at 25 °C until LCMS showed the consumption of starting material. The mixture was filtered with EtOAc (30 mL) and the filter cake was concentrated under reduced pressure to give 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3,8- diazabicyclo[3.2.1]octane (2.6 g, 7.4 mmol, 75%, HCl Salt) as a white solid. LCMS (ESI+): m / z 315.2 (M+H+).1H NMR (400 MHz, MeOD-d6): δ 7.65 (d, J = 8.8 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 4.19 (s, 2H), 3.80 (dd, J = 2.4, 13.1 Hz, 2H), 3.13 (d, J = 12.1 Hz, 2H), 2.13 (s, 4H), 1.33 (s, 12H) Step 5: Int.178:

[0383] To a solution of 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3,8- diazabicyclo[3.2.1]octane (2.4 g, 6.84 mmol, 1 Equiv., HCl) in methanol (24 mL) was added formaldehyde (2.78 g, 34.22 mmol, 2.55 mL, 37% purity, 5 Equiv.). The mixture was stired for 30 min under N2. Then Na(CN)BH3 (860.14 mg, 13.69 mmol, 2 Equiv.) was added to the reaction. The mixture was stired at 25 °C until the consumption of starting material was observed (LCMS). The reaction mixture was diluted by water (50 mL), extracted with EtOAc (2 x 50 mL). The combined organics were washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The resulting residue was triturated with methyl tert-butyl ether (20 mL), then filtered. The filter cake was colected to give Int.178 (1.07 g, 3.26 mmol, 48%) as a white solid. LCMS (ESI+): m / z 329.2 (M+H+).1H NMR (400 MHz, MeOD-d6): δ 7.58 (d, J = 8.6 Hz, 2H), 6.80 (d, J = 8.6 Hz, 2H), 3.53 - 3.48 (m, 2H), 3.35 - 3.32 (m, 2H), 2.99 (br d, J = 10.0 Hz, 2H), 2.36 (s, 3H), 2.14 - 2.06 (m, 2H), 1.81 - 1.74 (m, 2H), 1.32 (s, 12H)Int.179: Preparation of (1S,4S)-2-methyl-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)phenyl)-2,5-diazabicyclo[2.2.1]heptaneStep 1: (1S, 4S)-2-(4-bromophenyl)-5-methyl-2, 5-diazabicyclo [2.2.1] heptane:

[0384] A mixture of (1S,4S)-2-methyl-2,5-diazabicyclo[2.2.1]heptane;dihydrobromide (3.90 g, 14.2 mmol, 1.0 Equiv.), 1-bromo-4-iodo-benzene (4.03 g, 14.2 mmol, 1.0 Equiv.) , Pd2(dba)3 (391 mg, 427 μmol, 0.03 Equiv.) , t-BuONa (3.42 g, 35.6 mmol, 2.5 Equiv.) and [1-(2-diphenylphosphanyl-1-naphthyl)-2-naphthyl]-diphenyl-phosphane (88.63 mg, 142.34 μmol, 0.01 Equiv.) in toluene (160 mL) was degassed and purged with N2, then the mixture was stired at 110°C for 12hr under N2 atmosphere. After cooling to room temperature, the reaction mixture was concentrated to remove solvent. Water (50 mL) was added and the aqueous phase was extracted with EtOAc (30 mL×3), the combined organic phase was washed with brine (30 mL×3), dried over Na2SO4, filtered, and concentrated. The resulting residue was dissolved in water (50 mL) and acidified to pH of 5-6 with HCI (1 M), the aqueous phase was extracted with MTBE (30mL×3). Then the aqueous phase was alkalized to pH of 7-8 with saturated NaHCO3 and extracted with ethyl acetate (50 mL×3), the combined organic layers were dried over Na2SO4, filtered and the filtrate was concentrated to give (1S,4S)-2-(4-bromophenyl)-5-methyl-2,5-diazabicyclo[2.2.1]heptane (1.70 g, 6.12 mmol, 43.01% yield) as a yelow oil. LCMS (ESI+): m / z 267.2 (M+ H+). Step 2: Int.179:

[0385] A mixture of (1S, 4S)-2-(4-bromophenyl)-5-methyl-2,5-diazabicyclo[2.2.1]heptane (1.70 g, 6.36 mmol, 1.0 Equiv.), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1,3,2-dioxaborolane (2.75 g, 10.8 mmol, 1.7 Equiv.), KOAc (1.56 g, 15.9 mmol, 2.5 Equiv.), Pd(dppf)Cl2(232 mg, 318 μmol, 0.05 Equiv.) in dioxane (20 mL) was degassed and purged with N2. The mixture was stired at 100 °C for 12hr under N2 atmosphere. After cooling to room temperature, the reaction mixture was concentrated. The resulting residue was diluted with water (30 mL) and EtOAc (20 mL), the resultant mixture was filtered, and the filter cake was rinsed with EtOAc (20 mL x3), the resulting biphasic solution was separated, then the aqueous phase was extracted with EtOAc (30 mL ×3), the combined organic layers were dried over Na2SO4, filtered and the filtrate was concentrated. The resulting residue was purified by silica gel column chromatography (Pet. Ether / EtOAc, 1:0 to 20:1) to aford Int.179 (650 mg, 2.02 mmol, 31.74% yield) as a brown solid. LCMS (ESI+): m / z 315.2 (M+H+).1H NMR (400 MHz, DMSO-d6): δ7.44 (d, J = 8.0 Hz, 2H), 6.53 (d, J = 8.0 Hz, 2H), 4.32 (s, 1H), 3.30 (d, J = 9.2 Hz, 2H), 3.17 (d, J = 9.2 Hz, 1H), 2.78 (d, J = 8.8 Hz, 1H), 2.42 (d, J = 9.2 Hz, 1H), 2.24 (s, 3H), 1.84-1.91 (m, 1H), 1.75 (d, J = 8.8 Hz, 1H), 1.25 (s, 12H). Int.180: (2S,4R)-1-(3,3-difluoro-1-methylcyclobutane-1-carbonyl)-4-fluoropyrrolidine- 2-carboxylic acidStep 1: methyl (2S,4R)-4-fluoropyrrolidine-2-carboxylate hydrochloride:

[0386] To a solution of 1-(tert-butyl) 2-methyl (2S,4R)-4-fluoropyrolidine-1,2- dicarboxylate (5 g, 20.22 mmol, 1 Equiv.) in EtOAc (10 mL) was added dropwise HCl / EtOAc (4 M, 200 mL, 39.56 Equiv.). The mixture was stired until the complete consumption of starting material (LCMS). The reaction was concentrated under reduced pressure to aford methyl (2S,4R)-4-fluoropyrolidine-2-carboxylate hydrochloride (3.5 g, 17.16 mmol, 84.84% yield, HCl salt) as a white solid.1H NMR (400 MHz, DMSO-d6): δ 10.25 (br d, J = 1.1 Hz, 1H), 5.57 - 5.32 (m, 1H), 4.55 (dd, J = 7.3, 11.3 Hz, 1H), 3.66 - 3.34 (m, 3H), 2.79 - 2.51 (m, 3H), 2.43 - 2.21 (m, 1H). Step 2: methyl (2S,4R)-4-fluoropyrrolidine-2-carboxylate hydrochloride:

[0387] To a solution of 3,3-difluoro-1-methyl-cyclobutanecarboxylic acid (2.70 g, 17.97 mmol, 1.1 Equiv.) in DCM (30 mL) was added DIEPA (2.11 g, 16.34 mmol, 2.85 mL, 1 Equiv.). The mixture was stired at 20 °C for 10 min.3-[chloro-(2-oxooxazolidin-3- yl)phosphoryl]oxazolidin-2-one (4.58 g, 17.97 mmol, 1.1 Equiv.) was ad...

Claims

WHAT IS CLAIMED IS:

1. A compound of Formula (I): whereinR3is (a) C1-6alkyl, C2-6alkenyl, C2-6alkynyl, or C1-6haloalkyl, each substituted with 0 to 5 R3a, (b) C3-12cycloalkyl substituted with 0 to 5 R3b, or (c) heterocycloalkyl having 3 to 12 ring members and 1 to 4 heteroatoms, each independently N, O, or S, wherein the heterocycloalkyl is substituted with 0 to 5 R3c; (g) heteroaryl having 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein the heteroaryl is substituted with 0, 1, 2, 3, 4, or 5 R3g; each R3ais –OH, C1-6alkoxy, C1-6haloalkoxy, or –O–C(O)C1-6alkyl; each R3bis independently C1-6alkyl, C2-6alkenyl, C2-6alkynyl, –OH, C1-6alkoxy, halo, C1-6haloalkyl, C1-6haloalkoxy, or cyano; each R3cis independently C1-6alkyl, halo, C1-6haloalkyl, cyano, C3-6cycloalkyl, or oxo; each R3gis independently C1-6alkyl, halo, C1-6haloalkyl, or C3-6cycloalkyl; R4ais H or C1-6alkyl; R4band R4care each independently H, C1-6alkyl, C1-6haloalkyl, C3-6cycloalkyl, –C1-6alkyl–C3-6cycloalkyl, heterocycloalkyl, –C1-6alkyl–heterocycloalkyl, phenyl, –C1-6alkyl–phenyl, heteroaryl, or –C1-6alkyl–heteroaryl, wherein each heterocycloalkyl has 3 to 6 ring members and 1 to 3 heteroatoms, eachindependently N, O, or S, and each heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S; alternatively, R4cand R4atogether with the carbon and nitrogen to which each is atached combine to form a heterocycloalkyl having 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein the heterocycloalkyl is substituted with 0 to 4 R4a1; each R4a1is independently C1-6alkyl, –OH, C1-6alkyl–OH, C1-6alkoxy, or halo; R5a is H or C1-6alkyl; R5b and R5c are each independently H, C1-6alkyl, –C1-6alkyl–OH, C2-6alkoxyalkyl, C1-6haloalkyl, –C1-6alkyl–C(O)NR5b1R5b2, –C1-6alkyl–C(O)OR5b1, C3-6cycloalkyl, C1-6alkyl–C3-6cycloalkyl, heterocycloalkyl, –C1-6alkyl– heterocycloalkyl, phenyl, –C1-6alkyl–phenyl, heteroaryl, or –C1-6alkyl–heteroaryl, wherein each heterocycloalkyl has 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and wherein each cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl is substituted with 0 to 3 R5b5; each R5b1and R5b2are independently H, C1-4alkyl, or C1-4haloalkyl; alternatively, R5b1and R5b2together with the nitrogen to which each is atached combine to form a heterocycloalkyl having 3 to 6 ring members and 0 to 1 additional heteroatoms, wherein the heterocycloalkyl is substituted with 0 to 2 R5b3; each R5b3and R5b5 is independently C1-6alkyl, halo, C1-6haloalkyl, or cyano; X6is C6-7alkylene or C6-7alkenylene; R6a is H, C1-6alkyl, C1-6deuteroalkyl, C2-6alkoxyalkyl, C3-6cycloalkyl, –C1-6alkyl– C3-6cycloalkyl, heterocycloalkyl, –C1-6alkyl–heterocycloalkyl, phenyl, –C1-6alkyl–phenyl, heteroaryl, or –C1-6alkyl–heteroaryl, wherein the heterocycloalkyl has 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and the heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S; R6band R6d are each independently H or C1-6alkyl; R7ais H or C1-6alkyl; R7band R7care each independently H, C1-6alkyl, C2-6alkenyl, C1-6haloalkyl, C1-6alkyl–OH, C3-6cycloalkyl, or –C1-6alkyl–C3-6cycloalkyl;R8a is H, C1-6alkyl, C2-6alkoxyalkyl, C3-6cycloalkyl or –C1-6alkyl–C3-6cycloalkyl; R8b, R8d, and R8e are each independently H or C1-6alkyl; ring B is C6-12 aryl or heteroaryl having 5 to 12 ring members and 1 to 6 heteroatoms, each independently N, O or S; the subscript m8 is an integer from 0 to 5; each R8fis independently C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6deuteroalkoxy, halo, C1-6haloalkyl, cyano, –X8f–cyano, C3-12cycloalkyl, –X8f–C3-6cycloalkyl, –CH=CR8f1R8f2, heterocycloalkyl, –X8f–heterocycloalkyl, C6-12aryl, –X8f–C 6-12 aryl, heteroaryl, or –X8f–heteroaryl, wherein each heterocycloalkyl has 3 to 12 ring members and 1 to 4 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 10 ring members and 1 to 4 heteroatoms, each independently N, O, or S, wherein each alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is substituted with 0 to 3 R8f3; alternatively, two R8fgroups on adjacent ring vertices combine to form a C3-6cycloalkyl or a heterocycloalkyl having 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein the cycloalkyl or heterocycloalkyl is substituted with 0 to 3 R8f3; each X8fis independently C1-6alkylene, C2-6alkenylene, –O–C1-6alkylene, C(O), O, or S; each R8f1 and R8f2 are combined with the carbon to which they are atached to form a heterocycloalkyl having 3 to 10 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein the heterocycloalkyl is substituted with 0 to 3 R8f3; each R8f3is independently C1-6alkyl, –Y8–C1-6alkyl, C1-6deuteroalkyl, –Y8–C1-6deuteroalkyl, –OH, –C1-6alkyl–OH, –Y8–C1-6alkyl–OH, –C1-6alkyl–Y8–C1-6alkyl, –(C1-2 alkyl–O)1-4–C1-2 alkyl, C1-6alkoxy, halo, C1-6haloalkyl, –Y8–C1-6haloalkyl, cyano, –C1-6alkyl–cyano, –C1-6alkyl–NR8gR8h, oxo, C3-6cycloalkyl, –X8f3–C3-6cycloalkyl, heterocycloalkyl, –X8f3– heterocycloalkyl, phenyl, –X8f3–phenyl, heteroaryl, or –X8f3–heteroaryl, wherein each heterocycloalkyl has 3 to 12 members and 1 to 4 heteroatoms, each independently N, O, S, or S(O)2, and each heteroaryl has 5 to 10 ring members and 1 to 4 heteroatoms, each independently N, O, or S, and whereineach heterocycloalkyl and heteroaryl are substituted with 0 to 2 C1-4alkyl or halo; each X8f3is independently C1-6alkylene, O, C(O), or S(O)2; each Y8 is independently C(O), C(O)O, N(R8f4)C(O), O, S, or S(O)2; each R8g and R8h is independently H, C1-6alkyl, or C1-6haloalkyl; alternatively, two R8f3groups on the same or adjacent ring vertices combine to form a C3-6cycloalkyl or a heterocycloalkyl having 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein nitrogen atom ring members in the heterocycloalkyl are substituted with 0 to 1 C1-4alkyl; and each R8f4is independently H or C1-6alkyl; or a pharmaceuticaly acceptable salt thereof.

2. The compound of claim 1, or the pharmaceuticaly acceptable salt thereof, wherein R3is (a) C1-6alkyl, C2-6alkenyl, C2-6alkynyl, or C1-6haloalkyl, each substituted with 0 to 5 R3a, (b) C3-12cycloalkyl substituted with 0 to 5 R3b, or (c) heterocycloalkyl having 3 to 12 ring members and 1 to 4 heteroatoms, each independently N, O, or S, wherein the heterocycloalkyl is substituted with 0 to 5 R3c; each R3ais –OH, C1-6alkoxy, C1-6haloalkoxy, or –O–C(O)C1-6alkyl; each R3bis independently C1-6alkyl, C2-6alkenyl, C2-6alkynyl, –OH, C1-6alkoxy, halo, C1-6haloalkyl, C1-6haloalkoxy, or cyano; each R3cis independently C1-6alkyl, C1-6haloalkyl, C3-6cycloalkyl, or oxo; R4ais H or C1-6alkyl; R4band R4care each independently H, C1-6alkyl, C3-6cycloalkyl, –C1-6alkyl–C3-6cycloalkyl, heterocycloalkyl, –C1-6alkyl–heterocycloalkyl, phenyl, –C1-6alkyl–phenyl, heteroaryl, or –C1-6alkyl–heteroaryl, wherein each heterocycloalkyl has 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S;alternatively, R4cand R4atogether with the carbon and nitrogen to which each is atached combine to form a heterocycloalkyl having 3 to 6 ring members, wherein the heterocycloalkyl is substituted with 0 to 4 R4a1; each R4a1is independently C1-6alkyl, –OH, C1-6alkyl–OH, C1-6alkoxy, or halo; R5a is H or C1-6alkyl; R5b and R5c are each independently H, C1-6alkyl, –C1-6alkyl–OH, C2-6alkoxyalkyl, C1-6haloalkyl, C3-6cycloalkyl, C1-6alkyl–C3-6cycloalkyl, heterocycloalkyl, – C1-6alkyl–heterocycloalkyl, phenyl, –C1-6alkyl–phenyl, heteroaryl, or –C1-6alkyl–heteroaryl, wherein each heterocycloalkyl has 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and wherein each cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl is substituted with 0 to 3 R5b5; each R5b5 is independently C1-6alkyl, halo, or C1-6haloalkyl; X6is C6-7alkylene or C6-7alkenylene; R6a is H, C1-6alkyl, C2-6alkoxyalkyl, C3-6cycloalkyl, –C1-6alkyl–C3-6cycloalkyl, heterocycloalkyl, –C1-6alkyl–heterocycloalkyl, phenyl, –C1-6alkyl–phenyl, heteroaryl, or –C1-6alkyl–heteroaryl, wherein the heterocycloalkyl has 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and the heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S; R6band R6d are each independently H or C1-6alkyl; R7ais H or C1-6alkyl; R7band R7care each independently H, C1-6alkyl, C2-6alkenyl, C1-6haloalkyl, C1-6alkyl–OH, C3-6cycloalkyl, or –C1-6alkyl–C3-6cycloalkyl; R8a is H, C1-6alkyl, C2-6alkoxyalkyl, C3-6cycloalkyl or –C1-6alkyl–C3-6cycloalkyl; R8b, R8d, and R8e are each independently H or C1-6alkyl; ring B is C6-12 aryl or heteroaryl having 5 to 12 ring members and 1 to 6 heteroatoms, each independently N, O or S; the subscript m8 is an integer from 0 to 5; each R8fis independently C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6deuteroalkoxy, halo, C1-6haloalkyl, cyano, –X8f–cyano, C3-12cycloalkyl, –X8f–C3-6cycloalkyl, –CH=CR8f1R8f2, heterocycloalkyl, –X8f–heterocycloalkyl, C6-12aryl, –X8f–C 6-12 aryl, heteroaryl, or–X8f–heteroaryl, wherein each heterocycloalkyl has 3 to 12 ring members and 1 to 4 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 10 ring members and 1 to 4 heteroatoms, each independently N, O, or S, wherein each alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is substituted with 0 to 3 R8f3; alternatively, two R8fgroups on adjacent ring vertices combine to form a C3-6cycloalkyl or a heterocycloalkyl having 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein the cycloalkyl or heterocycloalkyl is substituted with 0 to 3 R8f3; each X8fis independently C1-6alkylene, C2-6alkenylene, –O–C1-6alkylene, O, or S; each R8f1 and R8f2 are combined with the carbon to which they are atached to form a heterocycloalkyl having 3 to 10 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein the heterocycloalkyl is substituted with 0 to 3 R8f3; each R8f3is independently C1-6alkyl, –Y8–C1-6alkyl, C1-6deuteroalkyl, –Y8–C1-6deuteroalkyl, –OH, –C1-6alkyl–OH, –Y8–C1-6alkyl–OH, –C1-6alkyl–Y8–C1-6alkyl, –(C1-2 alkyl–O)1-4–C1-2 alkyl, C1-6alkoxy, halo, C1-6haloalkyl, –Y8–C1-6haloalkyl, cyano, –C1-6alkyl–cyano, oxo, C3-6cycloalkyl, –X8f3–C3-6cycloalkyl, heterocycloalkyl, –X8f3– heterocycloalkyl, phenyl, – X8f3–phenyl, heteroaryl, or –X8f3–heteroaryl, wherein each heterocycloalkyl has 3 to 12 members and 1 to 4 heteroatoms, each independently N, O, S, or S(O)2, and each heteroaryl has 5 to 10 ring members and 1 to 4 heteroatoms, each independently N, O, or S, and wherein nitrogen atom ring members in each heterocycloalkyl and heteroaryl are substituted with 0 to 1 C1-4alkyl; each X8f3is independently C1-6alkylene, O, C(O), or S(O)2; each Y8 is independently C(O), C(O)O, N(R8f4)C(O), O, S, or S(O)2; alternatively, two R8f3groups on the same or adjacent ring vertices combine to form a C3-6cycloalkyl or a heterocycloalkyl having 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein nitrogen atom ring members in the heterocycloalkyl are substituted with 0 to 1 C1-4alkyl; and each R8f4is independently H or C1-6alkyl; or a pharmaceuticaly acceptable salt thereof.

3. The compound of claim 1, or the pharmaceuticaly acceptable salt thereof, wherein R3is (a) C1-6alkyl, C2-6alkenyl, C2-6alkynyl, or C1-6haloalkyl, each substituted with 0 to 5 R3a, (b) C3-12cycloalkyl substituted with 0 to 5 R3b, or (c) heterocycloalkyl having 3 to 12 ring members and 1 to 4 heteroatoms, each independently N, O, or S, wherein the heterocycloalkyl is substituted with 0 to 5 R3c; each R3ais –OH, C1-6alkoxy, C1-6haloalkoxy, or –O–C(O)C1-6alkyl; each R3bis independently C1-6alkyl, C2-6alkenyl, C2-6alkynyl, –OH, C1-6alkoxy, halo, C1-6haloalkyl, C1-6haloalkoxy, or cyano; each R3cis independently C1-6alkyl, C1-6haloalkyl, C3-6cycloalkyl, or oxo; R4ais H or C1-6alkyl; R4band R4care each independently H, C1-6alkyl, C3-6cycloalkyl, –C1-6alkyl–C3-6cycloalkyl, heterocycloalkyl, –C1-6alkyl–heterocycloalkyl, phenyl, –C1-6alkyl–phenyl, heteroaryl, or –C1-6alkyl–heteroaryl, wherein each heterocycloalkyl has 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S; alternatively, R4cand R4atogether with the carbon and nitrogen to which each is atached combine to form a heterocycloalkyl having 3 to 6 ring members, wherein the heterocycloalkyl is substituted with 0 to 4 R4a1; each R4a1is independently C1-6alkyl, –OH, C1-6alkyl–OH, C1-6alkoxy, or halo; R5a is H or C1-6alkyl; R5b and R5c are each independently H, C1-6alkyl, –C1-6alkyl–OH, C2-6alkoxyalkyl, C1-6haloalkyl, C3-6cycloalkyl, C1-6alkyl–C3-6cycloalkyl, heterocycloalkyl, – C1-6alkyl–heterocycloalkyl, phenyl, –C1-6alkyl–phenyl, heteroaryl, or –C1-6alkyl–heteroaryl, wherein each heterocycloalkyl has 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and wherein each cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl is substituted with 0 to 3 R5b5;each R5b5 is independently C1-6alkyl, halo, or C1-6haloalkyl; X6is C6-7alkylene or C6-7alkenylene; R6a is H, C1-6alkyl, C2-6alkoxyalkyl, C3-6cycloalkyl, –C1-6alkyl–C3-6cycloalkyl, heterocycloalkyl, –C1-6alkyl–heterocycloalkyl, phenyl, –C1-6alkyl–phenyl, heteroaryl, or –C1-6alkyl–heteroaryl, wherein the heterocycloalkyl has 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and the heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S; R6band R6d are each independently H or C1-6alkyl; R7ais H or C1-6alkyl; R7band R7care each independently H, C1-6alkyl, C2-6alkenyl, C1-6haloalkyl, C1-6alkyl–OH, C3-6cycloalkyl, or –C1-6alkyl–C3-6cycloalkyl; R8a is H, C1-6alkyl, C2-6alkoxyalkyl, C3-6cycloalkyl or –C1-6alkyl–C3-6cycloalkyl; R8b, R8d, and R8e are each independently H or C1-6alkyl; ring B is aryl or heteroaryl having 5 to 12 ring members and 1 to 6 heteroatoms, each independently N, O or S; the subscript m8 is an integer from 0 to 5; each R8fis independently C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6deuteroalkoxy, halo, C1-6haloalkyl, cyano, –X8f–cyano, C3-12cycloalkyl, –X8f–C3-6cycloalkyl, –CH=CR8f1R8f2, heterocycloalkyl, –X8f–heterocycloalkyl, aryl, –X8f–aryl, heteroaryl, or –X8f–heteroaryl, wherein each heterocycloalkyl has 3 to 12 ring members and 1 to 4 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 10 ring members and 1 to 4 heteroatoms, each independently N, O, or S, wherein each alkynyl, cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl is substituted with 0 to 3 R8f3; alternatively, two R8fgroups on adjacent ring vertices combine to form a C3-6cycloalkyl or a heterocycloalkyl having 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O or S; each X8fis independently C1-6alkylene, C2-6alkenylene, O, or S; each R8f1 and R8f2 are combined with the carbon to which they are atached to form a heterocycloalkyl having 3 to 10 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein the heterocycloalkyl is substituted with 0 to;each R8f3is independently C1-6alkyl, –Y8–C1-6alkyl, C1-6deuteroalkyl, –Y8–C1-6deuteroalkyl, –OH, –C1-6alkyl–OH, –Y8–C1-6alkyl–OH, –C1-6alkyl–Y8–C1-6alkyl, C1-6alkoxy, halo, C1-6haloalkyl, –Y8–C1-6haloalkyl, cyano, –C1-6alkyl–cyano, oxo, C3-6cycloalkyl, –X8f3–C3-6cycloalkyl, heterocycloalkyl, –X8f3– heterocycloalkyl, phenyl, –X8f3–phenyl, heteroaryl, or –X8f3–heteroaryl, wherein each heterocycloalkyl has 3 to 12 members and 1 to 4 heteroatoms, each independently N, O, S, or S(O)2, and each heteroaryl has 5 to 10 ring members and 1 to 4 heteroatoms, each independently N, O, or S, and wherein nitrogen atom ring members in each heterocycloalkyl and heteroaryl are substituted with 0 to 1 C1-4alkyl; each X8f3is independently C1-6alkylene, O, C(O), or S(O)2; each Y8 is independently C(O), C(O)O, N(R8f4)C(O), O, S, or S(O)2; alternatively, two R8f3groups on adjacent ring vertices combine to form a C3-6cycloalkyl or a heterocycloalkyl having 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O or S; and each R8f4is independently H or C1-6alkyl.

4. The compound of any one of claims 1 to 3, or the pharmaceuticaly acceptable salt thereof, wherein R3is (a) C1-6alkyl, C2-6alkenyl, C2-6alkynyl, or C1-6haloalkyl substituted with 0 to 5 R3a.

5. The compound of any one of claims 1 to 3, or the pharmaceuticaly acceptable salt thereof, wherein R3is (a) C1-6alkyl or C1-6haloalkyl substituted with 0 to 2 R3a.

6. The compound of any one of claims 1 to 5, or the pharmaceuticaly acceptable salt thereof, wherein each R3ais –OH.

7. The compound of any one of claims 1 to 3, or the pharmaceuticaly acceptable salt thereof, wherein R3is (b) C3-7 cycloalkyl substituted with 0 to 3 R3b.

8. The compound of any one of claims 1 to 3, or the pharmaceuticaly acceptable salt thereof, wherein R3is (b) C3-4 cycloalkyl substituted with 0 to 2 R3b.

9. The compound of claim 7 or claim 8, or the pharmaceuticaly acceptable salt thereof, wherein each R3bis halo or C1-4haloalkyl.

10. The compound of any one of claims 1 to 3, or the pharmaceuticaly acceptable salt thereof, wherein R3is (c) heterocycloalkyl having 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein the heterocycloalkyl is substituted with 0 to 5 R3c.

11. The compound of claim 10, or the pharmaceuticaly acceptable salt thereof, wherein each R3cis halo or C1-4haloalkyl.

12. The compound of claim 10, or the pharmaceuticaly acceptable salt thereof, wherein each R3cis fluoro or trifluoromethyl.

13. The compound of any one of claims 1 to 12, or the pharmaceuticaly acceptable salt thereof, wherein R3is14. The compound of any one of claims 1 to 13, or the pharmaceuticaly acceptable salt thereof, wherein R4a, R4b, and R4care each independently H or C1-6alkyl; alternatively, R4cand R4atogether with the carbon and nitrogen to which each is atached combine to form a heterocycloalkyl having 4 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein the heterocycloalkyl is substituted with 0 to 2 R4a1; and each R4a1is independently halo.

15. The compound of any one of claims 1 to 13, or the pharmaceuticaly acceptable salt thereof, wherein R4a, R4b, and R4care each independently H or C1-6alkyl.

16. The compound of any one of claims 1 to 13, or the pharmaceuticaly acceptable salt thereof, whereinR4bis H or C1-6alkyl; and R4cand R4atogether with the carbon and nitrogen to which each is atached combine to form a heterocycloalkyl having 4 to 6 ring members, wherein the heterocycloalkyl is substituted with 0 to 3 R4a1.

17. The compound of any one of claims 1 to 16, or the pharmaceuticaly acceptable salt thereof, wherein R4aand R4bare each H; and R4cis ethyl; alternatively, R4cand R4atogether with the carbon and nitrogen to which each is atached combine to form a pyrolidinyl, substituted with 0 to 2 fluoro.

18. The compound of any one of claims 1 to 17, or the pharmaceuticaly acceptable salt thereof, wherein R5a is H or C1-6alkyl; R5b and R5c are each independently H, C1-6alkyl, –C1-6alkyl–OH, C2-6alkoxyalkyl, C1-6haloalkyl, C3-6cycloalkyl, or C1-4alkyl–C3-6cycloalkyl, wherein each cycloalkyl is substituted with 0 to 3 R5b5; and each R5b5 is independently C1-4alkyl, halo, or C1-4haloalkyl.

19. The compound of any one of claims 1 to 18, or the pharmaceuticaly acceptable salt thereof, wherein R5a is H or C1-6alkyl; R5b is H; and R5c is C3-6cycloalkyl or C1-4alkyl–C3-6cycloalkyl.

20. The compound of any one of claims 1 to 19, or the pharmaceuticaly acceptable salt thereof, wherein R5a and R5b are each H; and21. The compound of any one of claims 1 to 20, or the pharmaceuticaly acceptable salt thereof, wherein X6is C6-7alkylene.

22. The compound of any one of claims 1 to 20, or the pharmaceuticaly acceptable salt thereof, wherein X6is C6-7alkenylene.

23. The compound of any one of claims 1 to 22, or the pharmaceuticaly acceptable salt thereof, wherein X6is ,, , , wherein the wavy bond atached to the double bond indicates E, Z, or a mixture of both isomers.

24. The compound of any one of claims 1 to 23, or the pharmaceuticaly acceptable salt thereof, wherein X6is, wherein the wavy bond atached to the double bond indicates E, Z, or a mixture of both isomers.

25. The compound of any one of claims 1 to 23, or the pharmaceuticaly acceptable salt thereof, wherein X6is.

26. The compound of any one of claims 1 to 25, or the pharmaceuticaly acceptable salt thereof, wherein R6a is H, C1-4alkyl, or –C1-4alkyl–C3-6cycloalkyl; and R6band R6d are each independently H or C1-6alkyl.

27. The compound of any one of claims 1 to 26, or the pharmaceuticaly acceptable salt thereof, wherein R6a is H, methyl, ethyl,; R6bis H; and R6d is H, methyl, or ethyl.

28. The compound of any one of claims 1 to 27, or the pharmaceuticaly acceptable salt thereof, wherein R7aand R7bare each independently H or C1-6alkyl; and R7cis C1-6alkyl, C2-6alkenyl, C1-6haloalkyl, C1-6alkyl–OH, or –C1-6alkyl–C3-6cycloalkyl.

29. The compound of any one of claims 1 to 27, or the pharmaceuticaly acceptable salt thereof, whereinR7aand R7bare each H; and R7cis C1-6alkyl.

30. The compound of any one of claims 1 to 29, or the pharmaceuticaly acceptable salt thereof, wherein R7aand R7bare each H; and R7cis isobutyl,31. The compound of any one of claims 1 to 28, or the pharmaceuticaly acceptable salt thereof, wherein R7aand R7bare each H; and R7cis isobutyl.

32. The compound of any one of claims 1 to 31, or the pharmaceuticaly acceptable salt thereof, wherein R8a, R8b, R8d, and R8e are each independently H or C1-6alkyl.

33. The compound of any one of claims 1 to 31, or the pharmaceuticaly acceptable salt thereof, wherein R8a is H or methyl; and R8b, R8d and R8e are each H.

34. The compound of any one of claims 1 to 33, or the pharmaceuticaly acceptable salt thereof, wherein ring B is phenyl.

35. The compound of any one of claims 1 to 33, or the pharmaceuticaly acceptable salt thereof, wherein ring B is biphenyl.

36. The compound of any one of claims 1 to 33, or the pharmaceuticaly acceptable salt thereof, wherein ring B is a heteroaryl having 5 to 6 ring members and 1 to 3 heteroatoms, wherein each heteroatom is N.

37. The compound of any one of claims 1 to 33, or the pharmaceuticaly acceptable salt thereof, wherein ring B is naphthyl, thiophenyl, benzofuranyl, indolyl, indazolyl, or quinolinyl.

38. The compound of any one of claims 1 to 33, or the pharmaceuticaly acceptable salt thereof, wherein ring B is pyrid-3-yl.

39. The compound of any one of claims 1 to 38, or the pharmaceuticaly acceptable salt thereof, wherein the subscript m8 is 1, 2, or 3.

40. The compound of any one of claims 1 to 39, or the pharmaceuticaly acceptable salt thereof, wherein at least one R8fis halo.

41. The compound of any one of claims 1 to 40, or the pharmaceuticaly acceptable salt thereof, wherein each R8fis independently C1-6alkyl, C2-6alkenyl, C1-6alkoxy, C1-6deuteroalkoxy, halo, C1-6haloalkyl, cyano, or –X8f–cyano.

42. The compound of any one of claims 1 to 40, or the pharmaceuticaly acceptable salt thereof, wherein each R8fis independently halo, C3-6cycloalkyl, –X8f–C3-6cycloalkyl, –CH=CR8f1R8f2, heterocycloalkyl, –X8f–heterocycloalkyl, phenyl, –X8f–phenyl, heteroaryl, or – X8f–heteroaryl, wherein each heterocycloalkyl has 3 to 10 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 10 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein each cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl is substituted with 0 to 3 R8f3; each X8fis independently C1-6alkylene, C2-6alkenylene, O, or S; and each R8f1 and R8f2 are combined with the carbon to which they are atached to form a heterocycloalkyl having 3 to 10 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein the heterocycloalkyl is substituted with 0 to 3 R8f3.

43. The compound of any one of claims 1 to 42, or the pharmaceuticaly acceptable salt thereof, wherein each X8fis independently C1-6alkylene.

44. The compound of any one of claims 1 to 40, or the pharmaceuticaly acceptable salt thereof, whereineach R8fis independently halo, C3-6cycloalkyl, –CH=CR8f1R8f2, heterocycloalkyl, phenyl, or heteroaryl, wherein each heterocycloalkyl has 3 to 10 ring members and 1 to 3 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 10 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein each cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl is substituted with 0 to 3 R8f3; each R8f1 and R8f2 are combined with the carbon to which they are atached to form a heterocycloalkyl having 3 to 10 ring members and 1 to 3 heteroatoms, each independently N, O or S, wherein the heterocycloalkyl is substituted with 0 to 3 R8f3.

45. The compound of any one of claims 1 to 40, or the pharmaceuticaly acceptable salt thereof, wherein each R8fis independently C1-4alkyl, C2-4alkenyl, C1-4alkoxy, C1-4deuteroalkoxy, halo, C1-4haloalkyl, cyano, or –C1-2 alkyl–cyano.

46. The compound of any one of claims 1 to 40, or the pharmaceuticaly acceptable salt thereof, wherein each R8fis independently halo, C3-6cycloalkyl, –O–C3-6cycloalkyl, heterocycloalkyl, –C2-4alkenyl–heterocycloalkyl, –O–heterocycloalkyl, phenyl, –O–phenyl, heteroaryl, or –O–heteroaryl, wherein each heterocycloalkyl has 3 to 6 ring members and 1 to 2 heteroatoms, each independently N, O, or S, and each heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein each cycloalkyl, heterocycloalkyl, phenyl, and heteroaryl is substituted with 0 to 3 R8f3.

47. The compound of any one of claims 1 to 40, or the pharmaceuticaly acceptable salt thereof, wherein each R8fis independently halo, C3-6cycloalkyl, –O–C3-6cycloalkyl, heteroaryl, or –O–heteroaryl, wherein each heteroaryl has 5 to 6 ring members and 1 to 3 heteroatoms, each independently N, O, or S, wherein each cycloalkyl, and heteroaryl is substituted with 0 to 3 R8f3.

48. The compound of any one of claims 1 to 40, or the pharmaceuticaly acceptable salt thereof, whereineach R8fis independently halo, heterocycloalkyl, –O–heterocycloalkyl, phenyl, or –O–phenyl, wherein each heterocycloalkyl has 3 to 6 ring members and 1 to 2 heteroatoms, each independently N, O, or S, wherein each heterocycloalkyl and phenyl is substituted with 0 to 3 R8f3.

49. The compound of any one of claims 1 to 48, or the pharmaceuticaly acceptable salt thereof, wherein each R8f3is independently C1-6alkyl, –Y8–C1-6alkyl, C1-6deuteroalky, –Y8–C1-6deuteroalkyl, –OH, –C1-6alkyl–OH, –Y8–C1-6alkyl–OH, –C1-6alkyl–Y8–C1-6alkyl, halo, C1-6haloalkyl, –Y8–C1-6haloalkyl, or oxo; each Y8 is independently C(O), C(O)O, N(R8f4)C(O), O, S, or S(O)2; and each R8f4is independently H or C1-6alkyl.

50. The compound of any one of claims 1 to 48, or the pharmaceuticaly acceptable salt thereof, wherein each R8f3is independently C1-6alkyl, C1-6deuteroalky, –OH, –C1-6alkyl–OH, halo, C1-6haloalkyl, or oxo.

51. The compound of any one of claims 1 to 48, or the pharmaceuticaly acceptable salt thereof, wherein each R8f3is independently C1-6alkyl or –Y8–C1-6alkyl.

52. The compound of any one of claims 1 to 51, or the pharmaceuticaly acceptable salt thereof, wherein each Y8 is independently a C(O) or C(O)O.

53. The compound of any one of claims 1 to 48, or the pharmaceuticaly acceptable salt thereof, wherein each R8f3is independently C3-6cycloalkyl, –X8f3–C3-6cycloalkyl, heterocycloalkyl, or –X8f3–heterocycloalkyl, wherein each heterocycloalkyl has 3 to 6 members and 1 to 2 heteroatoms, each independently N, O, S, or S(O)2; and each X8f3is independently C1-6alkylene, C(O), or S(O)2.

54. The compound of any one of claims 1 to 53, or the pharmaceuticaly acceptable salt thereof, wherein each R8f3is independently C3-6cycloalkyl or heterocycloalkyl, wherein each heterocycloalkyl has 3 to 6 members and 1 to 2 heteroatoms, each independently N, O, S, or S(O)2.

55. The compound of any one of claims 1 to 53, or the pharmaceuticaly acceptable salt thereof, wherein each X8f3is independently C1-6alkylene.

56. The compound of any one of claims 1 to 55, or the pharmaceuticaly acceptable salt thereof, wherein two R8f3groups on adjacent ring vertices combine to form a heterocycloalkyl having 3 to 6 ring members and 1 to 3 heteroatoms, each independently N, O or S.

57. The compound of any one of claims 1 to 48, or the pharmaceuticaly acceptable salt thereof, wherein each R8f3is independently C1-4alkyl, C1-4alkoxy, C2-6alkoxyalkyl, –S(O)2–C1-4alkyl, –C1-4alkyl–S(O)2–C1-4alkyl, halo, C1-4haloalkyl, oxo, –C(O)–C1-4alkyl, or –C(O)O–C1-4alkyl.

58. The compound of any one of claims 1 to 57, or the pharmaceuticaly acceptable salt thereof, wherein m8 is 1, 2, or 3; and each R8fis independently methyl, isopropyl, isobutyl, methoxy, ethoxy, fluoro, chloro, cyano,, , , , , ,, , , , , , ,, , , , , , ,; alternatively, ring B and three R8fgroups form the moietywherein the wavy line identifies atachment to the remainder of the molecule.

59. The compound of claim 1, or the pharmaceuticaly acceptable salt thereof, wherein R3isR4aand R4bare each H; R4cis ethyl; alternatively, R4cand R4atogether with the carbon and nitrogen to which each is atached combine to form a pyrolidinyl, substituted with 0 to 2 fluoro; R5a and R5b are each H; R5c is H, methyl, ethyl,, , , , , , X6is, , or ; R6a is H, methyl, ethyl, R6bis H;R6d is H, methyl, or ethyl; R7aand R7bare each H; R7cis isobutyl,R8a is H or methyl; R8b, R8d and R8e are each H; ring B is phenyl, naphthyl, biphenyl, thiophenyl, pyridyl, benzofuranyl, indolyl, indazolyl, or quinolinyl; m8 is 1, 2, or 3; and each R8fis independently methyl, isopropyl, isobutyl, methoxy, ethoxy, fluoro, chloro, cyano,, , , , , , , ,, , , , , , ,alternatively, ring B and three R8fgroups form the moiety, wherein the wavy line identifies atachment to the remainder of the molecule.

60. The compound of any one of claims 1 to 59, or the pharmaceuticaly acceptable salt thereof, having the compound of Formula (Ib):

61. The compound of any one of claims 1 to 59, or the pharmaceuticaly acceptable salt thereof, having the compound of Formula (Ic):

62. The compound of any one of claims 1 to 59, or the pharmaceuticaly acceptable salt thereof, having the compound of Formula (Id):, wherein the dashed bond is absent or a single bond, and wherein when the dashed line is a single bond in Formula (Id), the wavy bond atached to the double bond indicates E, Z, or a mixture of both isomers.

63. The compound of claim 1, or the pharmaceuticaly acceptable salt thereof, having the structure of any one of Examples 1-426.

64. The compound of claim 1, or the pharmaceuticaly acceptable salt thereof, having the structure.

65. The compound of claim 1, or the pharmaceuticaly acceptable salt thereof, having the structure.

66. The compound of claim 1, or the pharmaceuticaly acceptable salt thereof, having the structure.

67. The compound of claim 1, or the pharmaceuticaly acceptable salt thereof, having the structure.

68. The compound of claim 1, or the pharmaceuticaly acceptable salt thereof, having the structure.

69. The compound of claim 1, or the pharmaceuticaly acceptable salt thereof, having the structure.

70. The compound of claim 1, or the pharmaceuticaly acceptable salt thereof, having the structure.

71. The compound of claim 1, or the pharmaceuticaly acceptable salt thereof, having the structure.

72. A pharmaceutical composition comprising a compound of any one of claims 1 to 71 and a pharmaceuticaly acceptable excipient.

73. A method of treating a cancer mediated at least in part by cyclin A comprising administering a therapeuticaly effective amount of a compound of any one of claims 1 to 71, or a pharmaceuticaly acceptable salt thereof, or a pharmaceutical composition of claim 72, thereby treating the disorder or condition.

74. A compound of any one of claims 1 to 71, or a pharmaceuticaly acceptable salt thereof, or a pharmaceutical composition of claim 72 for use in a method for treating a cancer mediated at least in part by cyclin A.

75. Use of a compound of any one of claims 1 to 71, or a pharmaceuticaly acceptable salt thereof, or a pharmaceutical composition of claim 72 for the manufacture of a medicament for the treatment of a cancer mediated at least in part by cyclin A.

Images